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ABSTRACT
Over three decades have passed since the discovery of human 
immunodeficiency virus (HIV), and with no viable vaccine, new technologies to 
prevent the spread of the virus are urgently needed. Pre-exposure prophylaxis, 
the concept of chemically interrupting HIV transmission, effectively reduced HIV 
incidence in a number of clinical trials. However, it has been difficult to achieve 
high and consistent effectiveness in clinical trials due to variable adherence to 
the dosing regimens requiring frequent administration. This, along with the 
disproportionate burden of the HIV/AIDS pandemic in young women in sub- 
Saharan Africa, has catalyzed the research into long-acting, antiretroviral eluting 
drug delivery systems like intravaginal rings (IVR) in an attempt to increase 
adherence over dosage forms that require frequent administration, and provide a 
more consistent drug concentration where transmission occurs.
However, IVR technology is generally limited to releasing small quantities 
of hydrophobic, low molecular weight species that can diffuse through the IVR 
elastomer. This dissertation describes two adaptable drug delivery platforms that 
increased the diversity of the drugs that can be delivered from IVRs. Polyether 
urethane reservoir IVRs were engineered for the delivery of the thermally and 
hydrolytically unstable prodrug tenofovir disoproxil fumarate. This drug presents
a unique design challenge to minimize the hydrolytic drug degradation in the IVR 
core while also promoting hydration to solubilize and release the drug. This 
design delivered mg/day quantities of drug and conferred complete protection in 
macaques from multiple vaginal viral exposures. Next, we engineered a system 
that uncouples the mechanism of drug release from the interaction of the drug 
with the elastomer and provides nearly constant release of any stable molecule.
In this system, orifices control the hydration rate of the hydrophilic matrix 
contained within the core of the IVR, and release of the drug-containing gel. We 
evaluated the utility of this system for the topical delivery of macromolecules, and 
multiple different small molecule antiretrovirals, specifically for the delivery of 
drug microparticles. This work describes the design and evaluation of 
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CHAPTER 1
INTRODUCTION
1.1 HIV/AIDS Pandemic, Therapy, and Pre-exposure Prophylaxis
Despite a 38% reduction of new HIV infection since 2001, the number of 
new HIV infections remains alarmingly high with over 2 million occurring 
annually, continuing to drive biomedical advances to control the pandemic (1). 
The reduction in new infections is due in part to a number of factors including 
expansion of HIV testing, oral antiretroviral therapy, in addition to increased 
counseling and education (2). An important factor that increases the risk of 
sexual transmission of HIV is viral load in blood plasma (3). Therefore, effective 
viral suppression achieved with successful implementation of antiretroviral 
therapy is associated with vastly reduced HIV transmission rates and is termed 
treatment as prevention (4, 5). Combination antiretroviral therapy regimens, 
initially developed in the early 1990s, can effectively suppress viral replication in 
most individuals transforming HIV infection from a progressive illness to a chronic 
but manageable illness. However, despite improvements in potency and safety of 
antiretroviral drugs, HIV infection and life-long antiretroviral therapy is costly, 
leads to an accelerated immune senescence, and is associated with a number of 
side effects (6-8). Despite vast increases in HIV testing and access to
antiretroviral therapy, an estimated 19 million of the total 35 million HIV-infected 
individuals do not know their HIV status and 22 million HIV-infected individuals 
lack access to antiretroviral therapy (1). For example, only 37% of HIV-infected 
individuals in sub-Saharan Africa receive antiretroviral therapy (1). Due to a 
number of issues with current antiretroviral therapy, 20% of treated HIV-infected 
individuals in the US are not in long-term treatment associated with complete 
viral suppression (9). The Joint United Nations Program on HIV and acquired 
immunodeficiency syndrome (UNAIDS) has set the goal of achieving diagnosis of 
90% of HIV infections, achievement of 90% engagement with care, and 
suppression of viremia in 90% of the treated individuals by 2020 (10). However, 
even if this goal was obtained, greater than 30% of HIV-infected individuals will 
remain viremic and potentially continue to spread the infection since even a small 
undiagnosed cohort is capable of sustaining and even driving increases in HIV 
incidence (9, 11, 12). Treatment as prevention is having a significant effect in 
reducing the number of new HIV infections (13, 14), but without other prevention 
interventions, scaling up HIV testing and antiretroviral therapy is unlikely to 
control the HIV epidemic (15, 16); therefore, additional methods are required to 
further control the pandemic.
Since an effective HIV vaccine (17, 18) or cure (19, 20) remains elusive, 
there has been a significant effort towards developing pre-exposure prophylactic 
(PrEP) strategies to prevent HIV transmission where antiretroviral are dosed prior 
to sexual exposure (21, 22). PrEP is designed to chemically prevent HIV 
transmission where transmission occurs or before systemic infection can be
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established and can empower at-risk individuals to protect themselves from HIV 
infection. Approximately 70% of the global population living with HIV reside in 
sub-Saharan Africa (25 of 35 million), where biological and social gender 
inequalities continue to drive HIV incidence rates that are twice as high in young 
women (15-24 years) compared to young men, motivating the development of 
women-controlled HIV prevention modalities (2, 23). Additionally, men who have 
sex with men account for 63% of new HIV infections in the US (24), are 20x more 
likely to become infected than the general population (25), and young men who 
have sex with men experienced a 22% increase in new HIV infections per year 
from 2008 to 2010 in the US (26). Therefore, PrEP development has focused 
particularly on young women at high risk, men who have sex with men, and 
heterosexual serodiscordant couples, i.e. couples with one member who is HIV- 
infected. PrEP would likely be a time-limited strategy compared to antiretrovirals 
for HIV treatment that is a life-long intervention, and PrEP has been 
demonstrated to be cost-effective in sub-Saharan Africa where HIV is endemic 
(27).
Initial PrEP development for women focused on vaginal gels containing 
nonspecific agents focusing first on membrane solubilizing surfactants (e.g. 
nonoxynol-9, C31G) and then anionic polymers that act as entry inhibitors (e.g. 
cellulose sulfate, carrageenan). Unfortunately all of the nonspecific agents that 
were clinically tested showed no reduction in HIV acquisition rates, likely due to 
low potency (28-32). In fact, there were a number of safety concerns with the 
surfactants, most notably detected as an increased HIV susceptibility observed in
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a clinical trial (33). The low in vivo potency and safety issues associated with 
nonspecific agents lead the development efforts towards oral and topical 
products containing antiretrovirals specific against HIV.
A number of recent clinical trials evaluating oral and topical administration 
of antiretrovirals have proven that PrEP strategies can be effective in reducing 
HIV acquisition rates (34-39). Specifically, a number of clinical trials have shown 
that oral administration of tenofovir disoproxil fumarate (TDF) with and without 
emtricitabine can protect from sexual HIV exposure (34-37, 39). Based on a 
number of successful clinical trials evaluating oral PrEP, the FDA approved oral 
TDF and emtricitabine to reduce the risk of HIV infection in 2012. However, 
uptake of oral PrEP has been slow (40) and is due to a number of issues 
including a lack of awareness of oral PrEP, a low perceived risk of HIV infection, 
concerns regarding potential adverse effects, cost of the drugs and follow-up 
visits, and repeated HIV testing (41, 42). Moreover, particularly in clinical trials 
evaluating oral PrEP in women in sub-Saharan Africa, there is a stigma 
associated with taking oral antiretrovirals. Individuals who are not HIV-infected do 
not want to be perceived as HIV-positive by taking oral antiretroviral therapy (43). 
Taken together, it has been difficult to achieve consistent and high levels of 
protection in clinical trials due largely to variable adherence that corresponds to 
insufficient drug concentrations where transmission events occur. An important 
outcome of PrEP clinical trials has been the correlation of adherence determined 
from the drug concentration in blood plasma and effectiveness in reducing HIV 
incidence. (44-48) In an attempt to increase adherence and to improve drug
4
pharmacokinetics (PK), i.e. provide a more consistent drug concentration in the 
mucosal tissue, there has been a shift towards long-duration delivery systems 
such as intravaginal rings (IVRs) (49-51) that can be used for a month or more. 
Currently, there are two clinical trials evaluating the ability of IVRs delivering 
dapivirine to prevent HIV infection in women. Generally, as the duration between 
dosing events increases, the adherence increases as well (52, 53), and this has 
been well understood in contraceptive delivery systems for four decades (54). As 
an example, the most effective contraceptives are long-acting subcutaneous 
implants or intrauterine systems that are effective for multiple years after a single 
administration (55). The idea that limiting or simplifying user intervention to 
achieve better effectiveness is one of the main drivers for innovative and 
improved drug delivery technologies.
1.2 Vaginal Drug Delivery
This manuscript focuses on vaginal drug delivery from IVRs in the context 
of HIV prevention; however, even though vaginal drug dosing is less common 
than oral or dermal routes of administration, there are a number of advantages to 
vaginal drug delivery for other indications than prevention of HIV infection in 
women. Advantages of vaginal drug delivery include self-administration, 
avoidance of first-pass hepatic drug metabolism, potentially minimized systemic 
toxicity effects for local delivery, and prolonged retention and drug delivery to 
minimize fluctuations of drug concentration over time (56, 57). Typically, vaginal 
drug delivery systems focus on indications that are gender specific including
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contraceptives, atrophic vaginitis, vaginal bacterial or fungal infections, and 
precancerous lesions in the female reproductive tract. Vaginal drug delivery 
systems are available in a number of forms including IVRs, gels, creams, films, 
tablets, pessaries, and suppository. The global health community has 
hypothesized that including a contraceptive with a HIV PrEP agent into a single 
product will increase user demand and uptake (58, 59).
In addition to the motivation to develop long-acting drug delivery systems 
for HIV prevention in an attempt to improve adherence and drug PK, there is a 
compelling interest for on-demand HIV prevention modalities due to the varied 
preferences for prevention products voiced by the diverse population of 
individuals at high risk for HIV acquisition (60, 61). Simply put, choice between 
prevention products remains important to successful implementation of HIV 
prevention. Due in part to the low adherence to frequent gel administration 
observed in HIV prevention clinical trials, researchers are investigating other 
short to medium duration delivery systems that could be easier to use in an 
attempt to improve adherence. These formulations include films, tablets, 
electrospun fibers, and drug nanoparticles. Films (62-64), tablets (65), and 
electrospun fibers (66, 67) are typically designed to release drug immediately. To 
increase the drug dissolution rate, it is desirable for the drug to be amorphous in 
the polymer matrix, and particularly in the case of electrospun fibers, to maximize 
the surface area available for dissolution. Advantages of films, tablet, and 
electrospun fibers compared to a gel include a smaller volume for more discreet 
use and/or easier administration, and potentially improved drug stability
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compared to aqueous gels for hydrophobic drugs. Nanoparticles are often 
investigated to improve drug uptake into tissue and to date have been delivered 
to the vagina as a solution or semisolid gel (68-70). However, an intravaginal 
delivery system capable of delivering drug particulates would enable the 
sustained delivery of nanoparticles to complement the increased drug uptake into 
tissue.
1.3 Vaginal and Oral Pre-Exposure Prophylaxis
Vaginal gels to prevent HIV transmission in women containing the 
nucleotide analogue reverse transcriptase inhibitor, tenofovir, have displayed no 
or modest effectiveness in clinical trials (38, 45). There are a number of social 
and biological explanations for the limited effectiveness of the 1 % tenofovir gel; 
however, the most plausible and leading causes of these clinical failures are 
thought to be low adherence (22) to either coitally associated or daily gel dosing 
coupled with the application-dependent drug pharmacokinetics (47, 71). In the 
clinical trial CAPRISA 004, the success was modest and correlated with user 
adherence with a 39% overall effectiveness (38). Women with tenofovir 
concentration of 1 ^g/mL or greater in vaginal fluid exhibited a significantly lower 
HIV incidence corresponding to 74% effectiveness (48). However, a confirmatory 
trial displayed no effectiveness (72). In a different clinical trial (VOICE) evaluating 
the same 1% tenofovir gel with a daily compared to coitally associated dosing, no 
protection was observed (45). It was established from pharmacokinetic data of 
drug concentration in blood plasma that participants poorly adhered to the dosing
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regimen, leading to the lack in effectiveness (22). Moreover, the episodic nature 
of gel dosing confers a limited window of protection after gel dosing. This idea 
was confirmed in efficacy studies in macaques that showed that protection 
against vaginal virus challenge conferred by tenofovir or maraviroc containing 
vaginal gels depends on the relative timing of the gel and virus application (73, 
74). The small window of protection provided by the drug containing vaginal gels 
necessitates strict adherence to frequent dosing and has motivated the 
development of sustained topical delivery strategies that can provide consistent 
drug release to the tissue where HIV transmission occurs.
In HIV PrEP development, unlike HIV treatment, there is no clear biomarker 
for the drug effect to guide the drug product design and clinical trial design. It has 
been hypothesized that the drug concentration in the mucosal tissue where the 
initial HIV infection occurs (75) may better reflect prophylactic effect than 
systemic drug concentration for topical drug delivery. Currently, it is unknown 
how oral drug dosing is preventing infection, whether preventing early 
transmission events at the portal of viral entry, or preventing the establishment of 
a systemic infection. The role of mucosal drug concentration for oral drug dosing 
is less clear since tenofovir and tenofovir diphosphate, the active molecule, 
display differential accumulation at rectal and vaginal mucosal tissue. Oral dosing 
of TDF results in ~100-fold lower vaginal tenofovir concentration and ~50-fold 
higher plasma tenofovir concentration than vaginal tenofovir gel (47, 76), and oral 
TDF was shown to be highly effective in preventing HIV transmission in women 
(77). On the other hand, tenofovir and tenofovir diphosphate concentrations in
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both rectal mononuclear cells and tissue was higher than that achieved in 
peripheral blood mononuclear cells (PBMCs) after oral dosing of TDF in both 
macaques and humans (78-80). Interestingly, parity between rectal viral 
challenge studies in macaques and clinical studies of men who have sex with 
men has been observed for oral dosing of TDF and emtricitabine, i.e. a similar 
tenofovir diphosphate concentration in PBMCs was associated with a 90% risk 
reduction from both clinical and animal data (81, 82). If the drug concentration in 
mucosal tissue is the most relevant, topical dosing which confers higher tissue 
drug concentrations should be more effective in preventing the sexual 
transmission of HIV than oral dosing. Topical drug delivery also has the 
advantage of lower plasma drug concentrations compared to oral dosing which 
should reduce the risk of selecting for drug resistant virus. Nevertheless, clinical 
trials of vaginal gels exhibited the lowest effectiveness levels compared to oral 
trials, but inconsistent adherence levels between trials further complicate this. To 
effectively design and optimize HIV PrEP strategies, how different antiretrovirals 
delivered via different routes of administration prevent HIV infection must be 
known.
1.4 Drug Release from IVRs
Intravaginal rings are torus-shaped, elastomeric devices that are inserted 
by the user to deliver drug for weeks to months to provide sustained drug 
delivery. There are five rings currently on the global market that deliver hormones 
for the prevention of unwanted pregnancy and hormone replacement therapy
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(49, 83). In contrast to frequently applied dosage forms such as gels, IVRs may 
provide increased effectiveness resulting from higher user adherence due to 
infrequent user intervention (44, 84). Specifically the contraceptive NuvaRing® 
demonstrated 96% user satisfaction in international acceptability studies (84).
The most relevant evaluation of user adherence of IVRs for HIV prevention 
involved African women using a placebo IVR. This study found that >95% of 
women wore the IVR every day for at least 12 hours and 82% never removed the 
IVR for the 12-week period of use (50). User motivation and education are 
essential to high uptake and adherence, particularly in the case of populations 
where IVRs are not commonly used. Further clinical evaluations must be 
performed in a larger population; however, the 82% perfect use far exceeds 
adherence in gel clinical trials for HIV prevention and suggests that certain 
populations will be motivated to use IVRs that protect against HIV infection (44, 
45).
Drugs are released from nondegradable, elastomeric polymers by a 
permeation-controlled mechanism that depends on the solubility and diffusivity of 
the drug within the IVR elastomer (85, 86). The two main ring designs are matrix 
and reservoir. A matrix ring has drug homogeneously dispersed throughout the 
cross-section with a drug release profile that typically is proportional to t-1/2 and 
continually reduces with time. This continual reduction in the drug release rate 
from a matrix IVRs occurs due to an increased diffusional distance with time.
After a sufficient amount of drug is released, an annulus of polymer not 
containing drug can be observed upon visualization of the ring cross-section (87).
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The thickness of the drug-depletion zone increases with time and is the cause of 
the decreasing drug release rate. Reservoir type IVRs have a drug loaded core 
covered with a rate-controlling membrane and can have a time independent, 
constant drug release rate (88). Time independent, zero-order drug release only 
occurs with reservoir type devices if the drug concentration within the IVR is 
maintained at a constant value (89). Often the drug release rate continually 
decays with time due to a decreasing drug concentration within the reservoir (88, 
90). Also reservoir type devices are often characterized by a burst release in the 
first few days caused from a higher drug concentration in the rate-controlling 
membrane or drug crystallized on the surface of the device (91, 92).
Until recently, all clinically tested IVR technologies could only achieve low, 
Mg/day release rates of small hydrophobic drugs due to the limited drug solubility 
and diffusivity in silicone and poly(ethyl-co-vinyl acetate) elastomeric matrixes 
(49, 51, 93). These polymers are particularly useful for the delivery of hormones, 
whose relatively small molecular size and hydrophobic nature results in adequate 
solubility and permeation of the hormone through the elastomer. To overcome 
the low solubility and diffusivity in commonly utilized IVR elastomers, a high (30­
50 wt%) loading of hydrophilic excipient or drug can be utilized that exceeds the 
percolation threshold to form a connected, porous structure (94-97). Dissolution 
of hydrophilic drug or excipient from the polymer matrix leaves an interconnected 
water filled, porous network for drug to solubilize and diffuse. The drug release 
from this type of device is typically proportional to t-1/2. An additional drawback to 
this design is the device swells resulting in a significant reduction in stiffness
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during use making long-term device retention in the vagina difficult to impossible 
to achieve.
There has been a resurgence in the development of new IVR technologies 
due to the need for new HIV prevention technologies to control the pandemic. 
Initially, matrix IVRs were evaluated due to their simple design and 
manufacturability. However, often the large reduction in the drug release rate 
characteristic of matrix IVRs has driven the field towards reservoir and other new 
designs to achieve a higher drug release rate at the end of the IVR duration and 
a more controlled drug release rate. This has led to utilizing new polymers, in 
particular polyether urethanes (90, 98-100), and a number of new ring designs 
(101-104) to enable the delivery of hydrophilic and macro-molecules at mg/day 
delivery rates that are impossible to achieve with EVA or silicone and still 
maintain the necessary IVR stiffness for proper retention in the vagina. Polyether 
urethanes are a diverse class of polymers and are synthesized by condensation 
polymerization of diisocyanate, such as 4,4'-Methylenebis(cyclohexyl 
isocyanate), poly(ether diols) such as poly(tetramethylene oxide) and 
poly(ethylene oxide), and chain extenders such as 1, 4-butandiol. The equilibrium 
water absorption can be controlled by altering the ratio of poly(tetramethylene 
oxide) and poly(ethylene oxide) where an increase in the poly(ethylene oxide) 
content corresponds to an increased water uptake. Recently, Kiser and 
colleagues have been investigating IVRs composed of extruded polyether 
urethane tubing filled with a dry powder or semisolid paste of drug and excipient. 
An IVR of this design delivering TDF is described in Chapter 2. The drug release
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and ring mechanical properties can be tuned by altering the hardness and 
equilibrium water uptake of the polymer, IVR dimensions, and formulation of the 
core. (89, 100) This has enabled the delivery of more polar drug molecules at 
higher release rates that are presumed to be necessary for HIV prevention (87,
89, 99, 100). However, the polymer must still be matched to the drug and the 
drug release is typically limited by the drug solubility and diffusivity in the 
polymer.
Another new ring design is insert vaginal rings where small drug delivery 
systems are contained or held within the ring body (101-103, 105). This 
separates the drug delivery requirements from the mechanical properties 
necessary for proper ring insertion, retention, and biocompatibility. A number of 
drug delivery inserts have been embedded into IVR including drug-containing 
matrices consisting of compressed pellets or lyophilized solutions of water- 
soluble polymer, and silicone (101). Another example consists of compressed 
drug pellets coated with polylactic acid that acts as a rate-controlling membrane 
for drug release. The coated pellets are then embedded into body of the ring with 
one or more delivery channels. In this system, drug release is controlled by the 
solubility and diffusivity of the drug in the membrane, thickness and exposed 
area of the membrane, the number of pods embedded into a ring, and the area of 
the delivery channel(s). (102) To achieve sustained drug delivery, these 
alterative IVR delivery systems utilize permeation-controlled delivery systems 
where the drug must still diffuse through the polymer(s) of the insert (101, 102, 
105). This still leads to the requirement to match the drug to the polymer to
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achieve the desired release rate, and limits the surface area for the drug release 
compared to more traditional IVR designs where most of the ring surface area is 
available for drug release, making it difficult to achieve the high, mg/day release 
rates necessary with a number of the leading antiretroviral agents for HIV 
prevention. We were interested by osmotic pump technology where a 
concentration gradient of the osmotic agent, and not necessarily the drug, drives 
water entry across a semipermeable membrane to drive drug release (106). Until 
recently, osmotic pump technology had only been suggested (107) and not 
utilized for vaginal drug delivery (104). We designed an osmotic pump tablet 
composed of a compressed pellet of water swellable polymer, hydroxypropyl 
cellulose, and drug coated with a semipermeable membrane with an orifice, and 
achieved controlled drug release over a week duration (104). The equation 
describing release from an osmotic pump is shown below (Eq. 1.1) where dm/dt, 
the release rate, is proportional to the area and thickness of the semipermeable 
membrane, A and h; the water permeability, K; and importantly the osmotic 
pressure difference (An) and the total concentration of drug, C.
^  = K A h An C (Eq. 1.1)
dt
We were inspired by the osmotic pump and wondered if it could be 
integrated into an IVR for long-term delivery. One of the main goals of this 
dissertation was to create drug delivery devices where the drug release rate was 
not dependent on the solubility or diffusivity of the polymers of the ring enabling 
the delivery of drugs irrespective of their chemical properties (Chapters 3-5).
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1.5 Mechanical Properties of IVRs
IVRs are drug-device combinations and the performance is innately 
connected to the dimensions and mechanical properties of the ring. IVRs are 
inserted by the user in a compressed or figure eight configuration. Upon 
insertion, the IVR is retained by a force balance between the elastic recoil of the 
ring under compression by the vaginal walls. The ease of insertion and retention 
is determined by the ring geometry, design, and elastic modulus of the 
elastomer. Despite a range of vaginal shapes and sizes (108-110), IVRs typically 
have an outer diameter of 55 mm and the cross-section is determined by the 
polymer hardness and drug release considerations. A ring that is too soft results 
in an insufficient recoil force, and the IVR is not retained well and is easily 
expelled (111, 112). However, if the ring is too stiff, it can be difficult to insert and 
remove, and can cause damage to the vaginal epithelium (113, 114). These 
clinical studies provide the upper and lower bounds of acceptable ring stiffness 
and compressibility. Moreover, a large clinical study evaluated four different IVR 
representing a wide range of ring stiffness found all designs were well retained 
and found acceptable by the users with no safety issues (115). To date, typically 
a force to compress the ring 10 and 25% of the outer diameter is used as a 
quantitative measure of ring compressibility (87, 89, 90, 99, 116-118) with the 
goal of achieving values comparable to IVRs currently on the market. This, 
however, is a simplified measure not taking into account the ease or difficulty of 
insertion, or the hysteresis typically observed during a compression and 
relaxation cycle. Nevertheless, IVR mechanical properties are typically a
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secondary concern to the drug release due to relatively broad ranges of ring 
stiffness that have been found acceptable despite a large variation in vaginal size 
and shape (108-110).
1.6 Modeling Drug Release from Hydrophilic Matrix Tablets
There are many examples of drug release kinetics from IVRs being 
mechanistically described by solutions to the diffusion equation (85, 87, 90, 119­
123). However, new types of delivery systems can necessitate new or modified 
drug release models to facilitate the design and development of these devices. 
Early research into sustained release strategies largely focused on developing 
oral formulations to extend the duration of drug release and control the drug 
release kinetics to result in more consistent drug PK. Many of these oral 
formulations are compressed pellets or tablets containing water-soluble 
polymers, e.g. hydroxypropyl methylcellulose, natural polysaccharides, 
polyethylene oxide, and hydroxypropyl cellulose (124, 125). Drug release from 
these hydrophilic matrix tablets occurs through a combination of drug dissolution 
and diffusion from the swollen polymer matrix, and polymer dissolution.
Moreover, the interplay between these two mechanisms depends in part on the 
drug solubility in the release media, drug loading in the polymer matrix, and 
polymer chemistry and molecular weight. Particularly with hydroxypropyl 
methylcellulose, upon polymer hydration, a swollen polymer layer persists on the 
outer edge of the tablet acting as a rate-controlling membrane for drug diffusion. 
There are a number of models of drug release from hydrophilic solid matrices
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describing the mechanism and kinetic of water diffusion into the hydrophilic 
matrix, the resulting polymer swelling and dissolution, in addition to drug diffusion 
through the swollen polymer (126-131). The diffusion of the water into and drug 
release from hydrophilic matrix tablets is described by the diffusion equation (Eq. 
1.2) (132).
Following the free volume theory, the diffusion coefficient of water and 
drug in hydrophilic polymers displays a strong dependence on the water 
concentration (133). That is, as the polymer is hydrating and the water 
concentration increases, the free volume available for the water to diffuse 
increases, resulting in an increase in the water diffusivity in the polymer. A similar 
phenomenon is observed for drug diffusion. The diffusivity of water in a swollen 
polymer matrix increases exponentially as the water concentration increased until 
the self-diffusion is reached and the polymer concentration is too low to hinder 
water diffusion (Eq. 1.3). Dk is diffusion coefficient of each species and pk is a 
constant that characterizes the water concentration dependence of the diffusion 
coefficient. Dk, eq represent the diffusion coefficients of each species at the 
maximum water concentration, Cwater, eq (in equilibrium with the swollen matrix)
Typically, ideal swelling is assumed, and the volume of the swollen 
polymer equals the sum of the components. The system of equations is solved
(133).
with a moving boundary to account for expansion due to polymer hydration and 
swelling. Often the parameters are fit to experimental data and the model is then 
utilized to estimate the effect design changes have on the drug release profile. 
However, the water and drug diffusivities as a function of polymer concentration 
can be directly measured experimentally utilizing pulsed-field-gradient spin-echo 
nuclear magnetic resonance for the water and drug diffusivity (134, 135), Franz 
cell diffusion experiments for the drug diffusivity (136), and fluorescence recovery 
after photobleaching for polymer and drug diffusivity (137, 138). Much is known 
regarding the mechanism and kinetics of drug release from hydrophilic matrix 
tablets that can be utilized to model drug release from new drug delivery systems 
where a similar mechanism occurs. Chapter 4 of this manuscript describes a 
mechanistic model of drug release that includes the hydration, swelling, and 
diffusion of the water-soluble polymer from flux controlled pumps.
1.7 PK of Antiretrovirals Delivered from IVRs
In clinical trials evaluating the performance of dapivirine eluting IVRs (139­
141) and animal studies of IVRs releasing another hydrophobic antiretroviral 
(142), typically a higher concentration of drug in vaginal fluid was observed 
proximal to the ring compared to distal locations. Since the sexual transmission 
of HIV can occur along the female reproductive tract (143, 144), the drug 
concentration must be sufficient to prevent HIV transmission throughout the 
canal. A matrix IVR with dapivirine, a potent non-nucleoside reverse 
transcriptase inhibitor, homogenously dispersed in silicone is currently in Phase 3
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clinical studies in two separate trials. The results of the clinical trials are expected 
in 2015 and will be the first example of clinical effectiveness of HIV PrEP from an 
IVR. The in vitro drug release rate from this matrix IVR exhibited a significant 
reduction in the release rate over time characteristic of this design, with potential 
excess drug release early on and insufficient drug release near the end of the 28- 
day duration (118). This reduction in release rate in vitro over a month 
corresponded to a reduction in dapivirine concentration in vaginal fluid. However, 
the reduction of the dapivirine concentration in vaginal fluid and blood plasma 
was slight, suggesting that the large reduction of the drug release rate observed 
in vivo was attenuated compared to the in vitro release conditions (141). A similar 
phenomenon was observed with a matrix ring eluting IQP-0528, another 
hydrophobic, non-nucleoside reverse transcriptase inhibitor. In this study, the 
authors argued that the drug release from the ring was partition-controlled and 
not diffusion-controlled, meaning the rate-limiting step for drug release was the 
drug dissolution into the vaginal fluid instead of the drug solubility and diffusivity 
in the elastomer of the ring. This resulted in a reduced release rate in vivo 
compared to in vitro release conditions, and also likely resulted in a nearly 
constant in vivo drug release rate over a month duration. (142) In addition to the 
matrix dapivirine IVR, a reservoir dapivirine IVR has also been evaluated in 
humans consisting of a dapivirine containing silicone core covered with a silicone 
rate-controlling membrane. This reservoir IVR achieved more consistent 
dapivirine concentration in vaginal fluid and tissue compared to the matrix IVR 
during the 14-days of ring use. However, the advantage of more consistent
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release from the reservoir IVR was offset by the overall reduction in drug release 
compared to the matrix design. (140)
Moreover, sustained drug release from IVRs can achieve more consistent 
drug levels in vaginal fluid and tissue with a smaller daily dose compared to daily- 
applied gels. Recently, the PK of a tenofovir eluting IVR was compared to the 1 % 
tenofovir gel in sheep (103). The IVR consisting of hydrophilic polyurethane 
tubing filled with a tenofovir/glycerol paste achieved zero-order, 90-day tenofovir 
release. The authors demonstrated the IVR delivering a daily tenofovir dose ~10x 
less than a daily application of a 1% tenofovir vaginal gel achieved comparable 
tenofovir concentration in vaginal tissue and fluid in sheep. Moreover, the 
tenofovir concentrations in vaginal fluid and tissue were more consistent with the 
IVR compared to the gel. (103) These findings strongly support the development 
of IVRs for topical HIV PrEP since improved drug PK and possibly improved 
adherence can be achieved compared to a vaginal gel. This TFV IVR, a 
combination contraceptive and HIV prevention IVR, along with a TDF IVR of a 
similar design are currently being evaluated in small Phase 1 clinical trials.
1.8 Animal Models to Evaluate IVR Performance and Efficacy
There are a number of relevant animals model for evaluating safety, drug 
PK, and pharmacodynamics of vaginal products. The most important animals 
include rabbits, sheep, and monkeys, predominately pigtailed and rhesus 
macaques. Rabbits are typically used to assess safety and local toxicity of 
vaginal products (145-147). Rabbits are a relatively easy to use and low-cost
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small animal model for testing vaginal products; however, the vaginal anatomy 
and physiology of rabbits is quite different compared to humans (148, 149).
There are also a number of PK studies of vaginal solid dosage forms in rabbits. 
Typically, the device is in the form a segment of an IVR. To ensure retention, the 
rod is surgically inserted and sutured to the vaginal wall (90, 116, 121, 150). Not 
only is this procedure difficult and expensive, but the effects of the healing 
response on the device performance in unknown potentially confounds the 
analysis of any possible inflammatory response to the drug delivery system. In 
Chapter 3, we describe the design and evaluation of a retainer device that 
enables the long-term evaluation of drug-eluting segments in the rabbit model 
that does not require surgical insertion or retention of the device (103). Sheep 
possess a number of advantages for testing vaginal products stemming from 
their similar vaginal anatomy and stratified squamous epithelium. In addition to 
being utilized for systemic and local safety of vaginal products (89, 151, 152), in 
contrast to nonhuman primates and rabbits, most sheep breeds are of a similar 
body mass and vaginal dimensions, enabling evaluation of human-sized IVRs to 
avoid or minimize scaling issues such as the effect of ring size on the ring 
stiffness, drug dosing, and PK (153, 154).
Despite the difficulty in proving the effectiveness of PrEP in humans, there 
are many examples of HIV chemoprophylaxis in nonhuman primates. For these 
studies, macaques, either pigtailed or rhesus macaques, are challenged with 
simian or simian-human immunodeficiency virus (SIV or SHIV) while 
administered with the PrEP formulation and compared to either nontreated or
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placebo-treated control animals. Rhesus and pigtailed macaques are particularly 
relevant since they possess similar vaginal anatomy and physiology (155). There 
are two major regimens of SIV/SHIV efficacy studies, a single high-dose 
challenge or a repeat low-dose challenge. The repeat low-dose challenge is 
preferred over the single high-dose model since it provides a better 
representation of infection and pathogensis of HIV in humans (156, 157). A 
number of topical and systemic formulation of antiretrovirals have provided 
protection against vaginal and rectal virus challenges including vaginally applied 
gels containing tenofovir, maraviroc, and anti-HIV antibodies against vaginal 
transmission (73, 157, 158); oral administration of TDF with and without 
emtricitabine against both vaginal and rectal transmission (159, 160); parental 
administration of cabotegravir in the form of a intramuscular long-acting 
injectable against rectal transmission (161); and a number of antiretroviral 
releasing IVR formulations (which is the focus of this manuscript). To date, a 
number of different IVRs delivering antiretrovirals have provided complete or 
partial protection against high-dose vaginal SIV or SHIV challenge in rhesus 
macaques receiving high-dose depot medroxyprogesterone acetate, a long- 
acting hormonal contraceptive that results in thinning of the vaginal epithelium 
associated with increased viral transmission in animals (117, 162, 163).
However, a TDF IVR described in Chapter 2 demonstrated 100% protection from 
16 weekly low-dose vaginal viral exposures in normally cycling pigtailed 
macaques (100). Normally cycling pigtailed macaques, in similar way as humans, 
are more susceptible to vaginal SHIV infection during the luteal phase (156). This
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same ring was also tested for efficacy in pigtailed macaques receiving depot 
medroxyprogesterone acetate and protected 5 of 6 macaques from 12 weekly 
vaginal virus exposures (164). The combination of repeated vaginal viral 
exposures in the context of medroxyprogesterone acetate treatment represents 
the most stringent animal model to date for PrEP efficacy with the animals in an 
exaggerated and sustained luteal phase. There is considerable debate whether 
depot injection of medroxyprogesterone acetate increases HIV incidence in 
women; however, the high-dose administered to macaques results in a more 
severe thinning of the mucosal epithelium.
1.9 Long-acting Injectables fo r HIV Therapy or Prevention
Most recently, there have been a number of interesting manuscripts 
evaluating long-acting parenteral formulations of antiretrovirals. These are of 
particular interest for their potential capacity for both HIV treatment, and HIV 
prevention by multiple routes including rectal and vaginal intercourse, and 
intravenous exposure. There are still many questions to be answered regarding 
the acceptability of an intramuscular injection for HIV therapy or prevention, the 
optimal drug dose and duration between injections, and the ability to prevent HIV 
infection. Currently, there are long-acting injectables under clinical investigation 
for cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, a non­
nucleoside reverse transcriptase inhibitor. Both of these drugs are formulated as 
a nanosuspension of drug crystals and as a result of the hydrophobicity, long 
half-life, and high potency of the drugs, therapeutic drug concentrations in
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plasma are maintained for 3-4 months after a single injection (165-168). 
Additionally, the cabotegravir injectable completely protected macaques from 
multiple rectal and vaginal SHIV challenges (161, 169, 170). Despite that 
therapeutically relevant drug concentration is maintained for multiple months, the 
PK profile of the current parenteral antiretroviral formulations in the clinic are 
characterized by high plasma drug concentrations early on, with the maximum 
concentration (Cmax) observed days after administration, followed by a continual 
decrease in the drug concentration in plasma with time (165-168). This long tail 
in the drug concentration with time profile could potentially be an issue since low 
plasma drug concentration can select for drug resistant virus, making future HIV 
therapy more difficult. However, currently in clinical trials, no resistance has been 
observed, partially due to repeat administration of the parenteral formulation or 
oral drug administration to maintain therapeutic drug concentrations (171). There 
are a number of different parenteral antiretroviral formulations currently under 
preclinical evaluations including degradable and nondegradable implants, and 
injectables to improve drug PK and extend the duration compared to the 
nanosuspensions of cabotegravir and rilpivirine. The high burst release of drug 
due to the high surface area available for drug dissolution means excess drug is 
being released early on that could be used to extend the duration. Implants 
displaying controlled drug release would lack the burst release or possess an 
attenuated burst release which can be used to extend the duration of protective 




1.10 Dissertation Chapter Overview
An overview and publication information of each chapter is included below.
1.10.1 Chapter 2 overview
Chapter 2 describes the design and evaluation of a reservoir IVR for the 
delivery of the thermally and hydrolytically unstable prodrug TDF. We 
hypothesized that IVRs that achieve a more controlled drug release rate than 
matrix designs will provide a more consistent drug concentration in the tissue 
where infection occurs, resulting in complete protection from vaginal viral 
exposure. Due to the large reduction of the drug release rate characteristic of a 
matrix IVR, and to achieve a more controlled and increased TDF release rate, we 
designed a reservoir IVR consisting of a hot-melt extruded polyether urethane 
tube formed into a ring filled with a mixture of drug and excipient. This IVR 
delivered mg/day quantities of TDF over a month duration from a macaque-sized 
IVR. We evaluated the PK of TDF, tenofovir, and tenofovir-diphosphate (the 
active compound) in the vaginal fluid and surrounding tissue of macaques. The 
tenofovir concentration in vaginal fluid and tenofovir diphosphate concentration in 
tissue was similar or higher than previous benchmarks of efficacy established in 
this animal model. This IVR completely protected macaques from 16 weekly 
vaginal viral exposures over the course of 4 monthly IVR changes. This was the 
first IVR to completely protect macaques from multiple vaginal SHIV challenges, 
the most stringent animal model for PrEP efficacy.
This chapter was highly collaborative in nature and was not possible
without colleagues at the Center for Disease Control and Prevention who 
performed all of the macaque studies. My contributions to this manuscript include 
the design, in vitro evaluation, and fabrication of the IVRs with Dr. Rachna 
Rastogi. I assisted in writing and editing the manuscript including data analysis 
and assembling all of the figures.
Publication: Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PMM, 
Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, and Kiser 
PK. 2013. Intravaginal ring eluting tenofovir disoproxil fumarate completely 
protects macaques from multiple vaginal simian-HIV challenges. PNAS: 110(4) 
16145-16150.
1.10.1 Chapter 3 overview
The key features of Chapter 3 are first, the description and testing of a 
new drug delivery system for the sustained, vaginal delivery of macromolecules, 
and second, a nonsurgical technique for vaginal implantation in the rabbit model 
using a shape memory polyurethane ring. There are a number of promising anti- 
HIV macromolecules; however, sustained delivery of macromolecules has been 
difficult to achieve since their size makes diffusive release through elastomers 
challenging, and their activity depends on complex intra- and intermolecular 
structures.
We described the mechanism of drug release, and the effect of various 
polymeric osmotic attractants that allow for near zero-order release of
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macromolecules compounded into the pump. The device is made of a 
compressed water-soluble polymer pellet compounded with a macromolecular 
drug and enclosed in a hard polymer casing. The casing contains orifices to allow 
influx of fluid and efflux of the hydrated contents. We hypothesized that the drug 
release would be predominately controlled by the hydration and diffusion of the 
hydrophilic matrix from the core of the device and not the diffusivity of the model 
macromolecules. The orifice size and swelling kinetics of the hydrophilic polymer 
controlled the hydration rate and thereby drug release from the device. Another 
important part of this chapter is the description and use of the holder we 
engineered to retain the pump, or other solid dosage forms, in the abdominal 
vagina of the rabbit. The use of a shape memory polyurethane retainer to 
facilitate the nonsurgical intravaginal implantation of devices in the rabbit model 
is new and can enable safety and performance evaluations of vaginal drug 
delivery systems without tissue damaging survival surgery in this important 
animal model.
Publication: Teller RS, Rastogi R, Johnson TJ, Blair MJ, Hitchcock RW, and 
Kiser PK. 2014. Intravaginal flux controlled pump for sustained release of 
macromolecules. Pharm Res: 31(9):2344-53.
1.10.2 Chapter 4 overview
In Chapter 4, we sought to further design and characterize the flux 
controlled pump reported in Chapter 3. Our main aims were to 1) evaluate the
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device with other small molecule antiretrovirals to better understand the 
mechanism of drug release, and 2) develop a mechanistic model of drug release 
from this device to aid in the design. We achieved controlled drug delivery 
ranging from Mg/day to mg/day of multiple antiretrovirals by altering the orifice 
design, drug loading, and mass of pellets loaded in the device. This chapter 
further supports the idea that drug release is predominately controlled by the 
chemical properties, namely the swelling kinetics of the water-soluble polymer 
and not the drug diffusivity in the polymers of the ring. We hypothesize that the 
limited water solubility of IQP-0528 would result in the release of drug 
microparticles entrained within the swelling polymer from the flux controlled 
pump, and therefore, the drug release would be a function of the hydration and 
diffusion of the hydrophilic polymer from the core of the ring and not drug 
solubility and diffusivity in the swollen polymer matrix. A mechanistic model 
describing the hydration and diffusion of the hydroxypropyl cellulose matrix is 
presented, and good agreement between the quantitative model predictions and 
the experimental studies of drug release from this system was achieved. This 
device provides an adaptable platform for the vaginal drug delivery of many 
antiretrovirals with release kinetics nearly independent of the molecule being 
delivered.
Publication: Teller RS, Malaspina DC, Rastogi R, Clark JT, Szleifer I, and Kiser 
PF. 2015. Controlling the hydration rate of a hydrophilic matrix in the core of an 




1.10.3 Chapter 5 overview
Chapter 5 continues to describe the flux controlled pump, specifically 
evaluating the PK of IQP-0528, a potent non-nucleoside reverse transcriptase 
inhibitor, in a sheep model. Our main aims were to 1) measure the drug 
distribution along the vaginal tract, and 2) quantify the reduced release rate in 
vivo compared to in vitro release conditions. Previously, a higher drug 
concentration of hydrophobic antiretrovirals delivered from a ring was observed 
proximal to the ring compared to distal locations. This system releases a 
semisolid gel containing microparticles of the drug substance, and we 
hypothesized the water-soluble polymer would aid in distributing the drug along 
the vaginal canal. We characterized the reduced in vivo release rate and provide 
evidence that it can be overcome by increasing the orifice area.
Publication: Teller RS, Rastogi R, Anderson M, Nagaraja U, Hattaway H, Hope 
TJ, and Kiser PK. 2015. Vaginal pharmacokinetics of an antiretroviral delivered 
from an intravaginal ring containing dissolution controlled hydrophilic matrices. 
Antimicrobial Agents and Chemotherapy. To be submitted.
1.10.4 Chapter 6 overview
Chapter 6 includes brief conclusions of the dissertations work in addition 
to recommendations for future research into vaginal drug delivery specifically and 
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Topical preexposure prophylaxis in terrupts  HIV transmission at 
the  site o f mucosal exposure. In te rm itten tly  dosed vaginal gels 
conta in ing the  HIV-1 reverse transcriptase in h ib ito r teno fov ir 
protected pigta iled macaques depending on the  tim ing  o f v ira l 
challenge re la tive  to  gel application. However, modest or no 
protection was observed in clinical trials. Intravaginal rings (IVRs) 
may im prove efficacy by provid ing  long-term  sustained drug 
delivery leading to  constant mucosal antiretroviral concentrations 
and enhancing adherence. Although a fe w  IVRs have entered the 
clinical p ipeline, 100% efficacy in a repeated macaque vaginal 
challenge model has no t been achieved. Here w e  describe 
a reservoir IVR techno logy th a t delivers the  te n o fo v ir  prodrug 
tenofovir disoproxil fumarate (TDF) continuously over 28 d. With 
four monthly ring changes in this repeated challenge model, TDF IVRs 
generated reproducible and protective drug levels. All TDF IVR-trea- 
ted macaques (n =  6) remained seronegative and simian-HIV RNA 
negative after 16 weekly vaginal exposures to  50 tissue culture in­
fectious dose SHIV162p3. In contrast, 11/12 control macaques became 
infected, w ith  a median o f four exposures assuming an eclipse o f 7 d 
from infection to  virus RNA detection. Protection was associated w ith 
tenofovir levels in vaginal fluid [mean 1.8 x 105 ng/mL (range 1.1 x 
104to  6.6 x 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal 
lavage samples. These observations support further advancement o f 
TDF IVRs as well as the concept that extended duration drug delivery 
devices delivering topical antiretrovirals could be effective tools in 
preventing the sexual transmission o f HIV in humans.
contro lled  drug delivery | PrEP | nonhum an prim ate  | pharm acokinetics
The prodrug tenofovir disoproxil fumarate (TDF) and its hy­drolysis product tenofovir (TFV) have been the major focus 
of HIV prevention research. TDF is one component of the two- 
drug mixture Truvada, the first US Food and Drug Adminis­
tration-approved oral preexposure prophylaxis (PrEP) agent 
against HIV acquisition in discordant couples and other high-risk 
populations (1), and TFV is the active pharmaceutical ingredient 
in the first vaginal gel to show partial HIV protection (2). Both 
molecules have a long safety record and have been widely used 
in humans with minimal toxicity. The 1% (wt/wt) TFV vaginal 
gel formulation administered 30 min before virus exposure 
provided complete protection (6/6) against multiple simian-HIV 
(SHIV) challenges (3, 4) and retained partial activity protecting 
four of six macaques that were treated once weekly with gel and 
exposed to virus twice weekly; the second exposure being 3 
d after gel application (4). Unfortunately, the TFV gel provided 
only partial protection in clinical trials when women were asked 
to use the gel before and after coitus and no protection when 
daily dosing was evaluated (2, 5). There are many factors, both 
social and biological, that may have contributed to the TFV gel 
clinical trial outcomes. However, as far as we know the most
important factor in all gel trials to date is the difficulty of sustaining 
high adherence to frequent dosing (6). Simply put, if the course 
of protective antiretroviral levels does not match the kinetics 
of viral exposure, PrEP will not be highly effective. This 
motivates the development of long duration, drug delivery 
systems such as intravaginal rings (IVRs) that may overcome 
these limitations by facilitating adherence and providing less 
variation in mucosal drug levels (7, 8).
Matrix IVRs delivering the nonnucleoside reverse transcriptase 
inhibitor (NNRTI) dapivirine and the entry inhibitor maraviroc 
are being advanced through the clinical pipeline. Neither of these 
rings, which are currently in phase 3 and phase 1 trials, have been 
evaluated for efficacy in macaques. Among all antiretroviral IVR 
efficacy studies conducted to date, only one formulation con­
ferred protection against a single, high-dose viral challenge in 
nonhuman primates, whereas the remainder yielded partial pro­
tection (9-11). None has been evaluated in repeated vaginal 
challenge models designed to mimic the repeated viral exposure 
during human sexual transmission (12). Reasons for failure of these 
device-drug combinations to provide complete protection in ma­
caque models are complex and may reflect differences in the model 
system [species, use of depo-medroxyprogesterone (DMPA), viral 
dose, and strain], the pharmacologic properties of the drugs tested,
S ign ificance
Topical prevention o f HIV is designed to  pharmacologically 
in terrupt sexual transmission a t the genital mucosa. Attem pts 
at preventing transmission in women using vaginal gels have 
yielded disappointing results in part because o f poor rates o f 
adherence. Controlled topical drug delivery using intravaginal 
ring technology should improve efficacy and adherence by 
providing sustained mucosal delivery o f antiretrovirals. In this 
paper, w e  describe a reservoir intravaginal ring tha t delivers 
tenofovir disoproxil fumarate (TDF) fo r 1 month. The ring pro­
tected pigtailed macaques from  weekly vaginal simian-human 
immunodeficiency virus challenges fo r  4 mo. The steriliz ing 
performance o f th is drug delivery system supports the concept 
tha t an intravaginal ring delivering TDF could be an effective 
too l fo r prevention o f HIV sexual transmission in women.
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and/or inadequate drug release profile of the IVRs. We hypothesize 
that IVRs that maintain a consistent level of mucosal TDF may 
provide greater protection. This notion is supported by the higher 
cell permeability and at least 100 times greater potency of TDF 
compared with TFV against HIV in vitro (13). The bioactive 
form, TFV diphosphate (TFV-DP), has the further advantage of 
a long intracellular half-life (60-150 h) (14, 15) that could miti­
gate lapses in adherence and may prove advantageous compared 
with antiretrovirals (e.g., dapivirine) that can readily diffuse from 
the intracellular to the extracellular compartments in response to 
drug concentration gradients in time and space (16).
Developing IVRs to elute the thermally and hydrolytically 
unstable TD F at therapeutically relevant rates is a challenge. 
Although TDF is more hydrophobic than TFV, its polarity is too 
high for adequate polymer solubility to deliver protective doses 
of the drug from common elastomers used in IVR technology 
such as silicone and poly(ethylene-covinyl acetate) (13). Fur­
thermore, TDF is susceptible to hydrolysis, making formulation 
of this drug in any aqueous topical dosage form impossible (17, 
18) and precluding its use in gels. W e engineered a class of IVRs 
capable of achieving high fluxes of hydrophilic antiretrovirals 
such as TFV and TDF using hollow hydrophilic polyether ure­
thane (HPEU) elastomeric tubes (Fig. 1 A and B) (19). The 
hydrophilic-hydrophobic balance of H PEU  can be tailored to 
solubilize and deliver drugs with a range of physical properties
(20) and at fluxes that achieve clinically relevant concentrations
(21). We assessed the ability of TD F IVR designs to achieve 
monthly sustainable protective levels of TDF/TFV in vaginal 
fluid and tissue by performing pharmacokinetic (PK) studies in 
pigtailed macaques. Pigtailed macaques were chosen for the 
study because of their similarities in hormonal cycling, vaginal 
architecture, and microflora to women, and previous studies in 
this model provide data on intracellular TFV-DP levels that cor­
relate with protection (4). The IVR design that generated high 










C  1  8-1 
|o) 6­16




7 14 21 28 
Time (d)
Fig. 1. TDF IVR design and in v itro  release. (A) Schema depicting mechanism o f 
drug release from  TDF reservoir IVR. Vaginal flu id  hydrates the  swellable HPEU 
tub ing (Left)and w ater is driven into the  osmotically active drug-NaCl core along 
agradient, resulting inTDF dissolution and elution from  the  IVR (Right). NaCl aids 
in establishing soluble drug in the core and achieving equilibrium  drug release 
(Fig. 2B). (B) Photograph o f macaque (left) and human (right) TDF IVR. (Scale bar: 
1 cm.) (C) Comparison o f 28-d in v itro  TDF release rates from  matrix (n =  3) and 
reservoir (n =  6) IVRs under simulated vaginal conditions (2). Data represented as 
mean ±  SD. The SDs o f some o f the  collected data are to o  small to  be visualized.
evaluated in a more extensive terminal PK study to determine the 
levels of TFV-DP in the female reproductive tract and lymph 
nodes. Finally, we tested the ability of the IVR to provide con­
tinuous protection against infection by repeated weekly vaginal 50 
tissue culture infectious dose (TCID50) SHIV162p3 challenges 
over multiple monthly IVR changes coupled to ex vivo viral in­
hibition in cervicovaginal lavage (CVL) samples.
Results and Discussion
TDF IVR Design. IVRs are divided into two well-known controlled 
release device categories: matrix and reservoir. Matrix devices 
exhibit drug release rates that decrease with time, whereas res­
ervoir devices have a rate controlling membrane that allows for 
more consistent drug flux (Fig. 1A) (8). Because matrix devices 
are simple and more easily fabricated, we originally explored the 
same matrix design strategy as the dapivirine ring (22, 23). Poly­
ether urethane (PEU) matrix TDF devices containing 10 wt% 
TDF showed a 20-fold reduction in drug release rates in vitro 
from day 1 to day 28 (Fig. 1C). A  similar effect was seen in vivo in 
rhesus macaques (n = 3) in which more than a 2-log reduction 
was noted in mean TDF vaginal fluid concentrations from 1.5 x 
105 ng/mL (range 2.3 x  104 to3.3 x  105) on day 3 to 6.3 x  102 ng/ 
mL (range 0 to 2.2 x  103) on day 21 (Fig. 2A) and no detectable 
drug on day 28 (13). The chemical stability of TDF in this device 
was also unacceptable. Although high levels of TFV were still 
detected in vaginal fluid at day 28, TDF levels were undetectable.
Given the poor performance of the TDF matrix device, we 
investigated reservoir IVR designs composed of HPEU  tubing 
with a drug-bearing core sealed by induction-melt welding into 
a torus (19). The tubing wall acts as rate-controlling membrane 
for drug release while providing the necessary mechanical sup­
port for ring retention in the vaginal canal. Simply filling the 
device with T DF alone resulted in a long drug-release lag time of 
more than 20 d (Fig. 2B). Therefore, we included osmotic agents 
to attract vaginal fluid into the core to solubilize TDF and rap­
idly establish a concentration gradient of soluble and diffusible 
drug to drive release (Fig. 1A). A  reservoir IVR designed to 
deliver a TDF formulation with NaCl (14 wt%) as an osmotic 
excipient was selected by scanning a series of osmoattractants in 
vitro (Fig. S1A). Fig. 1B shows human and macaque reservoir 
IVRs with outer diameters of 55 and 25 mm, respectively. This 
IVR design delivers in vitro 0.4-4 mg/day TDF over 28 d, with an 
average release rate of 2.3 ±  0.3 mg/d [macaque reservoir IVR 
(mean ±  SD; n =  3); Fig. 1C]. This HPEU-reservoir IVR design 
eliminated the need for exposing TDF to elevated temperatures 
required for creation of thermoplastic matrix IVRs. Functionally, 
we found that the maximum rate of NaCl release preceded the 
large increase in TDF release (Fig. 2C), implying that core hy­
dration was rate-limiting in achieving sufficient drug release. Fi­
nally, we found that we could load the wall of IVRs with TDF 
after ring fabrication by exposing the loaded device to elevated 
temperature, which decreased the lag time of drug elution (Fig. 
2D), potentially providing a loading dose of TDF. We were able to 
obtain release rates of milligram per day quantities of TDF in vitro 
from the reservoir device and thereby achieve drug levels in vag­
inal fluid at all time points, exceeding the macaque (4) and clinical 
correlate of protection (24) of ~  1,000 ng/mL of TFV in vaginal 
fluid. This was not the case with the inadequate release observed 
over time from the matrix TDF IVR (Fig. 2A) (13). Although the 
in vitro release rate from the reservoir design was not constant 
over 28 d, the IVRs generated reproducible TFV levels (Fig. 3A) 
over the first 15 d when the in vitro release rate changed the most, 
potentially implying early saturation of the system with drug or 
differences between the in vitro and in vivo TDF release rates.
Drug PK Study in Pigtailed Macaques. W e investigated the TDF 
reservoir IVRs in pigtailed macaques (n = 6) in a “28 + 2” day 
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Fig. 2. M a trix  release and design eva luation o f reservoir TDF IVR. (A) 
Comparison o fTD F released fro m  m atrix  PEU IVR in v itro  on days 3 and 21 to  
drug concentrations in vagina l f lu id  o f Chinese rhesus macaques (n =  3) in 
a 28 +  3-d study. Each data p o in t represents a single sample and th e  bar 
corresponds to  th e  mean fo r  th a t  dataset. (B) In v itro  TDF release rate from  
HPEU reservoir IVR fille d  w ith  TDF and TDF-NaCl fo rm u la tio n  under simu­
lated vaginal conditions (n =  3). Data represented as mean ±  SD. (C) In v itro  
TDF and NaCl release rates fro m  HPEU reservoir IVR under sim ulated vaginal 
conditions (n =  3). Data represented as mean ±  SD. (D) Comparison o f  in itia l 
in v itro  TDF release (up to  day 3) fro m  heat-treated and contro l-unheated 
TDF IVR (n =  3). H eat t re a tm e n t o f  th e  TDF reservo ir IVR a t 65 °C fo r  5 d 
increased TDF release in th e  firs t 2 d. Data represented as mean ±  SD.
distribution and concentration in vaginal fluid and tissue (Fig. 3 A 
and B and Fig. S2). The TDF IVR provided high TFV (Fig. 3A, 
Upper) and TDF (Fig. 3A, Lower) mean vaginal fluid concentrations 
of 7.2 x  104 ng/mL (range 7.1 x  103 to 3.5 x  105)and 1.0 x  102 ng/mL 
(range 5 to  6.1 x  10 ), respectively. The former consistently 
exceeded the TFV concentration of 1,000 ng/mL recovered in 
cervicovaginal aspirates that correlated with protection in women 
receiving 1% TFV gel (24). In addition, we detected comparable 
but more variable concentrations of the more potent TDF. Levels 
of both drugs appear stable in vaginal fluid from days 3 to 28 and 
levels seemed similar proximally and distally (Fig. 3A). TFV levels 
also appeared stable over time in proximal and distal tissues (Fig. 
3B ), whereas TDF levels were more variable (Fig. S2). This 
suggests that despite the variable drug release in vitro, the IVRs 
exhibited a minimal lag time to reach high antiretroviral con­
centrations in the macaque vaginal vault.
Because TDF hydrolytically converts into TFV, we found 
variable levels of TDF in swabs and there was no quantifiable 
TDF detected in vaginal swabs 2 d after ring removal. However, 
mean TFV levels in swabs were 4.4 x  103  ng/mL (range 2.2 x  102 
to 6.9 x  104) and in tissue were 2.9 x  103 ng/g (range 5.4 x  102 to
2.5 x  104) 2 d after ring removal (Fig. 3 A  and B ), exceeding the 
TFV levels detected after TFV gel application in clinical studies 
(2, 25). In tissues, the TFV concentrations exceeded the in vitro 
IC50 by ~80 times. These high and sustained vaginal fluid and 
tissue levels of TFV likely reflect the diffusion of luminal pro­
drug through the vaginal tissue and its hydrolysis to TFV (8). We 
do not know the instantaneous in vivo TDF release rate in the 
macaque vagina. However, as determined by the amount of re­
covered TDF from the IVRs after use in this PK study, the time- 
averaged TDF release rate was similar under both in vitro and 
vivo conditions (Fig. S1B). It has been difficult for others in 
practice to obtain and sustain these levels of drug in vivo; our
IVR delivered ~50-fold more TDF in vivo compared with the 
one other TDF IVR in the literature (26). These data and the 
prolonged half-life of intracellular TFV-DP strongly suggest that 
this drug-device combination would pharmacologically tolerate 
removal of the device for hours without significant diminution of 
drug levels. Furthermore, the high TFV levels in vaginal fluid 
and undetectable TDF levels 2 d after ring removal suggest the 
presence of a tissue and/or cellular reservoir of drug that is 
continuously exchanging with vaginal fluid.
Terminal PK Study in Rhesus Macaques. To evaluate intracellular 
TFV-DP concentrations, we administered TDF IVRs to rhesus 
macaques that were scheduled to be euthanized because they had 
been previously infected with SHIV in other studies (n = 3). In this 
14-d study, we had the opportunity to evaluate levels of the bioactive 
metabolite TFV-DP in lymphocytes from vaginal, cervical, and rectal 
tissue as well as lymph nodes, which are sites where HIV trans­
mission and dissemination is presumed to occur. Previous challenge 
studies in pigtailed macaques with 1% TFV vaginal gel suggested 
protection from SHIV infection correlated when TFV-DP levels 
in vaginal lymphocytes exceeded the IC95 of 1.4 x  103 fmol/106 
cells (4). Mean TFV-DP levels after 14 d of IVR application were 
highest in vaginal and cervical lymphocytes, 3.3 x  103 fmol/106 
cells (range 1.5 x  103 to 7.5 x  103) and 1.7 x  103 fmol/106 cells 
(range 8.4 x  102 to 3.2 x  103), respectively. The mean of the in­
tracellular levels exceeds the TFV-DP IC95 of 1.4 x  103 fmol/106 
cells and is comparable to levels that showed complete protection 
in macaques (4) (Fig. 3C). Relative to vaginal and cervical lym­
phocytes, lower drug concentrations were detected in rectal and 
inguinal lymphocytes, 13 fmol/106 cells (range 6 to 1.3 x  102) 
and 81 fmol/106 cells (range 17 to 1.3 x  102), respectively (Fig. 
3C). Additionally, we observed similar TDF and TFV levels in 
vaginal fluid and tissue to those observed in pigtailed macaques 
(Fig. 3 A  and B ). These data indicate that the IVRs provide TFV- 
DP concentrations that exceed protective levels observed pre­
viously in macaques, suggesting that the ring could confer pro­
tection against vaginal SHIV challenge.
Repeat SHIV Challenge Study. Based on achieving the TFV con­
centrations in vivo described previously, we initiated a weekly 
challenge study in sexually m ature, normal cycling pigtailed 
macaques (12). Six TDF IVR-treated macaques received weekly 
50 TCID 50 SHIV162p3 vaginal inoculations starting 6 d after 
IVR insertion (Fig. 4A ). Control macaques (n =  6  real time and 
n =  6 historical controls) were challenged similarly, of which 1 1 / 
1 2  became infected after a median of four exposures to infection, 
assuming a 7-d eclipse period from time of infection to detection 
of viral RNA in plasma; peak viral RNA levels were 3.4 x  106 ±  
1.9 x  107 copies/mL, median ± SD (Fig. 4 B and C). In contrast, 
all TDF IVR-treated macaques (6 /6) remained SHIV viral RNA- 
negative and -seronegative after 16 weekly exposures spanning 
4 mo involving monthly IVR changes. A  nonparametric log-rank 
test was used to compare survival probabilities (P = 0.0007, Fig. 
4B ). Differences in infection probabilities between control and 
treated animals were statistically significant (Fisher’s exact test, 
P  < 0.0001). The median survival time among control animals 
was four exposures, 95% CL (2, 10). All TD F treated macaques 
remained uninfected after 4 additional weeks of follow-up with 
the IVRs in place. The infection probability per exposure among 
control animals was 0.162, 95% CL (0.084-0.271); the infection 
probability among treated animals was 0.0, 95% CL (0.0-0.038). 
Estimated efficacy was 100%, 95% CL (80.31-100).
The complete protection observed in the TDF IVR-treated 
macaques is consistent with the high TFV levels in vaginal fluid 
samples taken at the time of each ring change [Fig. 5A ; 1.8 x  105 
ng/mL (mean, range 1.1 x  104 to 6.6  x  105)]. With each monthly 
IV R  change, TD F and TFV levels in vaginal fluid samples 
rem ained high (Fig. 5A). Plasma TD F levels were below
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Fig. 3. Drug PK in p ig ta iled  (28 +  2-d) and rhesus (14-d) macaques. Each 
data p o in t represents a single sample and th e  bar corresponds to  th e  mean 
fo r th a t  dataset. (A) TFV (Upper) and TDF (Lower) concentrations in p ig ta iled 
macaque vagina l f lu id  w ith  28-d TDF IVR adm in is tra tion  (n =  6). Samples 
w ere  collected proxim al (open symbols) and distal (closed symbols) to  IVR 
placem ent fo r  th e  indicated tim e  points. (B) TFV concentrations in vaginal 
biopsies fro m  28-d TDF IVR adm in is tra tion . Samples w ere collected proxim al 
(open symbols) and distal (closed symbols) to  IVR placem ent fo r  th e  in ­
dicated tim e  points. (C) TFV-DP levels in lymphocytes isolated fro m  th e  in ­
dicated tissues o f  rhesus macaques a fte r 14-d IVR adm in is tra tion  (n =  3).
detection limit [n = 102, lower limit of quantification (LLOQ) = 1 
ng/mL] throughout the efficacy study. Detectable TFV levels 
(median 8 ng/mL, range 7-19 ng/mL; n = 102, LLOQ = 5 ng/mL) 
were observed in five of 102 blood samples collected with 4 se­
quential months of TDF IVR administration. The protection is 
also consistent with ex vivo antiviral activity of CVL samples 
from two additional TD F IVR-treated pigtailed macaques not 
exposed to SHIV in parallel to the challenge study. CVL col­
lected from these two macaques over the course of 28 + 1 d 
(28-d IV R  exposure and 1 d after removal) displayed high 
antiviral activity against HIV-1 in vitro (range 73-100% ) even 
after a 1:10 dilution (Fig. 5 B and C). Importantly, and con­
sistent with the persistence of TFV in vaginal fluid, CVL col­
lected 1 d following removal of the IVR inhibited HIV infection 
by 86% (Fig. 5B). The anti-HIV activity correlated with both 
TDF and TFV levels in the CVL (Spearman PK/pharmacody- 
namic (PD) correlation; TDF: r = 0.57, P = 0.04; TFV: r = 0.61, 
P = 0.02, Fig. 5C).
Potential Behavioral, Pharmacological, and Biological Implications.
The choice of TDF over the less potent TFV, comined with 
the HPEU  reservoir IVR delivery system, may overcome several 
of the behavioral and biological limitations observed to date with 
vaginal gels and other drug-IVR combinations studied preclinically 
and clinically. The major reason for embarking on the more
complex drug delivery technology for topical antiretrovirals is 
to facilitate PrEP use, increase adherence, and thereby improve 
clinical outcomes. Many studies have shown a general increase in 
adherence as device duration increases (27, 28). Thus, it is rea­
sonable to assume that it will be easier for women to adhere to 
long-duration IVR delivery systems compared with daily, ep­
isodic, or coitally dependent gels. This is supported by the fact 
that IVRs have seen excellent product demand and commercial 
success as a form of birth control in high-income countries and 
are gaining acceptance in low-income countries (7, 29).
Pharmacologically, sustained drug delivery from reservoir-type 
devices should provide tissue drug concentrations that are con­
sistently above the level required to protect immune cells resi­
dent in and trafficking through the mucosa and submucosa of the 
genital tract over the time course of mucosal exposure to virus. 
Furtherm ore, behaviorally we need to expect and plan for the 
fact that women will likely periodically remove IVRs either 
during sex or around the time of menses. This TD F IVR may 
meet all of these requirements, whereas other drug-ring com­
bination devices have limitations. First, TD F requires signifi­
cantly lower doses than TFV because of its increased potency, 
resulting from its capability to more efficiently perm eate cell 
membranes. This property combined with the long TFV-DP in­
tracellular half-life (14) and corresponding low tissue elimination 
rate may allow for sustained activity for many hours (possibly 
days) following ring removal. W ith this IVR, we observed an 
approximate 0.5-log drop in TFV concentration in vaginal fluid 
2 d after ring removal (Fig. 3a). This differs from an NNRTI such 
as dapivirine or MIV-150, in which the drug can m ore freely 
diffuse in and out of cells and can display, in the case of dapivirine 
matrix IVRs, approximately a 3-log drop in drug concentration 
from maximum levels to 2 d following IVR removal in humans 
(16, 22). It is therefore possible that NNRTI matrix rings that
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Fig. 4. TDF IVR protects macaques fro m  repeated vaginal v ira l challenge. 
(A) Six TDF IVR-treated cycling fem ale macaques received w eekly  50 TCID50 
SHIV162p3 inoculations s tarting 6  d a fte r th e  f irs t IVR insertion. Control 
macaques (n =  6 real t im e  and n =  6  h istorical controls) w ere challenged 
sim ilarly. The ring was replaced as shown in red (every 28 d s tarting 2 d a fte r 
th e  fo u rth  virus exposure). M acaqueswere m on ito red  w eekly (un til week 20) 
fo r  presence o f  SHIV by RT-PCR and confirm ed by W estern blot. Macaques 
w ere  defined as infected and exposures d iscontinued if vRNA was detected 
in plasma fo r  2 consecutive weeks. (B) Kaplan-M eier p lo t show ing tim e  to  
in fection  fo r  TDF IVR (n =  6 ; red) and contro l (n =  6 real t im e  and 6  historical 
naive; black) groups (nonparam etric  log-rank test; P =  0.0007). The median 
number o f  exposures to  infection in the  untreated group was four. (C) Plasma 
vira l load kinetics in infected macaques aligned a t peak. The red line is the  
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Fig. 5. Drug PK fro m  efficacy study and PK/PD corre la tion. (A) M on th ly  TFV 
(open symbols) and TDF (closed symbols) concentrations in vagina l f lu id  o f 
p ig ta iled  macaques in th e  efficacy study w ith  fo u r  TDF IVR changes (n =  6 
macaques). Each data p o in t represents a single sample (proxim al o r distal to  
IVR placem ent) and th e  bar corresponds to  th e  mean fo r  th a t  dataset (n = 
12; tw o  samples per anim al). (B) To m on ito r drug PK/PD during th e  efficacy 
challenge study, tw o  m acaqueswere trea ted  w ith  TDF IVR (closed symbol) or 
placebo IVR contro l (open symbol) and CVL samples w ere collected a t the  
indicated tim es in th e  absence o f  vira l challenge. CVL samples (1 :10 d ilu tio n ) 
w e re  assayed fo r  drug levels and a b ility  to  in h ib it HIV-1bbl in fection  in TZM- 
bl cells. Results are presented as percentage in h ib itio n  o f  in fection  relative 
to  contro l wells; each data p o in t represents th e  average o f  tw o  experim ents 
conducted in tr ip lica te  (n =  2 macaques, mean ±  SEM). (C) C orre la tion o f  CVL 
(d ilu ted  1:10) an tiv ira l activ ity  against HIV-1bbl in fection  in TZM-bl cells to  
TDF and TFV concentrations (Spearman PK/PD corre la tion; TDF, r =  0.57; TFV, 
r  =  0.61). Samples w ith  TDF o r TFV levels be low  th e  LLOQ w ere  a ttr ib u te d  
th e  value o f  0.1 ng/mL so th a t data could be p lo tted  on a log scale.
deliver compounds that are not retained inside target cells may 
be m ore prone to fail in women who remove the device for a 
sustained time, particularly late in the release curve when re­
lease rates are dropping along with tissue levels (16, 22).
HIV  sexual transmission occurs in a more complex environ­
ment of sexual intercourse, semen, contraceptive hormones, 
coinfections, and other variables not explored in these studies. 
Chemoprevention strategies have to be effective in the context of 
mucosal inflammation prevalent in many women. Sex (30, 31) 
and intercurrent sexually transmitted infections (32) are associ­
ated with an inflammatory environment that may recruit and 
maintain new target cells in the mucosa and possibly alter drug 
PK. The drugs and delivery systems used must protect in the 
context of these factors. Indeed, this effect may have contributed 
to the observation in Centre for the AIDS Programme of R e­
search in South Africa (CAPRISA) 004 that immune activation 
was associated with HIV acquisition, even among women using 
TFV gel (33). Another clear and related advantage of TDF over 
TFV is the potential for providing protection against HSV-2 
acquisition and outbreaks because TDF is ~100-fold more po­
tent against HSV-2 (13). In principle, the increased potency of 
TDF over TFV could allow for more effective protection in the 
more stringent context of human sexual HIV transmission.
We designed this ring to exceed drug levels in vaginal fluid and 
tissue that correlated with protection in CAPRISA 004 (24). 
However, it is possible that lower levels of TDF, because of its 
greater potency (13), may be protective (24). Future dose esca­
lation/deescalation studies are needed to identify the minimal 
protective TDF dose via vaginal route. It is also important to
consider the need for higher concentrations of drug in settings of 
possible increased risk of HIV: among women using DMPA, 
women with other sexually transmitted infections, and following 
exposure to acutely infected males with high viral loads in semen 
(34). H ere we report full protection in normally cycling mac­
aques, but the SHIV/macaque susceptibility model using DMPA 
or coinfections with STIs have been established and the effect of 
each of these conditions on transmission in the context of this 
ring can be modeled in future macaque studies (35).
The pigtailed macaque model used here (12) is one of the 
most rigorous experimental systems available to model vaginal 
HIV exposure and infection in women because of the repeated 
exposures and a probability of infection that is at least 200 times 
that of human unprotected intercourse. The model is able to 
predict a drop in efficacy resulting from intermittent adherence 
as well as providing a range of drug levels in vaginal fluids and 
target cells that correlate with protection (4, 12, 36). Although 
the model may not fully predict clinical trial outcomes, rigorous 
and intensive PK/PD and efficacy studies can be performed that 
are simply not possible in women.
In summary, we report on an antiretroviral eluting IVR con­
ferring complete protection in a nonhuman primate model against 
frequent vaginal viral challenges. This TD F reservoir IVR 
is designed to provide drug release rates that generate high and 
consistent drug concentrations in vaginal fluid and tissue. The 
design of this reservoir IVR is simple and can be manufactured 
cost-effectively. We have developed the analogous human-sized 
IVR (Fig. 1B) that is being considered for clinical evaluation.
Methods
IVR Fabrication and in V itro  Studies. Hydrophilic elastomer HydroThane AL 
25 93A (AdvanSource Biomaterials, Inc.) tub ing  (wall thickness =  0.7 mm) was 
extruded as described previously (19). Tubing was cut to  a 7 6  ±  0.5-mm length 
and the  end sealed inan  inductive tip -fo rm ing  welder(PlasticW eld Inc.) (19).The 
open tube  was filled  w ith  TDF only o r w ith  a m ixture o f TDF (Gilead Sciences) 
w ith  NaCl [US Pharmacopeia (USP) grade, Spectrum Chemicals] or sodium ace­
ta te  (anhydrous, USP grade, Spectrum Chemicals) in d iffe ring  ratios (Fig. S1A). 
The fina l fo rm u la tion  o f  TDF and NaCl (86:14) was filled  to  achieve a fina l 
concentration o f 130 ±  10 mg TDF and 20 ±  2 mg NaCl per IVR. For a placebo 
fo rm u la tion , one-end sealed tubesw ere  filled  w ith  20 ±  2 mg NaCl per IVR. The 
open end was sealed in a second inductive weld ing step to  fo rm  a sealed rod. To 
fo rm  reservoir IVRs, the  ends were butt-w elded w ith  a thermoplastic welding 
blade to  fo rm  a ring w ith  an average diam eter o f  25 mm as previously described 
(21, 37). The devices were packaged in heat-sealed pouches (LPS Industries) and 
were placed a t 65 °C fo r  5 d to  load the  w all o f  the  IVR w ith  TDF. To fabricate 
matrix TDF IVRs, TDF-loaded HPEU, ATPU-1 (DSM Biomedical) segments was 
extruded as described (13), cut to  a length o f 66  ±  0.5 mm fo llow ed by butt- 
weld ing as described previously. Formulations w ere tested fo r  in v itro  drug 
elu tion under physiologically relevant conditions in 25 mM acetate bu ffe r (pH 4) 
a t 37 °C. NaCl release was measured using a chloride ion selective electrode 
(M ettle r Toledo) coupled to  a Seven M u lti pH m eter (M ettle r Toledo). IVRs were 
analyzed fo r  residual drug content a fte r in v itro  and in vivo studies by chemical 
extraction fo llow ed by methods reported previously (13).
Drug PK. A ll macaques w ere housed a t th e  Centers fo r  Disease Contro l and 
Prevention (CDC) (Atlanta, GA). A ll procedures were conducted under approved 
CDC Institutional Anim al Care and Use Committee protocols 2003DOBMONC (PK) 
and 2004SMIMONC (term inal PK and efficacy) in accordance w ith  the  standards 
incorporated in the  Guide fo r  the  Care and Use o f Laboratory Animals (National 
Research Council o f  the National Academies, 2010). M atrix IVRs were adminis­
tered to  female rhesus macaques o f Chinese origin (n =  3; t  =  28 +  3d). Macaque­
sized reservoir IVRs were administered to  female pigtailed macaques (TDF IVR, 
n =  6 and placebo n =  2, t  =  28 +  2 d )  and female rhesus macaques o f  Indian 
origin (TDF IVR, n =  3, t  =  14 d). The la tter rhesus macaques were infected w ith  
SHIV162p3 virus in a previous study and were used fo r  the  term inal PK experi­
ment a fter virus was no longer detectable in plasma. A ll sampling procedures 
were performed under anesthesia w ith  ketamine. In the  pigtailed macaque PK 
study, IVRs were inserted a t day 0 and removed a t day 28 and evaluated fo r 
residual drug content. Samples were taken a t days -7 , 0, 3, 7,14, 21, 28, and 30. 
For the  term inal PK study, IVRs were inserted a t day 0 and removed a t day 14 
just b e fo re  being e u th an ized , w ith  samples ta ke n  on days 0, 7, and 14. 
C o llection  and processing o f vagina l flu id s  and biopsies w e re  perform ed as
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previously described (21, 38). TDF and TFV levels invag ina l flu id  collected using 
Weck-Cels (Beaver Visitec), CVL (wash o f  genita l trac t w ith  5 mL PBS), and 
vaginal tissue (days 7, 21, and 30) were determ ined using liquid chrom atog­
raphy (LC)-MS/MS as described (21, 38). Procedures involving euthanasia and 
evaluation o f  intracellu lar TFV-DP w ere perform ed as described previously (4).
TDF, TFV, and TFV-DP levels w e re  measured in blood, vaginal f lu id , CVL, 
tissueand lymphocytes by LC-MS/MS m ethodsasdescribed previously(38, 39). 
The LLOQ fo r  TDF was 1 ng/mL (tissue and blood) and 0.5 ng/mL (vaginal 
flu id ) , LLOQ fo r  TFV was 5 ng/mL, and LLOQ fo r  in tra ce llu la r TFV-DP was 
10 ng/mL, w h ich  is equ iva le n t to  ~13 fm o l/1 0 6 cells (40). The average f lu id  
and tissue mass was 0.04 g and 0.01 g, respectively. The concen tra tion  o f 
drug in vagina l f lu id  was de term ined by converting the  change in the  swab 
m assto volum e, assuming th e  density o f  vagina l f lu id  was 1.0 g/mL. Samples 
b e low  LLOQ w ere  assigned values m idw ay betw een zero and LLOQ and 
then d iv id ing by the  mass o r vo lum e o f  the  sample.
Efficacy Studies. TDF IVRs w e re  a d m in is te re d  to  n o rm a l cyc ling , n o n ­
synch ron ized  fem a le  p ig ta iled  macaques (n =  6) fo llo w e d  by w eek ly  in ­
ocu la tion  (12) vag ina lly  w ith  50 TCID50 SHIV162p3 in six TDF-treated and 
12 un tre a te d  con tro ls  (six real tim e  and six h istorica l con tro ls) (39).The firs t 
virus exposure was started 6 d a fte r IVR insertion; thereafter, the  macaques 
were inoculated on a w eekly basis. The firs t TDF IVR was replaced on day 30; 
subsequent IVR changes w ere  done every 28 d, which corresponded to  2 d 
a fte r th e  fo u rth , e igh th , and 12th  vira l inoculation resulting in a to ta l o f  fo u r
IVR changes in th e  study period (Fig. 4A). Vaginal swabs fo r  de te rm in ing  
d rug concentration w ere  collected w ith  every IVR change. In fection status 
was m on ito red  by RT-PCR and confirm ed by serology (ZeptoM etrix ) (3, 4). 
The de tection  lim it o f  the  assay was 50 copies/mL. Positive macaques w ere 
defined as having tw o  consecutive positive PCR resultsabove de tection  lim it. 
Macaques were m onitored fo r 28 d a fte r the last viral inoculation. The antiviral 
activity o f  CVL samples diluted 1:10 in PBS was assessed using HIV-1BaL in the 
TZM-bl assay as previously detailed (41).
Statistical Methods. Fisher's exact test was used to  com pare th e  trea ted  and 
contro l groups fo r  num ber o f  in fections per to ta l num ber o fv iru s  exposures. 
A  n o n p a ra m e tric  lo g -ra n k  te s t was used to  com pare surv iva l p ro b a b ility  
curves. Spearman ra n k -o rd e r co rre la tio n  co e ffic ien ts  w e re  ca lcu la ted to  
assess associations be tw een a n tiv ira l a c tiv ity  o f  CVL and d rug  levels.
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Fig. S1. (A) M axim um , mean, and m in im um  in v itro  te n o fo v ir d isoproxil fu m ara te  (TDF) release rates over 30 d fro m  hydroph ilic  po lye ther urethane reservoir 
in travag ina l rings (IVRs) fille d  w ith  TDF and NaCl or NaAc fo rm u la tions. TDF mass per IVR was kep t constant and th e  NaCl and NaAc am ounts varied (TDF:NaCl: 
93:7, 86:14, and 79:21; TDF:NaAc: 93:7, 85:15, and 74:26; w :w , n =  3). Data represented as mean ±  SD. (B) A m o u n t o f  TDF delivered fro m  TDF IVRs determ ined 
fro m  th e  residual drug in IVR a fte r 28-d in v ivo (n =  36) and in v itro  (n =  6) studies. Each data p o in t represents a single sample and th e  bar and whiskers 
correspond to  mean and SD, respectively.
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Fig. S2. TDF concentrations in p ig ta iled  macaque vaginal tissue (28 +  2-d pharm acokinetic study). TDF concentrations in p ig ta iled  macaque tissue w ith  28-d 
TDF IVR adm in is tra tion  (n =  6). Sam pleswere collected proxim al (open symbols) and distal (closed symbols) to  IVR placem ent fo r th e  indicated tim e  points. Each 
data p o in t represents a single sample and th e  bar corresponds to  mean fo r  th a t  dataset.
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A B S T R A C T
P u rp o s e  To design a flux contro lled  p um p  (FCP) capable o f  30- 
day, con tro lled  release o f m acrom olecules to  the  vaginal mucosa. 
M e th o d s  T h e  FCP is com posed o f  a single cham ber fabricated 
fro m  a rigid therm op lastic  w ith  orifices and encloses a pellet o f 
w ater-sw ellable  p o lym er containing the  drug substance. W e  per­
fo rm e d  testing bo th  in vitro  and in rabbits. To ensure vagina 
re ten tion  in the  rabbit, w e  designed and attached an oval shape- 
m e m o ry  po lye the r ure thane re ta iner to  the  FCP a llow ing fo r 
long -te rm  intravaginal evaluation o f a solid dosage fo rm  w ith o u t 
invasive surgical im plantation.
R e su lts  T h e  orifices and swelling properties o fth e  p o lym er pellet 
contro l w a te r e n try  fo r  p o lym er hydration and expansion, and 
subsequent extrusion o fth e  drug-conta in ing gel fro m  the  orifice. A  
FCP device  conta in ing  a p e lle t co m p ose d  o f h yd roxyp ro py l 
cellulose com pounded  w ith  a m odel m acrom olecule , achieved 
contro lled  in vitro release fo r  3 0  days w ith  an average release rate 
o f 2 4  ±  2  ^g /d a y  (m ean ±  SD) and range o f  16 to  4 2  ^ g /day. W e 
observed a slightly lo w e r average release rate in vivo o f 20  ±  
0 .6  ^ g /d a y  (m ean ±  SD).
C o n c lu s io n s  T h e  size o f the  orifice and nature o f  the  swelling 
p o lym er contro ls the  hydration rate and the re b y  m acrom olecule  
release rate and duration fro m  this FCP.
K E Y W O R D S  in vivo evaluation . m acrom olecules . 
non-surgical im planta tion . vaginal delivery
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A B B R E V IA T IO N S
ABS A cry lon itr ile  butadiene styrene
C G  Carrageenan
C T M R  5-(and-6)-carboxyte tram ethy lrhodam ine
FCP Flux con tro lled  pum p
H E C  H ydroxye thy l cellulose
H P C  H yd ro xyp rop y l cellulose
IVR Intravaginal ring
M P M ode l pro te in
PK Pharmacokinetics
SMP S hape-m em ory p o lye the r urethane
T g  Glass transition tem pera tu re
I N T R O D U C T IO N
The science of using intravaginal drug delivery is less advanced 
for macromolecules like proteins, oligonucleotides and synthetic 
polymers than for small molecules (1). There have been promis­
ing results in the potential use of macro molecules for the preven­
tion of sexually transmitted infections (2- 6), vaccination strategies 
(7), and treatment of endometriosis or uterine fibroids (8). Mac- 
romolecular classes for vaginal delivery include peptides and 
proteins (2- 5,8), antibodies (9- 11), oligonucleotides (12), small- 
interfering RNA (13), and synthetic and natural polymers (6, 14). 
However, to deliver these molecules the most common approach 
has been to utilize short duration formulations (2,3,6) like semi­
solid gels that may require frequent administration, and that then 
may result in poor user adherence and variable pharmacokinet­
ics (PK). Engineering long-acting, vaginal drug delivery systems 
may increase user adherence and provide favorable PK over 
frequently dosed formulations. (1, 15, 16)
Intravaginal rings (IVR) are commercially successful long 
duration, topical delivery vehicles for small molecules, and can 
have high user compliance (17,18). However, macromolecules 
are difficult to formulate compared to small molecules given their
^  Springer
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low solubility in biomedical elastomers from which the IVRs are 
made, their size makes diffusive release through elastomers chal­
lenging, and their activity depends on complex intra and inter- 
molecular structures. Pioneering work by Saltzman (9, 10) and 
Malcolm (11) addressed the need for new solid dosage forms 
eluting macromolecules to the vaginal mucosa. This work 
displayed first-order release kinetics proportional to t1/2, char­
acterized by an initial burst followed by a continuous reduc­
tion in release rate. (9- 11) In many therapeutic situations this 
is an acceptable release profile but in some applications like 
topical prevention o f H IV  acquisition or in cases where the 
drug is toxic at high levels, better control o fth e  drug release 
rate is required. T o  overcome the low solubility and inade­
quate diffusivity in commonly utilized elastomers, they incor­
porated a high (30-50 wt.%) loading of drug an d /o r  hydro­
philic excipient exceeding the percolation threshold, to form  a 
connected porous structure (9- 11, 19,20). H ere, a potential 
drawback o f high drug or porogen loading is the decrease in 
device stiffness upon drug release, potentially leading to poor 
vaginal retention. M orrow et al. improved upon previous 
designs and engineered a new intravaginal device with small 
inserts incorporated into an IVR to decouple macromolecule 
delivery from  IVR stiffness (11). Therefore, a need exists for 
intravaginal delivery systems with improved control o f the 
drug release rate and device mechanical stiffness.
This study presents a new m ethod ofdelivering macromol­
ecules intravaginally we call a flux controlled pum p (FCP). 
The FCP is made o f a compressed water soluble polymer 
pellet (11) com pounded with a macromolecular drug and 
enclosed in a hard polymer casing. T he casing contains ori­
fices to allow influx of water/vaginal fluid and efflux o f the 
hydrated contents. M odel compounds, fluoresecently labeled 
dextran and a  model protein (MP) insulin, were selected based 
on similar molecular weights as candidate antiviral macro­
molecules (2- 5). We investigated several swelling polymers all 
p rev iously  u tilized  in  vag inal fo rm ula tion s (6 , 21 , 22), 
exhibiting a  range o f swelling rates and swelling extents. We 
controlled the release rate and duration by altering the iden­
tity o f the swelling polymers and orifice diameter. As part of 
this report, we also describe the design o f a shape-memory 
polyether urethane (SMP) retainer device as a non-surgical 
approach for long-term evaluation o f solid dosage forms for 
PK  and safety in the female rabbit reproductive tract. Lastly, 
we evaluated the FCP design in a 30-day in vivo P K  study using 
our SMP vaginal device retainer.
MATERIALS AND METHODS 
Preparation of Compressed Pellets
M o d e l c o m p o u n d s , M P , 5 - ( a n d - 6 ) - c a rb o x y te t r a -  
methylrhodamine (CTMR) labelled insulin (see supplemental
2345
materials) or 10 kDa rhodamine B dextran (Sigma Aldrich, St. 
Louis, MO), a t 1 wt.% were mixed with water-swellable poly­
mers; LF, JF and G F hydroxypropyl cellulose (HPC: Klucel 
Pharm, Mw 95, 140 and 370 kDa respectively; Hercules, Wil­
mington, DE), hydroxyethyl cellulose (HEC: Natrasol™ 250 
Hx; Ashland Chemicals, Covington, KY), or carrageenan (CG: 
Gelcarin® PC 379; FMC BioPolymer, Philadelphia, PA); using 
a homogenizer (Qiagen Tissuelyser II, Valencia, CA) for 9 min 
at 30 Hz. Pellets were formed by compression on a manual 
bench top press (Carver, Wabash, IN) at 2 metric tons for 20 s or 
2 min using a punch and die set specifically designed for 3 mm 
diameter pellets (Fig. S1; Rapid Machining, Nashua, NH).
Fabrication of Rabbit Vaginal Device Retainer
Barium sulfate at 35 wt.% (USP grade, Spectrum Chemicals, 
Gardena, CA) was compounded with SMP category MM- 
3520 with glass transition temperature (Tg) o f 35°C (SMP 
Technologies, Tokyo, Japan) using a Haake-Minilab twin screw 
extruder (Thermo Scientific, Newington, NH). T he extruder 
barrel temperature was set to 200°C with the screw speed at 
70 rpm. T o  ensure homogeneity, the mixture was extruded 
twice into strands that were pelletized using a variable-speed 
pelletizer (Randcastle Extrusion Systems, C edar Grove, NJ). 
T he subsequent pelletized extrudate was injection molded into 
an ellipsoidal shaped stem-attached devices (25 mm major axis, 
17 mm minor axis with a 2 m m  cross-section ellipse and a 5 mm 
long, 4 m m  cross-section attached rod; Fig. 1a) using a 
Babyplast 6 /10P  micro-injection molding system (ALBA En­
terprises, Rancho Cucamonga, CA) and a custom-fabricated 
aluminum mold (Sorenson Mold Inc., Midvale, UT). Injection 
molding temperatures ranged from 120°C to 190°C and mold 
temperatures ranged from 12°C to 14°C. After device fixtures 
were injection molded, SMP devices were heated to 37°Cin an 
oven and the ellipsoidal flattened to the other axis (in-line with 
stem) to allow for insertion into the vaginal catheter (Fig. 1c). 
T he devices were allowed to cool to room temperature while 
held in this position. The details o f SMP retainer device devel­
opment are described in supplemental material.
Fabrication of Flux Controlled Pump
FCPs (16 mm long, 5 m m  outer diameter and 3.1 m m  inner 
diameter) were designed in SolidWorks® and fabricated on a 
lathe from  A ” acrylonitrile butadiene styrene (ABS) rod stock 
(McMaster-Carr, Robbinsville, NJ). T he dimensions o f the 
FCP were based on previous reports testing intravaginal de­
vices (23- 25). Additionally, the dimensions o f the FCP were 
designed based on the length o fth e  rabbit abdominal vagina 
taking into account the SMP vaginal retainer. T he inner 
diameter was chosen to enclose a 100 mg pellet tightly in  the 
chamber. Orifices were manually drilled, and the diameter of 




Fig. I FCP-SMP retainer device. a Photograph showing the FCP-SMP retainer device with tw o 1.5 mm diameter orifices, containing 1 wt.%  MPin GF HPC with 
a schematic dep i ct i ng polymer swell i ng and chai n relaxati on. b X-ray o f a devi ce retai ned i n a rabb it. The SMP retai ner devi ce contai ned 35 wt.%  bari um sulphate 
as the radiocontrast agent. c Vaginal catheter to  insert the FCP-SMP retainer device composed of clear tubing with marks showing insertion length (10 cm) and 
plunger (white rod) included with an FCP-SMP device in the compressed configuration.
images were taken and distances were measured by compar­
ing to a scale. For example, 1.5 mm diameter orifices measured 
1.58 ±0.097 mm (n= 8  orifices with 3 measurements per ori­
fice). The compressed pellets were placed inside the FCP and 
the ends were closed with two 3 mm diameter ABS plugs of 
equal length and secured with ABS cement (ACE hardware, 
O ak Brook, IL) followed by curing overnight at room temper­
ature. For in vivo studies, the FCPs were butt-welded to the SMP 
retention devices (Fig. 1a) and cured overnight at room tem­
perature. The joint flashing was then trimmed flush. The device 
was wiped with isopropyl alcohol, dried overnight in a sterile 
laminar flow hood and sealed in pouches until the study.
Measure Swelling Rate of Polymers
Swelling studies were performed in D D I water at room tem­
perature on 100 mg pellets of water-swellable polymers (CG, 
H EC  or LF, J F  or GF HPC) m ade with a A ” pellet press at 
2 metric tons for 20 s. Time dependent increases in the axial 
dimension and mass of pellets were measured for LF, J F  and 
GF H PC , and CG, H EC  and H PC. Swelling index was 
calculated as a fractional increase in either mass or axial 
dimension. Swelling rate was calculated as the slope of the 
swelling index vs. time graph. (26)
In Vitro Release of Rhodamine B Dextran and MP
Release studies were perform ed in 25 m M  acetate buffer 
p H  4.2 and PBS pH  7.4 at 37°C and shaken at 80 rpm 
(25,27). D rug content was measured by dissolving a known 
amount ofmodel compound into release media and creating a 
standard curve by serial dilutions. Fluorescence measurements 
were perform ed using a Synergy2 plate reader (BioTek,
Winooski, VT) at 540 ±20 nm  excitation and 620 ±40  nm 
emission wavelengths. Total pellet content at the end of the 
studies was measured in terms of mass of polymer remaining. 
Cumulative release was calculated from measured daily re­
lease using the trapezoidal rule to calculate the area under the 
curve. Average release rates were calculated as the cumulative 
release divided by the elapsed time.
Rabbit Studies
In vivo studies were performed according to the guidelines set 
by National Institutes of Health and Association for Assess­
m en t and  A cc red ita tio n  o f L ab o ra to ry  A nim al C are  
(AAALAC). The study protocol was approved by the Institu­
tional Animal Care and Use Committee (IACUC; Protocol 
No. 09-11013) at the University of Utah. New Zealand White 
adult female rabbits (N=6; 15-16 week old, 3.5-4 kg) were 
quarantined for 1 week for acclimatization before the begin­
ning of the study. The devices were inserted using a custom- 
designed vaginal catheter system. T he system is composed o fa  
catheter m ade using an 18 cm long Tygon® tubing (3606; ID 
1 /4 ”, O D  5 /1 6 ”; Cole Parmer, V ernon Hills, Illinois) and a 
plunger with a flatten end. W e inserted the catheter 10 cm 
beyond the introitus (28) and used the plunger to expel to 
FCP-SM P device into the upper vaginal tract beyond the 
urinary sphincter. (Figure 1c) The animals were anaesthetized 
using 35 m g/kg ketamine and 5 m g/kg xylazine intramuscu­
lar m aintained with inhalation of 1.0-2.5%  isoflurane during 
device insertion. T he vaginal catheter was lubricated with 
universal placebo gel (21) to facilitate insertion. Upon com­
pletion of the study and confirmation of device retention by 
X -ray, the animals were euthanized with 3 ml saturated 
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was resected; a transverse section was cut and fixed in 10% 
formalin. H&E staining was performed by A RU P Laborato­
ries (Salt Lake City, UT).
Statistics
Single factor ANOVA and two-tailed t-test assuming equal 
variances were used to compare three or greater, and two 
different sets o f values respectively. All data has been repre­
sented as mean ± SD, N = 3 , except N = 4  for the 20 and 30- 
day arm  o f the rabbit study, with p-values denoting signifi­
cance. In vitro release o f rhodamine B dextran was plotted as 
N =  12 until day 10, N = 6  for days 15 and 20, and N = 3  for 
days 25 and 30.
RESULTS
Effect ofType and Molecular Weight of Swelling 
Polymers on in Vitro Release
The in vitro release profiles were determined for FCPs with two
1.5 m m  diam eter orifices and a  range o f  different swelling 
polymers: C G , H EC  and three different molecular weight 
H PCs (LF,JF  and GF; 95, 140, and 370 kDa respectively). 
The release rate depended greatly on the polymers used, with 
polymers with higher swelling rates imbibing more water in a 
given time and resulting in higher release rates. We initially 
compared the swelling rates o f C G , H EC and GF H PC  and 
observed that C G  swells the most and G F H PC  the least (mass 
swelling rates: C G  1.8±0.1 s-1/2 > H EC  1.4±0.09 s-1/2 > 
GF H PC  0.38±0.02 s-1/2; p <0.01; Fig. 2a). W ith the C G  
formulation, 390 ±31 i g  o f M P was observed on day 1 in 
comparison to 1 1 0 ± 3 9  i g  and 41 ± 6 .6  fig from H EC and GF 
H PC containing FCPs respectively (p< 0.01) resulting in near­
ly 100% release from  C G  FCPs in 5 days (CG (100±4.0%) > 
H EC (55±4.9%) > GF H PC (19±3.1%); _p<0.01; Fig. 3a). 
The average M P release [t=5 days] was C G  210± 8.0 i g /  
day, H EC 110± 10 ig /d a y , and GF H PC 38±6.2  ig /d a y  
(p <0.01; Fig. 3b).
Comparison ofswelling rates ofH PC s showed high molec­
ular weight H PC (GF) had the maximum swelling rate but 
disintegrated and dissolved slower than J F  and LF H PC  (axial 
swellingrates: G F6 .8 ± 1 .5  s-1/2 > JF 3 .3 ± 1 .1  s-1/2 > L F 2 .1  
± 1 .4  s-1/2; p <0.05; Fig. 2b and c). LF H PC disintegrated 
most rapidly as seen by quickly asymptoting followed by a 
decline in mass upon dissolution (Fig. 2c). This led to higher 
initial M P release with up to 45± 16%  released by day 5; 
in com parison, m oderate and  high m olecular weight 
H PCs (JF and GF respectively) resulted in 27±1.4%  and 
19±3.1%  released in the same duration (p<0.05; Fig. 3c). 
The average M P release [t= 10 days] was 69 ±18  ig /d a y  
LF, 51±11  ig /d a y  J F  and 41± 4 .2  ig /d a y  G F (p =0.07;
2347
Fig. 3d). Due to the high initial release rate for the LF 
and J F  formulations, the release dropped significantly after 
day 10 (data not shown).
Effect of Orifice Size on in Vitro Release
D rug release was observed to vary with orifice size, with a 
smaller diam eter orifice resulting in lower release (Fig. 4). For 
the orifice sizes tested; 1.0, 1.5 and 2.0 m m  diameters; the 
average M P release [t= 10days] was 3 6± 5 .0 ,4 1 ± 4 .2  and 51 
± 2 .0  ig /d a y  respectively (p<0.01; Fig. 4b). Interestingly, a 
linear relationship between total orifice area and average 
release was observed (R2 = 0.976; Fig. 4b). Furthermore, we 
performed a power law fit o f  the cumulative release (Fig. 4a) 
with an exponent value o f 1 representing zero-order release 
(29). The exponent values were 1.2, 0.99 and 0.88 for the 1.0,
1.5 and 2.0 m m  orifices respectively (R2>0.98).
Comparison of MP and Rhodamine B Dextran Release
FCPs with two 1.5 mm diameter orifices and GF H PC as the 
swelling polymer were tested in a 30-day in vitro release study 
with rhodamine B dextran as the model compound resulting 
in an average o f 24±  2.1 ig /d a y  and 79% cumulative release 
with a maximum and minimum daily release rates o f 42± 
8.2 ig /d a y  on day 3 and 16± 1.8 ig /d a y  on day 20 respec­
tively (Fig. 5). T he average release rate o f rhodam ine B 
dextran was statistically comparable to M P [t= 10 days] with 
35± 7 .0  ig /d a y  and 41± 4 .2  ig /d a y  o f rhodamine B dextran 
and M P respectively (p = 0.2, Fig. 5 and Fig. S2a and b). A 
power law curve fit o f the cumulative release profiles for both 
model compounds was performed (29), with exponent values of 
0.99,0.83 (rhodamine B dextran, R 2 = 0.99 over 10 and 30 days 
respectively), and 0.99 (MP over 10 days, R 2 = 0.99) validating 
that near zero-order release was achieved in the first 10 days 
(Fig. 5b and Fig. S2a and b ). The release rate over 30 days 
appeared biphasic with an increased release rate in the first 
10 days compared to beyond day 10 (Fig. 5a). This was appar­
ent by comparing the calculated average release rate over 
different time periods. The average release rate was 35 ± 
7.0 ig /d a y  from days 1-10, 20±1.8  ig /d a y  from days 10­
30, and 24± 2.1 ig /d a y  from days 1-30. Depending on the 
device design and polymer used there are multiple processes 
that are driving release, however if the rhodamine B dextran 
and GF H PC release correlate this suggests that hydration and 
transport o f the H PC gel out of the FCP was the major factor 
controlling rhodamine B dextran flux. Cumulative percent 
release o fG F  H PC was 40±4.1% , 63±5.9%  and 78±1.9%  
on days 10, 20 and 30. This was comparable to the cumulative 
percent release of rhodamine B dextran o f 39±7.8% , 54± 
7.4% and 79±6.9%  on days 10, 20 and 30 (p = 0.58, 0.11 
and 0.93 for days 10, 20 and 30 respectively). The cumulative 




Fig. 2 Swelling properties of hydrophilic polymers. a Swelling rate of GF HPC, HEC and CG determined by mass. b Swelling rate of LF JF and GF HPC 
determined by axial dimensions. c Mass swelling indices of LF, JF and GF HPC demonstrating that LF asymptotes the quickest because of dissolution compared to 
the others.
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in vitro elution profile correlated to cumulative percent release of 
GF HPC measured from residual content on days 10, 20 and 
30 (Spearman correlation of r =0.90, p =0.002; Fig. S2c).
Furthermore, we performed in vitro release on the rhoda- 
mine B dextran containing FCPs in two release medias for 
10 days, PBS pH  7.4 and 25 m M  acetate buffer pH  4.2, to 
mimic pH  conditions in the rabbit and hum an vaginal tracts 
(25,30). No statistical difference was observed in the two cases;
therefore an average of the two is reported (p = 0.8; Fig. 5). For 
assessment of how the FCP functions, we fabricated a clear, 
acrylic device to visualize polymer hydration and dissolution. 
W ater entered through the orifices with initial polymer hy­
dration visually observed around the orifices which spread 
longitudinally towards the ends by day 5. The photographs 
illustrate the time-dependent hydration and release of the M P 
containing HPC gel during the initial 15 days. (Figure 6)
Fig. 3 In vitro MP release. a 
Cumulative release of MP and (b) 
average release rate and cumulative 
release of MP over 5 days from 
FCPs with GF HPC, HEC and CG 
as the swelling polymers. c 
Cumulative release of MP and (d) 
average release rate and cumulative 
release of MP over 10 days from 
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Fig. 4 In vitro MP release. a 
Cumulative in vitro release of MP 
from FCPs as a function of orifice 
size: 1.0, 1.5 and 2.0 mm. b In vitro 
average release rate and cumulative 
release compared to orifice area. A 
linear correlation between orifice 
area and average release [t =
10 days] was observed (R2 = 
0.976).
In Vivo Rabbit Study
In a 30-day study we tested the safety and PK  of rhodamine B 
dextran loaded FCP-SMP retainer devices in adult female 
New Zealand White rabbits (Fig. 1). D rug release calculated 
by residual polymer extraction after 10, 20 and 30 days in vivo 
application was lower compared to in vitro samples. W e noted 
a marked difference for all time points (p = 0.020, 0.002 and 
<0.0001 for 10, 20 and 30-day arms; Fig. 7a). The diminished 
release measured in vivo com pared to in vitro resulted in a 
calculated average rhodamine B dextran release rates of 20 
±0.6  in vivo and 24±0 .8  in vitro ^ g /d ay  over 30 days, a 16% 
reduction. The latter is not significantly different from the 
average release rate calculated from the 30-day cumulative 
profile (24 ±2.1 ^g /day , p  =0.98). No irritation or immune 
cell infiltration was observed in tissue sections from treated 
animals in comparison to the naive suggesting that the devices 
were well tolerated (Fig. 7 and Fig. S6).
DISCUSSION
The main objectives of these studies were to first determine if 
the FCP could be used for prolonged vaginal delivery of 
macromolecules based on simultaneous control o f water entry
into the device and polymer gel extrusion out of the device. 
Next, we sought to improve testing of vaginal solid drug 
delivery systems in the rabbit model by engineering a retainer 
device that could be used without surgery. To achieve these 
objectives, we fabricated a series of prototype devices which 
we evaluated in vitro for drug release properties and then for 
in vivo perform ance in the rabbit. O ur initial design was 
inspired by the semipermeable membrane of the elementary 
osmotic pum p that controls the hydration of the core pellet 
and thereby the release rate of its contents (31). W e substituted 
the function of semipermeable m embrane for an orifice of 
variable size in a non-perm eable rigid polym er casing 
imparting control of hydration and release of the gel from 
the device and providing mechanical integrity for long dura­
tion delivery. O ur device consists of a cylindrical ABS ther­
moplastic casing with two orifices for opposing water diffusion 
in and drug-loaded gel extrusion out of the casing (Fig. 1a). In 
the case of pellets made from high molecular weight polyelec­
trolytes like CG, the polymer swelling is driven by osmotic 
gradients between the hydrating gel and water, and solvent- 
polymer mixing (32); in non-ionic polymers like H EC and 
H PC , pellet hydration  and swelling is driven by water- 
polymer mixing only (29). O ur data show that by modulating 
the size of the orifice and swelling properties of the polymers 
we can modify the release rate o f the molecules entrained in
Fig . 5 In vitro release of rhodamine 
B dextran in GF HPC. a In vitro 
release rate and (b) cumulative 
release of rhodamine B dextran 
over 30 days. The line on the 
cumulative release graph (b) 
represents a power law curve fit of 
the data with the associated 
exponent and R2 values. FCPs 
contained 1 wt.%  rhodamine B 
dextran in GF HPC with two 
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Fig. 6 Mechanism of release from the FCP Photographs showing acrylic MP 
loaded FCP depicting polymer hydration and release duringthe initial 15 days. 
The devices had two 1.5 mm diameter orifices and contained a GF HPC 
pellet with 1 wt.%  MP Water enters in through the orifices due to  a 
concentration gradient resulting in polymer hydration, expansion and release.
the core pellet. A 100 mg pellet of GF H PC with 1 wt.% drug 
enclosed in the FCP resulted in an average release rate of 
24 ^g /d ay  over 30 days in vitro (Fig. 5).
O u r observations support that polymer hydration and 
swelling rate are critical variables in controlling the drug 
release rate. We observed dramatic differences in in vitro re­
lease rates from FCPs containing three polymers with different 
kinetics and extent of hydration: CG, H EC and GF HPC. All 
polymers selected have been tested for safety in vaginal for­
mulations (6,21,22). CG  formulations exhibited the greatest 
swelling rate and extent followed by H EC  and GF H PC 
resulting in the highest release rate  with approxim ately 
100% drug released by day 5 (Fig. 3a and b). We previously 
published on a vaginal osmotic pum p that is conceptually 
similar to this FCP and delivered a small molecule drug in a 
crystalline form (33). Formulations containing CG  or HEC 
that displayed nearly complete release over 5 and 10 days
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could be suitable for several important indications in wom en’s 
health, including antibiotics for treatment of bacterial vagino­
sis, antifungals for vaginal candidiasis, and antiprogestins for 
cervical ripening. GF H PC formulations showed controlled 
release over the initial 5 days with the largest am ount of 
hydrogel remaining within the casing compared to C G  and 
HEC; therefore we tested the effect of H PC molecular weight 
on in vitro release for longer duration release. Generally, poly­
m er dissolution depends on chain length, with shorter poly­
m er chains dissolving more rapidly (29). Among the three 
molecular weights tested, high molecular weight H PC (GF) 
exhibited greater polymer swelling rate and lower dissolution 
rate (Fig. 2b and c). Low (LF) and m edian (JF) molecular 
weight H PC displayed higher initial release that decreased 
beyond day 10, compared to GF (Fig. 3c and d). Since the 
lower molecular weight LF and JF HPCs swelled less and 
dissolved more readily (Fig. 2) the mechanism of release may 
be more influenced by diffusion ofthe model drug through the 
swollen material in the casing and out of the orifice than the 
simultaneous co-transport of the gel and its contents from the 
orifice as in the case of GF H PC, H EC and CG.
W e established that orifice size was another im portant 
design variable impacting release. T he average release rate 
linearly depended on orifice area suggesting drug release rate 
was dependent on the rate of water entry and polymer swell­
ing and that these rates can be modulated with orifice area. 
We selected the 1.5 mm diameter orifice FCP for 30-day 
in vitro release studies since the 2.0 mm diameter orifice FCP 
released approxim ately 50% of the model com pound in 
10 days, leaving an insufficient amount to achieve controlled 
release over 30 days. M oreover, the 1.5 mm  orifice FCP 
exhibited a more zero-order release profile in the first 10 days 
of release compared to the 1.0 and 2.0 mm orifices. (Figure 4)
W e evaluated the release of two model macromolecules, 
rhodamine B dextran [10 kDa] and M P [7.4 kDa], in the 
design with GF H PC as the swelling polymer and two 1.5 mm 
diameter orifices. In vitro studies with the extended high radius 
of gyration rhodamine B dextran molecule and compact MP 
molecule demonstrated release rate was comparable and was
Fig. 7 In vivo rabbit study. a Mass and percent of polymer pellet released under in vivo and in vitro conditions determined by residual content. Representative H&E 
histology sections o f vaginal tissue from (b) Naive and (c) FCP-SMP device treated animals (30 days). No significant immune cell infiltrates, epithelial inflammation 
o r disruption was seen.
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a function o f polymer swelling and dissolution (Fig. S2a and 
b). The 30-day release profile (Fig. 5) ofrhodam ine B dextran 
was biphasic with a higher, nearly zero-order release rate in 
the first 10 days followed by a reduced and nearly constant 
release rate for the remaining duration. T he decreased release 
rate after day 15 likely occurred from the decreasing am ount 
o f hydrated polymer in the casing causing slower extrusion 
and dissolution o f the gel from the device (Fig. 5). O ften a 
time-independent release rate is desired to maintain a protec­
tive and safe drug concentration in the therapeutic window. 
However a release profile with an  increased release rate early 
on could provide a loading dose to m ore quickly attain high 
drug concentration in tissue while the lower release rate later 
on could provide a m aintenance dose. (1) W e propose that 
drug release was initiated by water entry through the orifices 
diffusing down its concentration gradient. As w ater continues 
to enter, the polymer expands and exerts an internal pressure 
on the rigid polymer casing, causing extrusion o f the visco­
elastic drug-loaded gel from the orifice (Fig. 6). In addition to 
the extrusion o f the polymer with the entrained model com­
pound, it  is possible for the m odel com pound to diffuse 
through the swollen polymer out o f the device. The diffusion 
coefficient o f the entrained compound in the polymer will 
increase as the water content increases (29). However, the 
cumulative percent release ofrhodam ine B dextran correlated 
to GF H PC  from the FCP on days 10, 20 and 30 (Fig. S2c). 
This supports that the predominate mechanism ofrhodam ine 
B dextran release was from  extrusion o f  H PC  gel from the 
FCP and not diffusion o f the rhodamine B dextran through 
the swollen H PC  gel within the FCP casing.
Development o f new intravaginal drug delivery technolo­
gies necessitates small animal models to assess safety and PK  as 
a function o f device design. The rabbit model is the standard 
non-rodent species approved for vaginal irritation studies 
(34—36) during preclinical testing o f vaginal products (37). 
However, the application o f this model for understanding 
intravaginal device safety and PK  is limited by the invasive 
surgical procedure needed to suture the device to the vaginal 
wall to ensure retention (23- 25). While peritonitis and inflam­
mation were not reported, it  is unknown if the traum a and 
resulting healing response influences drug release and PK. 
Therefore, a non-surgical approach could significantly im­
prove and expand the use ofthe rabbit model for intravaginal 
device testing.
Accordingly, we designed an ellipsoidal SMP vaginal de­
vice retainer attached to the FCP for non-surgical retention in 
the rabbit cervicovaginal tract (Fig. 1 and Fig. S5). Prior to 
insertion, the device was warmed to 37°C, above the SMP Tg, 
and the m ajor axis flattened for placem ent into a vaginal 
catheter used to introduce the drug delivery system. We 
allowed the device to equilibrate  to room  tem pera ture  
resulting in a device maintaining the elongated, flat arrange­
ment. (Figure 1c) Upon insertion, the SMP transitioned from
2351
room  to rabbit body temperature, and the straight arrange­
m ent necessary for device insertion relaxed into the native, 
ellipsoidal shape for device retention (Fig. 1a and b ). Utilizing 
the SMP elastomers with a Tg between room  and body 
temperature facilitated easy insertion through the catheter. 
W e observed attenuated release in vivo compared to in vitro 
conditions with a  16% reduction in total release over 30 days. 
Possibly the reduced release rate observed in vivo resulted from 
insufficient fluid to drive polymer hydration and drug release 
compared to in vitro sink conditions. Additionally, no signifi­
cant immune cell infiltrates or inflammation was observed 
with the devices, suggesting good tolerance. (Figure 7 and 
Fig. S6)
A sustained, solid dosage form  for vaginal delivery has 
multiple design inputs including three key requirements: de­
sired drug release rate and duration, device retention, and 
manufacturability. However, except for a  recent publication 
(11), prior reports in the field emphasized macromolecular 
delivery with less attention towards device retention or ease of 
fabrication. These device designs demonstrated high hydro­
philic drug a n d /o r  excipient loading (30-50 wt.%) in hydro­
phobic polymers can form  a connected porous structure 
resulting in osmotically driven controlled and sustained re­
lease (9- 11, 19,20). M orrow et d . presented the first hum an 
device for intravaginal macromolecular delivery, displaying 
28-day in vitro release o f BSA, with a daily release profile 
approximately proportional to t1/2 that decreased constantly 
with time (11). By adjusting the design o f the FCP, we were 
able to obtain a more constant release rate over a month 
duration (Fig. 5). Additionally, the FCP is simple to manufac­
ture, including thermoplastic parts suitable for injection mold­
ing or hot-m elt extrusion, and pellets by tablet manufacturing 
technology.
Increasing interest in developing multipurpose prevention 
technologies for sexually transmitted infections and unwanted 
pregnancy prevention can benefit from a platform capable of 
simultaneous delivery o f both  small and m acrom olecular 
drugs (38). O u r results provide motivation for integrating up 
to four FCPs into an IVR as pods or segments, for simulta­
neous, controlled delivery o f  macromolecular and small m o­
lecular weight drugs from  the FCP and IV R  respectively 
(11,39—41). While the mechanical stiffness o f the IVR will be 
altered by the incorporation o f one or multiple FCPs, this 
design would not exhibit reduced rigidity upon macromole­
cule release as observed with previous matrix designs with 
high loadings above the percolation threshold (9, 10, 19,20). 
T he FCP design provides a tunable platform  where drug 
release rate can be controlled by altering the num ber ofFCPs 
per IV R  and drug loading. Furthermore, altering the swelling 
polymers and orifice size modifies the release rate and dura­
tion. Moreover, by incorporating multiple FCPs into an IVR, 
i t  would be possible to deliver different drugs a t individual 




drug release from the FCP and this can lead to macromolec- 
ular degradation reactions. M oreover the drug could interact 
or bind to the swellable polymer and this could reduce the 
overall drug release. Therefore, the activity and physical sta­
bility ofthe macromolecule released from  this system needs to 
be assessed.
CONCLUSIONS
This study presents the use an FCP device for delivery of 
macromolecules to the vaginal mucosa for prolonged dura­
tion. The simple design involves a single cham ber with two 
orifices, enclosing a drug loaded polymer pellet that when 
swollen pressurized the FCP chamber. In this first study, we 
demonstrate tens o f micrograms release p er day of model 
macromolecular compounds, M P and rhodamine B dextran, 
from  a rabbit-sized device. We observed a small decrease in 
drug release rate in vivo compared to in vitro. Further, this study 
describes an improved in vivo methodology for testing vaginal 
solid dosage forms in the rabbit model that does not require 
surgery by using an ellipsoidal device for vaginal retention. 
These results support further development o f the FCP for 
sustained intravaginal delivery o f macromolecules. Utilizing 
the FCP technology in combination with other drug delivery 
schemes adds to our ability to create drug delivery devices to 
improve women’s health.
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MATERIALS AND METHODS 
Fluorescent labeling of Insulin
Bovine insulin was fluorescently tagged with 5-(and-6)-carboxytetramethylrhodamine (CTMR) 
succinimidyl ester for ease of detection. CTMR succinimidyl ester was prepared by reacting 
CTMR (3.0 mg, 7.0 |jmol), N, N'-Discuccinimidyl carbonate (2.2 mg, 8.5 |jmol) (Sigma Aldrich, 
St. Louis, MO), and 4-Dimethylaminopyridine (0.93 mg, 7.6 |jmol) (Acros Organics, Morris 
Plains, NJ) in 0.43 ml of dry DMF. The reaction was run at RT for 4 hrs. The percent 
esterification was determined by HPLC using relative peak areas of CTMR before and after the 
reaction. The reaction mixture was run on a Hewlett-Packard 1050 Series HPLC on a Jupiter 
C18 column (4.6 x 250 mm, 5 |jm; Phenomenex, Torrance, CA) at 25°C at a flow rate of 1.0 
ml/min using an acetonitrile (ACN)-water (0.1% TFA) gradient (0-2 min: 10% ACN, 2-7 min: 10­
73% ACN, 7-9 min: 73% ACN, 9-10 min: 73-10% ACN, 10-12 min: 10% ACN). Data collected at 
254 nm was used to calculate a percent esterification of 90%. Bovine insulin (25 mg, 0.88 mmol; 
Sigma Aldrich, St. Louis, MO) was dissolved in 5 ml of 0.1 M NaHCO3 solution with 1.25 M urea, 
pH 8. This solution (1.5 ml) was added to the CTMR ester in a molar ratio of 1:4.8. The reaction 
was continued for 3 hrs at RT, followed by addition of 0.1 M HCl (2 ml) to stop the reaction. The 
mixture was stored at 4°C until separation. The unreacted dye was separated using HiTrap™ 
desalting columns (GE Healthcare, Bellefonte, PA) according to manufacturer's protocol, and 
the fractions containing labeled insulin were lyophilized. The labeled product was mixed with 
insulin in a 1:50 ratio by suspending in DDI water followed by lyophilization and stored at -20°C 
until the study.
Fabrication of O-shaped vaginal retainer devices
O-shaped devices were produced similarly to oval SMP devices as described previously in the 
main methods section, with the following alteration. Tecoflex® EG-85A polyether urethane
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(Lubrizol, Wickliffe, OH) was compounded with barium sulphate (35 wt%) using a Haake-Minilab 
at 145°C and 70 rpm. A custom-fabricated aluminum mold was used to produce a device with 
17 mm outer diameter and 2 mm cross-section ring with an attached rod, 5 mm long and 4 mm 
cross-section. Injection molding temperatures ranged from 120°C to 180°C and mold 
temperatures ranged from 12°C to 14°C during fabrication.
Fabrication of T-shaped vaginal retainer devices
5.5 mm diameter Tecoflex® EG-85A polyether urethane rod was extruded using a Haake- 
Minilab at 145°C and 70 rpm. The extruded rod was cut into 12 mm segments. Then 8 mm of 
the rod was bisected. Each side of the bisection were held apart in a T-shape with a mold and 
annealed at 65°C for 15 mins and cooled to RT.
RESULTS AND DISCUSSION 
Effect of compression time on release
The release rate did not depend on compression time for pellet fabrication under the conditions 
tested: compression times of 20 s and 2 min (p = 0.6 comparing 10 day cumulative release; Fig. 
S1). For further studies, all FCPs had pellets compressed for 20 s with a force of 2 metric tons. 
We hypothesize that due to constraints with tooling used, we could not make a harder and 
stronger pellet that could result in a reduced release rate.
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Figure S1. (a) In vitro release rate and (b) cumulative release of MP from FCPs comparing 
different compression times for pellet fabrication: 20 s and 2 min.
a b c
□ Rhodamine B dextran □ Rhodamine B dextran
Time (d) Time (d) HPC release (%)
Figure S2. (a) In vitro release rate and (b) cumulative release of MP and rhodamine B dextran 
over 10 days. The line on the cumulative release graph (b) represents a power law curve fit of 
the data with the associated exponent and R2 values. (c) Cumulative rhodamine B dextran 
release calculated from in vitro elution profile correlated to GF HPC release from residual 
content on days 10, 20 and 30 (Spearman correlation of r = 0.90, p = 0.002). FCPs were 1 wt% 
model compound in GF HPC with two 1.5 mm diameter orifices.
Design of vaginal device retainer fo r in vivo studies
To improve upon previous surgical implantation procedures utilized for vaginal devices, initial 
rabbit studies tested three different retainer designs, O, T and oval shaped elastomeric devices, 
for device retention in the cervicovaginal tract and adverse effects for 14 days (Fig. S3). The 
design requirements for the retainer devices include: (1) device insertion without surgery, (2) 
proper retention in the cervicovaginal tract without rotation, (3) easy incorporation of a 
representative segment of an IVR formulation, and (4) no observable mucosal irritation or 
inflammation. In the first study, we tested two different retainer device configurations, O's and 
T's (n = 3). Only one O-device was properly retained, the second was expelled and the third 
was retrieved from the urovaginal tract. No T-devices were expelled, however all devices
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rotated 90° with two retrieved from the cervicovaginal tract and one from the urovaginal tract. 
(Fig. S3) Moreover, marked epithelial disruption was noted with T-devices (Fig. S4).
Figure S3. Summary of the retention and orientation of different designs of retainer devices 
during 14 day studies, including O, T and oval-shaped devices.
The second study evaluated a higher number of O-devices (n = 12) to further elucidate critical 
parameters in device retention. Since no T-devices were retained without rotation and tissue 
disruption was observed, the design was discontinued. Out of the 12 O-devices, six were 
located in the cervicovaginal tract, five were properly retained and one was found rotated 180°; 
two retrieved from the urovaginal tract with one rotated 180°; and four expelled (Fig. S3). 
Measurements of resected vaginal tracts and their correlation to device retention suggested 
increasing the retainer device width without altering the overall length may lead to less 
expulsion. Furthermore, the retainer devices were difficult to compress and push through a 
catheter. Therefore, we made two design modifications; (1) altered the shape from circular to 
ellipsoidal and (2) the retainer was fabricated from SMP instead of Tecoflex. The SMP utilized 
with a Tg of 35°C resulting in a malleable, elastomeric device at body temperature and a stiff
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device at RT facilitating easy insertion with the vaginal catheter. Prior to insertion, retainer 
devices were warmed to 37°C, the major axis flattened to ease insertion through the catheter. 
Upon introduction in the vaginal tract, the SMP transitioned from room to body temperature, and 
relaxed into the native, ellipsoidal shape necessary for device retention. In study 3, we tested 
the oval-SMP retainer devices (n = 8). All devices were properly retained without rotation for 14 
days (Fig. S3 and S5). No epithelial disruption or inflammation was noted (Fig. S4) leading to 
oval-SMP retainer devices to be utilized for further in vivo experiments described in the main 
text of the paper. Additional H&E micrographs from the 20 and 30-day time points evaluating the 
FCP-oval SMP retainer device are presented in Fig. S6.
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Figure S4. Representative images of H&E stained vaginal sections from the different study 
groups: (A, B) naive, (C, D) T-device, (E, F) O-device and (G, H) oval-SMP device. Epithelial 
disruption noted for panel D.
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Figure S5. Time dependent x-ray of barium sulphate loaded oval retainer devices attached to a 
drug delivery segment during a 14 day study.
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Time = 20 days Time = 30 days
Figure S6. Representative images of H&E stained vaginal sections from the 20 and 30 day 
endpoints evaluating the FCP-oval SMP retainer device.
CHAPTER 4
CONTROLLING THE HYDRATION RATE OF A HYDROPHILIC MATRIX IN THE 
CORE OF AN INTRAVAGINAL RING DETERMINES 
ANTIRETROVIRAL RELEASE
Ryan S. Teller, David C. Malaspina, Rachna Rastogi, Justin T. Clark, Igal
Szleifer, and Patrick F. Kiser
Manuscript submitted to The Journal of Controlled Release
4.1 Abstract
Intravaginal ring technology is generally limited to releasing low molecular 
weight species that can diffuse through the ring elastomer. To increase the 
diversity of drugs that can be delivered from intravaginal rings, we designed an 
IVR that contains a drug matrix encapsulated in the core of the IVR whereby the 
mechanism of drug release is uncoupled from the interaction of the drug with the 
ring elastomer. We call the device a flux controlled pump, and it is comprised of 
compressed pellets of a mixture of drug and hydroxypropyl cellulose within the 
hollow core of the ring. The pump orifice size and chemistry of the polymer 
pellets control the rate of hydration and diffusion of the drug-containing 
hydroxypropyl cellulose gel from the device. A mechanistic model describing the 
hydration and diffusion of the hydroxypropyl cellulose matrix is presented. Good 
agreement between the quantitative model predictions and the experimental 
studies of drug release was obtained. We achieved controlled delivery of multiple 
antiretrovirals ranging from Mg/day to mg/day release rates by altering the orifice 
design, drug loading, and mass of pellets loaded in the device. This device could 
provide an adaptable platform for the vaginal drug delivery of many molecules.
4.2 Introduction
Over 2 million new HIV infections occur annually, predominately through 
sexual transmission (1), urging the development of new technologies to control 
the pandemic. Recently, several clinical trials have provided evidence that 
prophylactic oral and vaginal administration of antiretrovirals can prevent the
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sexual transmission of HIV (2, 3). In particular, clinical studies evaluating a 1% 
tenofovir vaginal gel resulted in modest to no reduction in HIV incidence (4, 5). 
The clinical failures of the tenofovir gel likely stem from low user adherence and 
application-dependent drug pharmacokinetics of the gel formulation (5, 6) leading 
to an insufficient drug concentration in the local tissue where the initial 
transmission events occur (7, 8). This drives the developmental efforts towards 
longer duration delivery systems like intravaginal rings (IVRs) that may provide 
higher adherence than gels (9-11) and improved drug pharmacokinetics as a 
result of the sustained drug delivery (8, 12). Despite more than four decades of 
research into IVR technology, the chemical properties and delivery requirements 
of the drug typically governs the elastomer selection, previously limiting this 
product for delivery of hydrophobic molecules (8, 13, 14). However, the need for 
new HIV prevention technologies resulted in a resurgence of IVR development in 
the last decade. This has led to new ring designs and utilizing new polymers to 
enable the delivery of hydrophilic and macro-molecules at mg/d delivery rates 
that were previously unachievable (12, 15-18). Of particular interest to this work 
are pod/insert vaginal rings where small drug delivery systems are held within the 
ring body, separating the drug delivery requirements from the mechanical 
properties (15, 18-20). Nevertheless, even with these new materials and designs, 
to achieve extended duration release, the drug molecule must still diffuse through 
either the ring elastomer or the polymer of a drug delivery device embedded in 
the ring body leading to the requirement to match the polymer to the drug. New 
IVR designs where drug release does not depend on the drug solubility and
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diffusivity in the polymers of the IVR are needed and would enable the delivery of 
drugs irrespective of the chemical properties of the drug.
Osmotic pumps can achieve controlled and sustained release of drugs 
with a range of chemical properties and molecular weights, with the drug 
potentially acting as the osmotic agent or simply releasing as a suspension of 
particles in a solution or semisolid gel (21, 22). However, osmotic pump 
technology has been under-utilized for topical drug delivery. We designed the 
first intravaginal osmotic pump tablet for multiday antiretroviral delivery and 
achieved controlled release over 10 days in sheep (17). We then modified the 
osmotic pump design by substituting the function of the semipermeable 
membrane with orifices in a rigid non-water permeable casing. The orifices and 
swelling properties of the polymer pellet control both water entry into and release 
of a drug containing semisolid gel from the orifices of this flux controlled pump 
(FCP) (23). The design and function of the FCP is fundamentally different from 
an osmotic pump. Fluid entry occurs through the semipermeable membrane of 
an osmotic pump, whereas fluid entry only occurs through the orifices of a FCP, 
reducing the hydration kinetics and thereby resulting in longer duration controlled 
release. However, in both osmotic pump tablet and FCP designs, we exploited 
the expansion of a high molecular weight polymer caused by hydration to deliver 
a drug-loaded gel through an orifice (17, 23).
Herein we present the design and evaluation of a FCP integrated into an 
IVR with pseudo zero-order release kinetics of many leading HIV prevention 
antiretrovirals. We demonstrated a linear relationship between the release rate of
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the hydrophobic drug IQP-0528 from the device to drug loading and orifice area 
in vitro. Moreover, depending on the molecule delivered, we observed that the 
hydration kinetics and swelling properties of the polymer pellet control drug 
release. This suggests that for hydrophobic and macro-molecules, the drug 
solubility and diffusivity in the swollen polymer matrix has a negligible influence to 
the overall drug release, whereas for more hydrophilic molecules, the drug 
diffusion through the polymer matrix contributes to drug release. This 
differentiates the FCP from other IVR platforms where drug release depends 
entirely on drug diffusion and solubility in the ring elastomer (8, 13, 14). In 
addition, to aid in the design of this system and to understand the mechanism of 
drug release, we developed a finite element model that reproduces the drug 
release behavior for different orifice geometries, and drug type and loading. This 
model results in a fast and accurate tool to design this FCP device and supports 
the hypothesis that polymer hydration controls drug release from these systems.
4.3 Materials and Methods
4.3.1 Fabrication of flux controlled pumps
IQP-0528 (ImQuest Biosciences, Frederick, MD), dapivirine and maraviroc 
(DPV and MVC respectively; International Partnership for Microbicides, Silver 
Spring, MA), tenofovir and tenofovir disoproxil fumarate (TFV and TDF 
respectively; Gilead Sciences, Foster City, CA), and 10 kDa rhodamine B dextran 
(Sigma Aldrich, St. Louis, MO) were each geometrically mixed with 
hydroxypropyl cellulose (HPC; GF, MW = 370 kDa; Klucel Pharm, Hercules,
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Wilmington, DE) to achieve a range of loadings from 0.9-15 wt% IQP-0528 in 
HPC, 10 wt% DPV, MVC, TFV, and TDF in HPC, and 0.9 wt% rhodamine B 
dextran in HPC. Pellets, 4 mm in diameter and 51 ± 1 mg, were formed by 
compression as previously described (23). Tecoflex aliphatic polyether 
thermoplastic polyurethane (EG-65D; Lubrizol Advanced Materials, Wickliffe,
OH) tubing was fabricated by hot-melt extrusion to create final tubing dimensions 
of 0.7 mm wall thickness and 5.5 mm diameter (12). The tubing was cut to a 
length of 36, 40, and 44 ± 0.5 mm for FCP with 2, 3, and 4 pellets, respectively. 
Tubing lengths were chosen so that 2, 3, and 4, 50 mg pellets fit snugly inside 
the device. One end was sealed by inductive tip-forming welding (PlasticWeld 
Systems, Inc., Newfane, NY). The orifices were manually drilled and the diameter 
was measured using a stereomicroscope and compared to a scale. The standard 
deviation of the orifice diameter was 3-4% of the diameter (at least 3 orifice with 
3-4 measurements each). Next 2, 3, or 4 compressed pellets were inserted into 
the open end of the device followed by sealing the second end by inductive tip- 
forming welding similarly to the first weld.
4.3.2 In vitro drug release testing
In vitro drug release was measured from individual FCPs in 20 mL of 25 
mM acetate buffer pH 4.2 at 37°C and 80 rpm shaking (N = 3). The release 
media was replaced daily. To measure the release rates of IQP-0528 and DPV, 
the complete release media was collected on days 1, 2, 3, 5, 7, 10, 15, 20, 25, 
and 30 and diluted with methanol to dissolve the released drug. To measure the
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release rates of TFV, TDF, MVC, and rhodamine B dextran, an aliquot of the 
release media was collected for analysis on the same schedule and the 
remainder discarded. Cumulative release was estimated by integration of the 
release rate profile using a trapezoidal approximation. Average release rates 
were calculated as the cumulative release divided by the elapsed time. For FCPs 
with four to one, 1.5 mm orifices, the mass of the device was measured on the 
same days the media was collected.
To measure the decay of the pseudo zero-order portion of the release rate 
profile, dimensional analysis was performed. The IQP-0528 release was plotted 
with both variables normalized to the maxima of the experiment. Then a linear fit 
from the maximum release rate to the end of the release curve was performed 
and the dimensionless slopes were compared. The day 30 point was excluded 
for the FCPs containing two, 50 mg pellets with two, 1.5 mm orifices, and four, 50 
mg pellets with four, 1.5 mm orifices since the release on that day was drastically 
different from the preceding days. All linear and power law curve fitting were 
performed using OriginPro8 (OriginLab Corporation, Northampton, MA).
4.3.3 Drug extraction from pellets and FCPs
For determination of drug loading in HPC pellets, pellets were placed in a 
volumetric flask and dissolved overnight in methanol or 1:1 water: methanol 
mixture for TFV. Upon completion of in vitro release studies, FCPs were placed 
in a 50 mL centrifuge tube with methanol or 1:1 water:methanol mixture for TFV 
and shaken overnight. The solution was transferred to a volumetric flask and the
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FCP casing was rinsed at least 5 times and drug content was determined by UV- 
HPLC. To determine the amount of pellet, i.e. the sum of drug and HPC, 
remaining, a portion of the extraction solution was dried to constant mass. To 
confirm drug recovery, known amounts of drug and HPC were dissolved in 
parallel with a similar amount of Tecoflex EG-65D present in the case of FCP 
extractions.
4.3.4 Measure drug diffusivity in HPC solutions
The diffusivity of TFV, TDF, and MVC were measured as a function of 
HPC concentration using Franz cells (Permegear, Hellertown, PA). The solutions 
were made with 0.1 wt% drug and 1.2, 2, 3, 5, and 10 wt% HPC in 25 mM 
acetate buffer pH 4.2. The concentration of each drug in the HPC solutions was 
determined by dissolving 100 mL of gel in a 10 mL volumetric flask in methanol 
for TDF and MVC or methanol:water for TFV. Durapore membrane filters 
(hydrophilic PVDF, 25 mm diameter, 0.45 Mm pore size; Millipore, Billerica, MA) 
were fitted to a Franz cells with a 20 mm orifice diameter and receptor 
compartment with 15 mL of 25 mM acetate buffer pH 4.2. Then 1.5 mL of each 
drug-HPC solution at 37°C was placed on the donor compartment and covered 
with parafilm to minimize evaporation. Samples of 0.5 mL were taken from the 
receiver compartment with an analytical syringe at predetermined time points; 10, 
20, 30, 45, 60, 75, and 90 min; and then replaced with fresh buffer. The drug 
concentration at each time point was measured by UV-HPLC (methods below). 
The cumulative amount of drug that diffused from the donor compartment to the
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receptor (Mt) with respect to the square root of time was plotted and the slope of 
the line was used to calculate the diffusion coefficient, D, according to the 
diffusion equation (Eq. 4.1) solved for semi-infinite geometry and a completely 
dissolved solute (24) where Co is the initial drug concentration in the HPC 
solution, and A is the exposed area. All data are presented as the mean ± SD.
Mt = 2 C0A y jD t/n  (Eq. 4.1)
4.3.5 Drug content analysis
IQP-0528 (25), TDF (26), and TFV (12) concentration for extraction and in 
vitro release studies was measured by UV-HPLC methods described previously. 
The same method was used for TDF and MVC as described previously with the 
addition of monitoring 197 ± 4 nm to quantify MVC (26). DPV was quantified by 
UV-HPLC using an Agilent 1260 Infinity series system with an Eclipse XDB-C18 
column (4.6x150 mm, 5 ^m; Agilent, Santa Clara, CA) at 25°C at a flow rate of
1.5 mL/min Data were collected at 280 ± 8 nm. A gradient of 0.1% TFA in 
acetonitrile (ACN) - 0.1% TFA in water (0-1 min: 30% 0.1% TFA in ACN, 1-9 min: 
30-95% 0.1% TFA in ACN, 9-10 min: 95-30% 0.1% TFA in ACN) was used for 
elution. Rhodamine B dextran concentration was determined by reading the 
fluorescence using a Synergy2 plate reader (BioTek, Winooski, VT) at 540 ± 20 
nm excitation and 620 ± 40 nm emission wavelengths.
84
4.3.6 Model of drug release
The release kinetics of FCPs under in vitro conditions was modeled using 
a transport model based on a generalized diffusion equation. For the model 
calculations, we implemented a finite element analysis in a cylindrical geometry 
following the dimensions described above (Fig. 4.1c). The mass transport is 
modeled with a diffusion equation of the form (Eq. 4.2): 
dCk d (  dCk\  d (  dCk\  d /  dCk\nr= + 3^ 17)+d°!iS  <Eq- 42)
where k represents each of the diffusing components of the system, and Ck and 
Dk are their concentration and diffusion coefficients, respectively.
The model assumes that the release kinetics of the FCP system is mainly 
governed by the hydration and diffusion of the polymeric matrix (HPC). Thus, the 
two components that we consider are 1-water and 2-HPC. As drug transport is 
not directly considered in this model, drug release profiles were obtained by 
applying the weight fraction of drug in the HPC released.
We assumed that the release dynamics of the HPC depend on the extent 
of hydration, thus, more hydrated regions diffuse faster than less hydrated ones. 
To describe the water concentration dependence of the diffusion coefficients, we 
used a Fujita dependence (27), which is based on a free volume approach. This 
type of model has been successfully used to describe drug diffusion in 
hydroxypropyl methylcellulose (HPMC) (28, 29), polymer diffusion in 
polyethylene oxide (PEO) (30), and other similar systems (31-33). In this 
approach, diffusion coefficients are dependent on the water concentration 
according to (Eq. 4.3):
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Dk =  DKeqe x p ( - f i t (  1 -  (Eq. 4.3)
y \  ^water, eq)I
where Ck are the concentrations of each species (k), Dk are diffusion coefficients, 
and pk is a constant that characterizes the water concentration dependence of 
the diffusion coefficient. Dk, eq represent the diffusion coefficients of each species 
at the maximum water concentration Cwater, eq (in equilibrium with the swollen 
matrix).
The solution of the diffusion equation in the geometry of the device was 
obtained using the COMSOL Multiphysics package (COMSOL Inc., Burlington, 
MA). We used the following assumptions and boundary conditions:
i. Diffusion is isotropic and there is no convective flow.
ii. There is no water in the device at time equal to zero (dry matrix condition).
iii. The concentration of water outside the device is constant and equal to
Cwater eq.
iv. The concentration of HPC and drug outside the device is equal to zero 
(perfect sink conditions).
v. The water and drug transport through the casing is negligible.
4.3.7 Comparison between model and experiments
For the model to help in the design of FCPs, we fitted the parameters of 
Eq. 4.3 to experimental data for a device with three orifices of 1.5 mm in diameter 
and four, 50 mg pellets containing 10 wt% IQP-0528 in HPC. This allowed us to 
test the flexibility of the model under new experimental conditions. The fitted 
parameters are: D h p c , eq = 1.02 x 10-10 m2/s, P h p c  = 2.1 and fiwater = 0.5 and Dwater,
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eq = 5.6 x 10-10 m2/s. All other device configurations are predicted using these 
parameters.
To test the performance of the model, we compared the values of 
cumulative release at different experimental conditions. The comparison was 
made by the coefficient of determination (R2) and by the root mean square 
deviation (RMSD) between the model and the experimental data. Additionally, we 
consider that the experimental average release rate and the model release rate 
are not a good quantity to be compared. This is due to the fact that the 
experimental release rate is a measure of amount released per day while the 
model release rate is the derivative of the cumulative release with a higher time 
resolution. Therefore, we included the values of release rate for the model but 
the comparison of the performance of the model was done on the cumulative 
release only.
4.4 Results
4.4.1 Effect of orifice size and number on the IQP-0528 release rate
We measured the in vitro drug release kinetics as a function of orifice size 
on FCPs with four, 50 mg pellets of 10 wt% IQP-0528 in HPC with different 
orifice configurations, one, two, three, and four orifices of 1.5 mm in diameter 
(Fig. 4.2a and b) and three orifices of 2.3 and 2.7 mm in diameter (Fig. 4.2d and 
e). As expected, a larger orifice area generally resulted in a higher release rate 
due to the higher rate of water entry. However, after ~75% cumulative release 
was attained, the drug release rate dropped dramatically. In the first 10 days, the
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average release rates for FCPs with four, three, two, and one, 1.5 mm orifices 
were 700 ± 60, 570 ± 14, 410 ± 33, and 170 ± 32 ^g/d, respectively. This 
corresponded to peak drug release rates of 900 ± 38, 670 ± 29, 480 ± 110, and 
224 ± 40 Mg/d for the devices containing four to one orifices, respectively. 
However, the drug release rates from the FCPs with four and three orifices 
reduced to the level of the two orifice FCPs by day 25. This resulted in 30-day 
average drug release rates of 610 ± 12, 490 ±12, 350 ± 15, and 190 ± 19 ^g/d, 
and calculated cumulative drug releases of 93 ± 1.8, 75 ± 1.8, 54 ± 2.3, and 30 ± 
2.9% for four, three, two, and one, 1.5 mm orifice FCPs, respectively (Fig. 4.2b, p 
< 0.001, single factor ANOVA). The 30-day average release rates and orifice 
areas presented a linear dependence for FCPs with one to four, 1.5 mm orifices 
(Fig. 4.2f, Spearman correlation of r = 0.97 and p = 0.0002). The 30-day IQP- 
0528 cumulative release calculated from the release rate was comparable to 
values measured by residual drug extraction for FCPs with one to four, 1.5 mm 
orifices (p = 0.33, 0.65, 0.042, and 0.12 for one to four, 1.5 mm orifice FCPs, 
respectively; paired t-test for means). This confirms the discrete integration 
method utilized for calculating cumulative release profiles.
Comparing the IQP-0528 release rate from FCPs containing three orifices 
of 2.7, 2.3, and 1.5 mm in diameter (Fig. 4.2d and e), we found the peak release 
rates were 1.9 ± 0.055, 1.3 ± 0.075, and 0.70 ± 0.014 mg/d, respectively. This 
corresponded to 10-day average release rates of 1.4 ± 0.16, 1.1 ± 0.027, and 
0.57 ± 0.014 mg/d for three, 2.7, 2.3, and 1.5 mm orifice FCPs, respectively. The 
drug release rate for FCPs with three, 2.7 and three, 2.3 mm orifices dropped to
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nearly 0 on day 20 and day 25, respectively, and remained low for the study 
duration. The drastic reduction of the release rate on days 20 and 25 
corresponded to calculated cumulative release of 90 ± 8.0 on day 20 for the 
three, 2.7 mm orifice FCP and 99 ± 6.8% on day 25 for the three, 2.3 mm orifice 
FCP (Fig. 4.2e). This confirms that the severe decrease of the release rate 
resulted from an insufficient amount of drug remaining within the device.
The release rate displayed a biphasic behavior with a few day lag time to 
reach a maximum release followed by a pseudo-steady state that decayed for 
the remainder of the 30 days (Fig. 4.2a). For FCPs with four to one, 1.5 mm 
orifices, the 10-day average release rate was higher than the 30-day average 
release rate for each design except the one, 1.5 mm orifice devices. This 
difference resulted from a more extreme maximum release rate for the four, 
three, and two, 1.5 mm orifice FCPs and the differences in the decay of the 
release rate after the maximum release rate was achieved. To enable 
comparisons of the release rate decay in the later portion of the curve between 
devices with different release rates, we performed dimensional analysis by 
normalizing the IQP-0528 release rate and time to the maximum values. Then we 
performed a linear fit of the portion of the plot after the initial lag from the peak 
release rate and beyond. A steeper slope, i.e. a slope with a reduced negative 
value, represents increased release rate decay. The slopes of such fits were - 
1.0, -0.93, -0.57, and -0.36 for the four, three, two, and one, 1.5 mm orifice FCPs, 
respectively (R2 = 0.961, 0.992, 0.998, and 0.549). For FCPs with three, 2.3 and
2.7 mm orifices, the decay slopes were -1.4 and -1.9, respectively (R2 = 0.992,
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and 0.875). The lower R2 value for the one, 1.5 mm orifice FCPs (R2 = 0.549) 
suggests that orifice configuration did not exhibit a linear decay. The 30-day time 
point was excluded from the fitting for the four, 1.5 mm orifice FCPs due to the 
anomalous behavior. Similarly, days 25 and 30 for three, 2.3 mm, and days 15­
30 for three, 2.7 mm FCPs were excluded since the release dropped to negligible 
levels. Generally, a larger orifice area corresponded to a greater decay of the 
release rate during the later portion of the release profile.
To understand hydration kinetics, we measured the mass of the FCPs with 
one to four, 1.5 mm orifices on the same days media was collected for drug 
concentration analysis. We estimated the cumulative media uptake in the FCPs 
(Fig. 4.2c) by adding the cumulative pellet release, assuming the HPC and IQP- 
0528 were released concurrently, to the increase in FCP mass. An increased 
orifice area, changed here by increasing the number of 1.5 mm orifices, 
correlated to increased hydration kinetics. The only exception was on day 30 for 
the four, 1.5 mm orifice devices where we hypothesize that the HPC polymer 
remaining in the FCP was sufficiently small to lead to a dilute solution inside the 
FCP that readily diffused out of the device. Next the cumulative media uptake 
curves were fitted to a power law equation (y = a*tb where y is the cumulative 
media uptake and t is time). The exponent b, which determines the shape of the 
curve, was similar for the different devices containing one to four, 1.5 mm orifices 
(p = 0.11, single factor ANOVA). However, the hydration-scaling factor, a, that 
determines the magnitude of the curve exhibited a linear relationship to the total 
orifice area (Fig. 4.2f, Spearman correlation of r = 0.91 and p < 0.0001). This
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provides evidence that the dependence on the release with respect to the orifice 
area correlates with the hydration kinetics.
4.4.2 Effect of orifice size and number in the model
The model parameters were optimized for the FCP with three orifices of
1.5 mm in diameter and four, 50 mg pellets of 10 wt% of IQP-0528, as mentioned 
above. Using these parameters, we calculated the effect of the orifice number 
shown in Fig. 4.2a and b (solid lines). The model predictions are in good 
agreement with the experimental data. The comparison of the cumulative release 
between the model and the experiments (Fig. 4.2b) exhibited an R2 of 0.983, 
0.998, 0.990, and 0.975 for four, three, two, and one orifice, respectively. The 
RMSD of the model with respect to experiments was ±5.2, ±1.3, ±2.0, and ±1.7% 
for four, three, two, and one orifice, respectively. When we investigated the effect 
of the orifice size on the behavior of the model (Fig. 4.2d and e, solid lines) we 
observed that the model was again in good agreement with the experimental 
data. The comparison of the cumulative release between the model and the 
experiments (Fig. 4.2e) had an R2 of 0.998, 0.992, and 0.957 for the devices with 
three orifices of 1.5, 2.3, and 2.7 mm, respectively. The RMSD of the model was 
±1.3, ±4.5, and ±6.9% for 1.5, 2.3, and 2.7 mm, respectively. As you can 
observe, there are slightly higher deviations when we modify the orifice diameter 
compared to altering the orifice number (Fig. 4.2a and d). Nevertheless, the R2 
shows that the deviations are still comparable with the deviations from the 
experimental data.
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4.4.3 Effect of the drug loading on the drug release rate
We observed a linear increase in drug release with the increase of IQP- 
0528 loading in the pellets (Fig. 4.3a, b, and c). This was readily apparent when 
the cumulative drug release was normalized to the IQP-0528 loading and 
presented as a percent (Fig. 4.3b), and from the linear correlation of the 30-day 
average IQP-0528 release rate and IQP-0528 loading (Fig. 4.3c, Spearman 
correlation of r = 0.98 and p < 0.0001). The 30-day average release rates for 
FCPs with 0.9 and 15 wt% IQP-0528 were 40 and 700 ^g/d, respectively. The 
30-day cumulative release was 68 ± 2.0, 77 ± 3.3, 74 ± 3.6, 81 ± 0.93, and 72 ± 
1.9% for FCPs containing 0.9-15 wt% IQP-0528 in HPC pellets (Fig 4.3b). 
Additionally, upon dimensional analysis, comparable release rate decay beyond 
day 5 was observed for all IQP-0528 loadings tested. Furthermore, for FCPs with 
10 wt% IQP-0528 in HPC and three, 1.5 mm orifices, the cumulative percent 
release of IQP-0528 correlated in a linear fashion to the cumulative percent 
release of the pellet, i.e. the sum of IQP-0528 and HPC measured from residual 
content on days 10, 20, and 30 (Fig. 4.3c, Spearman correlation of r = 0.95 and p 
= 0.004). Taken all together, the data suggest that the release rate of insoluble 
IQP-0528 was controlled by the polymer hydration and diffusion with negligible 
contributions from drug diffusion through the hydrated HPC semisolid.
We then evaluated the release kinetics of other antiretrovirals, DPV, TDF, 
TFV, and MVC in addition to the model macromolecule rhodamine B dextran 
loaded into the pump with three, 1.5 mm orifices (Fig. 4.3e). To compare the 
release of the different compounds, the release was normalized to the total drug
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load. The average release calculated over 30 days was 2.5 ± 0.06, 2.7 ± 0.08,
2.6 ± 0.04, 3.0 ± 0.20, 3.1 ± 0.37, and 3.5 ± 0.01%/d for IQP-0528, DPV, 
rhodamine B dextran, TDF, TFV, and MVC, respectively. The average release 
rate and cumulative release of TFV (p = 0.06), TDF (p = 0.01), and MVC (p = 
0.001) were all higher than that of IQP-0528; however, only MVC and TDF were 
significantly higher than IQP-0528 (paired t-test for means). MVC, TFV, and TDF 
are ~100,000x more water soluble than IQP-0528 with solubilities in 25 mM 
acetate buffer pH 4.2 of 11 mg/mL for MVC and 7 mg/mL for TDF and TFV 
compared to 0.14 ^g/mL for IQP-0528, suggesting the hydrophilic drugs can 
diffuse independently of the HPC polymer. The antiretrovirals with a higher 
aqueous solubility were observed to solubilize within the device during in vitro 
release testing with dissolution initial observed near the orifice and then spread 
along the length of the device. We measured the diffusivity of the three more 
hydrophilic antiretrovirals as a function of the HPC concentration. We observed a 
comparable trend of an exponential decrease of the diffusivity of MVC, TDF, and 
TFV in HPC solutions as the HPC content was increased (Fig. 4.3d), suggesting 
differences in diffusivity do not explain the different drug release rates observed.
4.4.4 Effect of the drug loading in the model
We show in Fig. 4.3a and b the comparison between experimental 
observations (symbols) and the model predictions (solid lines) for different initial 
loadings of IQP-0528 in the HPC pellets. The model was in good agreement with 
the experimental data for different loadings of IQP-0528 (Fig. 4.3a and b). The R2
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of the model for the cumulative release was 0.998, 0.996, 0.995, 0.998, and 
0.997 for 0.9, 2, 4, 10, and 15 wt% IQP-0528 in HPC, respectively. The RMSD of 
the model for the cumulative release was ±3.5, ±2.2, ±3.7, ±1.3, and ±2.0% for
0.9-15 wt%, respectively. These results are in line with our postulate that the 
polymer dissolution and the constraint imposed by the orifice control the 
mechanism of drug release for this device. This is supported by the experimental 
results (Fig. 4.3c) and is evidenced in our model by the good predictive power, as 
compared to the experimental observations, when we conserve the same 
geometry. Furthermore, Fig. 4.3e shows that the drug release profile displays an 
almost identical behavior for DPV as with IQP-0528, despite the difference in the 
chemistry between the two drugs. This suggests that for small hydrophobic 
drugs, the variables that control release are the geometry and hydration 
dynamics of the polymeric matrix. The R2 between model and DPV was 0.998 
with an RMSD of ±3.7% for the cumulative release. In the case of rhodamine B 
dextran, the hydrophilic character of the molecule probably does not play a role 
since the high molecular weight of the molecule limits the diffusivity in the HPC 
matrix. The R2 between model and rhodamine B dextran was 0.997 with an 
RMSD of ±1.3 % for the cumulative release. However, we see deviations 
between the model predictions and the experimental results for TDF, TFV, and 
MVC, suggesting that for hydrophilic, small molecule drugs, the drug diffusivity in 
the swollen HPC matrix modify the release mechanism adding an extra 
contribution. The R2 between model and TDF, TFV, and MVC was 0.984, 0.964, 
and 0.992, respectively with an RMSD of ±12.0, ±7.9, and ±21.3% for the
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cumulative release. Not surprisingly, the hydrophilic drugs were released faster 
than IQP-0528, supporting an additional diffusive contribution to release of the 
soluble molecules.
4.4.5 Effect of number of pellets on the drug release rate
We measured the release kinetics of IQP-0528 from FCPs with two, 1.5 
mm orifices and two, three, and four, 50 mg pellets of 10 wt% IQP-0528 in HPC 
and observed an increased rate of decay of the release rate for devices loaded 
with a smaller number of polymer-drug pellets (Fig. 4.4). We reduced the FCP 
length to correspond to the reduced length of less pellets. The 30-day cumulative 
release from the FCPs with two, 1.5 mm orifices and two, three, and four, 50 mg 
pellets were 9.8 ± 0.35, 9.9 ± 0.07, and 11 ± 0.35 mg corresponding to 110 ± 4.0, 
73 ± 0.49, and 60 ± 1.9%, respectively (Fig. 4.4b). By performing dimensional 
analysis of the IQP-0528 release rate, the FCPs with two pellets exhibited an 
increased decay in the release rate compared to the three pellet FCPs that in 
turn decayed more readily than four pellet FCPs. This can be seen particularly on 
days 15, 20, and 25 as the differences in the drug release rates between the 
three configurations increased. The slopes of the normalized drug release and 
time plots for FCPs containing two, three, and four pellets were -0.90, -0.76, and 
-0.50, respectively (R2 > 0.98). On day 30, the FCPs with two pellets and two, 1.5 
mm orifices demonstrated a burst similar to FCPs with four pellets and four, 1.5 
mm orifices (Fig. 4.2a and 4.4a). This was likely caused by the low concentration 
and viscosity of the polymer solution remaining within the device and easily
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diffusing out of the FCP from shaking during in vitro release testing. Therefore, 
we did not include day 30 for this device configuration for the calculation of the 
release rate decay.
4.4.6 Effect of number of pellets in the model
Reducing the number of pellets within the device was modeled by 
reducing the length of the cylindrical geometry that represents our system. The 
results are presented in Fig. 4.4 (solid lines). Since the experimental data were 
measured in a FCP with an orifice configuration (two, 1.5 mm orifices) that 
differed from the design used to fit the model parameters (three, 1.5 mm orifices), 
some differences appear between the model predictions and the experimental 
results. Nevertheless, the model predictions are in good agreement with the 
experimental data. This can be explained in terms of our postulate that the 
release of hydrophobic molecules like IQP-0528 is controlled by the release of 
the HPC polymer and the constraint imposed by the orifices. This implies that the 
length of the device is not one of the controlling parameters for the release and 
the differences between the experimental data and the model are not significant. 
The R2 of the model for the cumulative release was 0.990, 0.995, and 0.988 for 
four, three, and two pellets, respectively. The RMSD of the model for the 
cumulative release of four, three, and two pellets was ±2.0, ±3.4, and ±4.5%, 
respectively, for the cumulative release.
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4.5 Discussion
We designed a device for the sustained and controlled drug delivery to the 
vaginal mucosa. This design presents a number of advantages compared to 
previous IVR delivery technologies, particularly for the delivery of hydrophobic 
drugs. First the mechanism of release from this IVR can decouple drug release 
from the drug solubility and diffusivity in the ring elastomer and the polymer of the 
insert, which can lead to high and controlled drug release rates irrespective of the 
solubility of drug molecule in the elastomer. The release rate can easily be 
modulated over a significant range of low ^g/d to mg/d quantities by altering the 
orifice size and number, and drug loading in the swellable polymer pellets. 
Additionally, the polymer chemistry and molecular weight of the hydrophilic 
polymer within the device can be altered to achieve vastly different release rates 
and durations (23). As a potential approach to improve user demand and 
adherence, there is a compelling interest to develop multipurpose technologies 
for the prevention of HIV, unwanted pregnancy, and/or other sexually transmitted 
infections (34). Such multipurpose technologies will likely require segmented IVR 
incorporating segments of dissimilar materials and designs to tailor the drug 
release rate for drugs with disparate physical properties and delivery 
requirements (12, 15, 16, 35, 36). We designed the FCP to be incorporated into a 
ring as a segment occupying less than a quarter of the total ring with the 
remainder of the ring containing another drug delivery segment (Fig. 4.1a). 
Additionally, since polymer hydration rate is the predominate factor controlling 
drug release, one can deliver one or multiple drugs at differing fluxes by
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changing the drug loading in the hydrophilic swelling polymer pellet. This could 
be utilized to delivery multiple antiretrovirals for improved potency and a higher 
barrier to development of drug-resistant virus strains (37, 38).
We present a model based on a finite element calculation of the diffusion 
of the water into and drug containing semisolid gel from the device that supports 
the idea that the swelling properties of the polymer and the orifice area are the 
controlling factors for drug release in this FCP design. When the FCP contacts in 
vitro release media, a steep water concentration gradient exists at the interface 
of the polymer pellet at the orifice resulting in water entry into the polymer 
contained in the device (Fig. 4.1b). As the polymer hydrates, polymer chain 
relaxation occurs and the semisolid gel containing the drug diffuses from the 
device. Following this idea, our model uses a Fujita free-volume theory (27); as 
the water concentration increases and the polymer concentration decreases 
inside the device, the free volume available for diffusion increases, resulting in an 
increase in the diffusivity of the water and polymer. The model performed 
remarkably well for different configurations and offers a fast and efficient tool to 
aid in the design of new FCP geometries and configurations.
We determined that the total orifice area (varied herein by changing both 
orifice diameter and number) (Fig. 4.2) as well as the drug loading in the HPC 
pellets (Fig. 4.3) are important design parameters controlling the IQP-0528 
release rate and duration. We observed a linear dependence between orifice 
area and average drug release rate (Fig. 4.2f), and IQP-0528 loading and 
average drug release rate (Fig. 4.3c). The good agreement of the model with the
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experimental data when we varied IQP-0528 loading in the HPC from 0.9 to 15 
wt% (Fig. 4.3a and b) and the number of 1.5 mm orifices from one to four (Fig. 
4.2a and b) implies that the model mechanistically captures the hydration and 
diffusion of the polymer with these configurations. However, we observed 
increased deviations (RMSD) between the model and experimental results for 
the largest orifice areas tested compared to altering the IQP-0528 loading in the 
HPC or the number of 1.5 mm orifices (Fig. 4.2 and 4.3). This can be interpreted 
as a missing term due to the transport resistance imposed by the orifice that is 
implicitly taken in account into the parameters DHPC and pHPC. Re-fitting of these 
parameters to a new geometry can minimize the error in the predictions from 
geometry to geometry. Nevertheless, providing the design critical parameters of 
the device (type of drug, orifice size, and number), the model represents a 
robust, fast, and accurate way to predict the drug release performance of these 
FCPs, with a deviation in the prediction lower than 7% and R2 higher than 0.9 for 
all of the configurations tested with IQP-0528.
The daily release rate of IQP-0528 appeared biphasic, with a lag time in 
the first few days to reach a maximum followed by near constant drug release 
that decayed with time (Fig. 4.2a and 4.3a). We quantified the release rate decay 
by performing a linear fit of the decay portion of the normalized release profile. 
Generally, larger orifice areas that corresponded to higher release rates were 
also associated with increased release rate decay (Fig. 4.2a and d). From 
monitoring the cumulative uptake of release media into the FCP, we found that 
the increased drug release rate associated with a larger orifice area
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corresponded to an increased hydration rate (Fig. 4.2c). Interestingly, we 
observed a linear dependence the hydration-scaling factor and orifice area (Fig. 
4.2f). These observations together with the correlation of the cumulative release 
of IQP-0528 and the pellet, i.e. IQP-0528 and HPC (Fig. 4.3c), support the 
hypotheses that the release of IQP-0528 was controlled by the swelling 
properties of the polymer and the orifice area, and not the drug diffusivity in the 
swollen polymer pellet.
Additionally, we tested a number of more water-soluble antiretrovirals in 
this system to further understand the mechanism of drug release, specifically to 
increase the drug solubility and diffusivity in the hydrated HPC matrix and 
contribute to drug release from the FCP (Fig. 4.3e). The experimental release 
data of MVC, TDF, and TFV were higher than both the measured and model 
predicted IQP-0528 release. This likely occurred due to an additional mechanism 
of drug release from the drug diffusing through the HPC matrix. This can be 
explained by the much higher aqueous solubility of MVC, TDF, and TFV 
compared to IQP-0528. Furthermore, the diffusivities of MVC, TDF, and TFV as a 
function of HPC concentration were comparable (Fig. 4.3d). To accurately predict 
the drug release for MVC, TDF, and TFV using the model, we need to add an 
additional component of the drug dissolution and diffusion in the hydrated 
polymer matrix. The model was in good agreement with the release of the high 
molecular weight compound rhodamine B dextran, suggesting that despite the 
hydrophilic nature of the molecule, the diffusivity in the swollen HPC matrix was 
sufficiently hindered to not contribute to the overall release. The model only takes
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into account the hydration and diffusion of the HPC polymer and therefore 
accurately predicts the drug release when the drug diffusion through the swollen 
polymer network does not contribute to the overall release (Fig. 4.3e).
We observed a relationship between the IQP-0528 release rate and the 
total polymer and drug loading (Fig. 4.4). Devices with a smaller drug and 
polymer load exhibited a slight increase in the decay rate of the release rate from 
day 10 and beyond, and the model accurately reproduced this change in the drug 
release rate due to the change in the number of pellets (Fig. 4.4). Specifically, 
this signifies that FCPs with two pellets did not contain sufficient water-swellable 
polymer inside the device to sustain the same release rate as the FCPs with four 
pellets. A similar behavior existed with FCPs with the two largest orifice areas 
tested: three, 2.3 or 2.7 mm orifices. After ~75% of the drug was released, the 
drug release rate drastically reduced (Fig. 4.2b). Together, these observations 
support our initial hypothesis that release was controlled by the polymer 
hydration and diffusion from the device. After a certain cumulative release was 
achieved, the polymer concentration within the device was insufficient to drive 
the diffusive release of the drug-containing semisolid gel out of the FCP orifice.
4.6 Conclusions
We describe the design of an extended duration, vaginal drug delivery 
system where the drug release is predominately controlled by the hydration, 
swelling, and dissolution of a hydrophilic matrix contained within the IVR. This is 
in contrast to other IVR designs where drug release occurs by drug diffusing
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through the IVR elastomer. We argue because of the unique mechanism of drug 
release, this type of system is capable of high, mg/d drug release rates of both 
hydrophobic small molecules and macromolecules, whereas previous IVRs were 
incapable of achieving this. Finally we also provide a model to aid in the design 
of future FCP configurations, providing accurate information of the release 
dynamics with an easy implementation.
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Figure 4.1. Photograph and schematics of the flux controlled pump-IVR. (a) The 
photograph depicts an FCP (top), and an FCP integrated into an IVR (bottom). 
The FCP contains compressed pellets of drug and hydrophilic polymer within a 
sealed polymer tube with orifices. (b) Schematic of drug (orange dots) release 
from an f Cp with water entry through the orifices causing polymer hydration and 
expansion resulting in release of a drug-loaded gel. (c) Scheme of the geometry 
implemented in the finite element calculation (three orifices of 1.5 mm diameter).
108
Figure 4.2. In vitro release of IQP-0528 comparing different orifice configurations. 
(a and d) IQP-0528 release rate and (b and e) cumulative release from FCPs 
with four, three, two, and one, 1.5 mm diameter orifices and three, 2.7, 2.3, and 
1.5 mm diameter orifices containing four, 50 mg pellets of 10 wt% IQP-0528 in 
HPC. Panels a, b, d, and e compare the experimental (symbols) and model (solid 
lines) results. (c) Cumulative water uptake as measured by device mass increase 
and calculated cumulative pellet release. (f) 30-day average release rates and 
the hydration-scaling factor correlated linearly with orifice area for FCPs with 
four, three, two, and one, 1.5 mm orifices (Spearman correlation of r = 0.97 and p 
= 0.0002, for the 30-day average release rate, and r = 0.91 and p < 0.0001 for 
the hydration-scaling factor). The hydration-scaling factor was from fitting the 
cumulative water uptake of each device to a power law equation.
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Figure 4.3. Loading dependent in vitro release of IQP-0528 and other 
antiretrovirals. (a) IQP-0528 release rate and (b) cumulative release from FCPs 
with three, 1.5 mm orifices with pellets of 0.9-15 wt% IQP-0528 in HPC 
represented in ^g/d (a), and as a percent of loaded IQP-0528 (b). (c) 30-day 
average IQP-0528 release rate linearly correlated to the IQP-0528 loading with 
devices containing pellets with 0.9-15 wt% IQP-0528 in HPC (Spearman 
correlation of r = 098 and p < 0.001). The cumulative pellet release linearly 
correlated to the cumulative IQP-0528 release after 10, 20, and 30 days of 
release for FCPs with three, 1.5 mm orifices and 10 wt% (Spearman correlation 
of r = 0.95 and p = 0.004). (d) Diffusivity of TDF, MVC, and TFV as function of 
HPC concentration. (e) Cumulative percent release of multiple different drugs 
loaded into FCPs. Panels a, b, and e compare the experimental (symbols) and 
model (solid lines) results.
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Figure 4.4. In vitro release of IQP-0528 comparing four, three, and two pellets 
per FCP. (a) IQP-0528 release rate and (b) cumulative amount release from 
FCPs with two, 1.5 mm orifices and four, three, and two, 50 mg pellets of 10 wt% 
IQP-0528 in HPC comparing results from experiments (symbols) and the model 
(solid lines).
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5.1 Abstract
There is widespread agreement that inconsistent adherence has driven 
the unreliable effectiveness levels achieved in clinical trials evaluating 
antiretrovirals for HIV prevention. This has motivated the development of long- 
acting drug delivery systems that require less frequent user interventions in an 
attempt to achieve higher adherence levels. Intravaginal rings containing flux 
controlled pumps formulated with the antiretroviral drug IQP-0528, a potent non­
nucleoside reverse transcriptase inhibitor, were evaluated in an ovine model. We 
measured high and consistent drug concentration in vaginal fluid over the month 
duration that resulted in near complete inhibition of viral replication in a cell- 
based assay. This device provides an adaptable platform for topical drug delivery 
and, due to its small size, can be readily combined with other intravaginal ring 
delivery systems for multiple women’s health applications.
5.2 Introduction
Recent clinical trials evaluating oral and vaginal pre-exposure prophylaxis 
(PrEP) have failed to consistently demonstrate protection from HIV acquisition, 
and low adherence remains the primary cause (1, 2). Independent markers for 
adherence in HIV prevention trials, i.e. antiretroviral concentration in plasma or 
vaginal fluid, typically indicate that the antiretroviral concentration correlates to 
protection (3-6). Moreover, multiple PrEP modalities have successfully protected 
nonhuman primates from mucosal SHIV infection depending on the relative 
timing between drug and viral dosing (7-12). Together, these data suggest topical
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and oral administration of antiretroviral can prevent sexual transmission of HIV 
when a sufficient drug concentration is present when and where infection occurs. 
One approach to increase adherence to topical PrEP modalities is to increase 
the duration between dosing events, motivating the investigation of long-acting 
drug delivery systems like intravaginal rings (13-15).
Until recently, almost all published intravaginal ring designs necessitated 
diffusion of the drug molecule through the ring elastomer, thus limiting the type of 
drug molecules and release rates that were possible (16-18). In addition to the 
drug release properties, the ring stiffness and elastic recoil are innately linked to 
the ring dimensions, drug loading, and elastomer composition (19, 20). In order 
to decouple drug release from the elastomer chemistry, we designed a flux 
controlled pump (FCP), a device that consists of compressed pellets of drug and 
the water-soluble polymer contained within a hollow tubing core. An FCP has 
orifices in the elastomeric casing that simultaneously control the hydration rate of 
the hydrophilic matrix and resulting flux of a drug-containing semisolid gel from 
the device. (16) However, the major challenge to further development of this 
technology is its incorporation into an intravaginal ring for long-term retention in 
the female reproductive tract. If the elastomer utilized for the casing of the FCP is 
not sufficiently rigid, ring compression during insertion and use could result in 
luminal constriction and a burst of drug release. Concurrently, the overall ring 
compressibility and elastic recoil must be similar to commercially available 
intravaginal rings to achieve proper insertion, retention, and biocompatibility (21, 
22).
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This study presents the pharmacokinetic (PK) evaluation of a FCP 
intravaginal ring for the controlled delivery of IQP-0528, a non-nucleoside reverse 
transcriptase inhibitor with nanomolar activity against HIV-1, in an ovine model 
over a month duration. To measure drug distribution along the sheep vaginal 
canal, we utilized a multiswab to collect vaginal fluid at two locations in the sheep 
vagina with respect to the introitus (23). We then quantified the drug 
concentration and the antiviral activity of the material eluted from the swabs.
5.3 Materials and Methods
5.3.1 Fabrication of FCP vaginal rings
Compressed pellets, 4 mm in diameter and 51 ± 1 mg, consisting of 10 
wt% IQP-0528 (ImQuest Biosciences, Frederick, MD) in hydroxypropyl cellulose 
(HPC GF, MW = 370 kDa; Klucel Pharm, Hercules, Wilmington, DE) were formed 
as previously described (16). Two types of Tecoflex aliphatic polyether 
thermoplastic polyurethanes (EG-65D and EG-85A; Lubrizol Advanced Materials; 
Wickliffe, OH) were formed into tubing by hot-melt extrusion with final dimensions 
of 0.7 mm wall thickness and 5.5 mm diameter (24). To fabricate the FCP, 
Tecoflex EG-65D tubing was cut to a length of 44 ± 0.5 mm, and one end was 
sealed by inductive tip-forming welding (PlasticWeld Systems, Inc., Newfane,
NY) (25). The orifices were manually drilled, four compressed pellets were 
inserted into the open end of the device, and then the second end was sealed. 
Rings were made consisting of two FCPs and two placebo segments in an 
alternating manner with similar segments on opposing sides of the ring (Fig. 5.1a
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and b). The placebo segments were made by cutting Tecoflex EG-85A tubing to 
a length of 63 ± 0.5 mm and sealing both ends by inductive tip-forming welding. 
The ends of the placebo and FCP segments were joined using a split-die 
induction welder (PlasticWeld Systems, Inc., Newfane, NY) to form a ring with an 
outer diameter of 55 mm (25). The rings were annealed into a circular shape by 
heating the rings to 65°C for 15 min followed by cooling the rings to room 
temperature in a custom-designed aluminum mold with ring sized cavities. The 
force to compress the rings 10% of the outer diameter was measured on an 
Instron 3342 uniaxial mechanical testing system as described previously (24).
5.3.2 In vitro drug release testing, drug content analysis, 
and pellet and device extractions
In parallel to the sheep PK studies, the in vitro drug release rate was 
measured from rings in triplicate in 25 mL of 25 mM acetate buffer pH 4.2 
changed daily at 37°C and 80 rpm shaking. The release media on days 1, 2, 3, 5,
7, 10, 15, 20, 25, and 30 was collected and the drug was dissolved by the 
addition of 25 mL of methanol. Cumulative release was calculated by numerical 
integration of the release rate profile using a trapezoidal approximation. To 
determine the IQP-0528 loading in HPC pellets, pellets were placed in a 50 mL 
volumetric flask and dissolved overnight in methanol. Upon completion of in vitro 
and in vivo studies, the FCPs were cut out of the ring and then placed in a 50 mL 
centrifuge tube with approximately 10-15 mL of methanol and shaken overnight 
to dissolve the IQP-0528 and HPC. The methanol solution was transferred to a
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50 mL volumetric flask and the FCP casing was rinsed at least 5 times with 
methanol. To confirm drug recovery, known amounts of drug, HPC, and Tecoflex 
EG-65 were dissolved in parallel. IQP-0528 content for extraction and in vitro 
release studies was measured by UV-HPLC using methods already described 
(26).
5.3.3 Multiswab design and fabrication
Multiswabs were fabricated on a lathe and mill from %” acrylonitrile 
butadiene styrene rod (McMaster-Carr, Robbinsville, NJ). Orifices to hold the 
multiswab sponges were made with a square end mill to an outer diameter of 5 
mm and depth of 4 mm. Pairs of such orifices on opposing sides were spaced 
longitudinally 2, 5, 8, and 11 cm from the handle end, representing the length 
from the introitus during application. Additional pairs, rotated 45° with respect to 
the first, were milled on opposing sides with a 0.5 mm offset towards the handle. 
The leading edge was rounded, and a handle was fashioned at a reduced 
diameter and approximately 5 cm long. (23)
5.3.4 Sheep pharmacokinetics studies
All animals were housed at the Center for Comparative Medicine at the 
University of Utah. All procedures were conducted under approved IACUC 
protocols in accordance with the standards incorporated in the Guide for the 
Care and Use of Laboratory Animals (National Research Council of the National 
Academies, 2010). IQP-0528 pharmacokinetics from FCP vaginal rings (N = 3)
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was evaluated in adult, Columbian cross-bred ewes (Ovis aries) for 15 or 30 
days (Table 5.1). Vaginal fluid was collected using a multiswab device (23), with 
swabs (5 mm in diameter cut from Ultracell® Nasal packs, Beaver Visitec 
International, Waltham, MA) inserted at 11 and 5 cm from the introitus with the 2 
and 8 cm positions empty. For vaginal fluid collection, the multiswab was covered 
with a sheath of 12 cm long silicone tubing (1/2” inner diameter and 5/8” outer 
diameter platinum-cured silicone tubing; Cole-Parmer, Court Vernon Hills, IL).
The tubing was lubricated with KY® Intrigue silicone lubricant (Johnson and 
Johnson, New Brunswick, NJ) for ease of insertion. Upon insertion, the sheath 
was removed and the multiswab remained in place for 2 min prior to removal. 
Vaginal fluid samples were collected at day 0 (baseline) and various days during 
the study: 1, 2, 3, 5, 7, 10, 15, 20, 25, and 30 days after ring insertion; and 1, 2,
3, and 5 days after ring removal (Fig. 5.1d).
5.3.5 Measuring the drug concentration in and antiviral 
activity of vaginal fluid
To measure the drug concentration in vaginal fluid, IQP-0528 was 
extracted from the swabs using methanol:water (4:1) as extractant solution and 
IQP-0532, a congener of IQP-0528 (27), as an internal standard used for 
recovery and quantitation measurements. Each swab was transferred to an 
Ultrafree® Centrifugal filter unit (Durapore®- PVDF, 0.65 ^m, EMD Millipore, 
Billierica, MA) and 50 ^L of an IQP-0532 standard in methanol was added. Two 
hundred ^L of extractant solution was added, allowed to equilibrate for 10 min at
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room temperature and then centrifuged at 16,000g for 10 min. The process was 
repeated with 100 of extractant solution. Then the complete extractant was 
transferred to a vial for analysis on an Agilent 1200 LC-6130 single quad MS 
fitted with an APCI-ESI multimode front end (Santa Clara, CA). The HPLC was 
equipped with a chilled autosampler (set to 10°C), a two-position 6-port valve 
column switch, and an isocratic and quaternary pump. The columns 
compartment was maintained at 40°C. The analyte and internal standard were 
eluted through the precolumn (Zorbax SB-C18 column, 2.1x30 mm, 3.5 ^m; 
Agilent) onto the analytical column (Zorbax SB-C18 column, 2.1x100 mm, 3.5 
^m; Agilent) with a 5 min gradient of 0.1% formic acid in water and 0.1% formic 
acid in 90:5:5 methanol:water:acetonitrile (0-5 min: 40-0% 0.1% formic acid in 
water) at 0.4 mL/min. After 5 min, the precolumn was removed from the circuit 
and back-flushed with 0.1% trifluoroacetic acid in 75:25 water:acetonitrile at 0.3 
mL/min, and 0.1% formic acid in 90:5:5 methanol:water:acetonitrile was pumped 
through the analytical column at 0.4 mL/min. Positive secondary ions of IQP- 
0528 and IQP-0532 (341.2 and 343.4 m/z) were detected at approximately 9-10 
min. The method was 20 min long. The lower limit of quantification (LLQ) for IQP- 
0528 calculated using the average mass of absorbed fluid for all samples was
0.1 ^g/mL. Density of 1 g/mL was assumed. The area under the curve (AUC) 
was calculated by numerical integration of the drug concentration profile for each 
swab location using a trapezoidal approximation. To evaluate the antiviral 
activity, the material was eluted from the swab similarly except the extractant 
solution was 200 ^L of complete DMEM repeated once. TZM-bl cells were plated
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at 3x104 per well, allowed to adhere overnight, and then exposed to 
approximately 103 TCID50 HIV-1BaL in the presence of a 1:5 dilution of the swab 
extracts. The plates were left in culture for 48 hrs at 37°C and then the media 
was removed by washing once with 100 pL of PBS. Cells were lysed in 20 pL 
luciferase cell culture lysis reagent and luciferase activity was measured using 
luciferase assay buffer (Promega, Fitchburg, WI) either immediately or stored at - 
20°C until the day of measurement. Data presented as means from two 
independent experiments and as the percent inhibition relative to cells in the 
present and absence of virus.
5.4 Results
The force required to compress the rings depended upon the axis of 
compression. The force to compress the rings 10% of the outer diameter was 1.4 
± 0.1 N (mean ± SD) when compressing the placebo portions and 3.8 ± 0.3 N 
when compressing the FCP portions. The force measured when compressing the 
placebo portion was in the range of NuvaRing® (0.7 N) and Estring® (1.6 N); 
however, along the axis of the FCPs, the rings were considerably stiffer than 
NuvaRing® and Estring®.
The first two PK studies evaluated FCPs containing three, 1.5 mm and 
four, 2.3 mm in diameter orifices for 15 days (Table 5.1). Both of these device 
configurations achieved high and consistent IQP-0528 concentrations in vaginal 
fluid with an average [range] of 180 [8-920] and 310 [8-1,800] pg/mL from days 
5-15 with the FCPs with three, 1.5 mm and four, 2.3 mm orifices, respectively
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(Fig. 5.2a and b). The FCPs with four, 2.3 mm orifices achieved higher drug 
exposure in the vaginal fluid compared to the three, 1.5 mm orifice devices with 
an average [range] AUC0-i 5 of 4,200 [1,200-7,300] ^g*d/mL for the four, 2.3 mm 
FCPs, and 2,300 [470-5,700] ^g*d/mL for the three, 1.5 mm FCPs (p = 0.003; 
paired t-test for means). A lag time to reach a consistent drug concentration in 
vaginal fluid was observed with both devices as seen by the low and more 
variable drug concentration in vaginal fluid in the first 3 days with a number of 
samples below the LLQ. Notably, FCPs with three, 1.5 mm orifices exhibited 
lower and more variable drug levels compared to the four, 2.3 mm orifice design 
during the lag period (days 1-3). We observed comparable drug concentrations 
at each time point at the two locations tested, 11 and 5 cm from the introitus, in 
both of the 15-day studies (p = 0.29-0.66 for three, 1.5 mm orifice FCPs and p =
0.082-0.99 for four, 2.3 mm orifice FCPs for days 5-15; paired t-test for means at 
each time point). To study the drug washout kinetics, we measured the drug 
concentration in vaginal fluid after ring removal. In the study of the three, 1.5 mm 
orifice FCPs, all samples on day 15+3 (3 days after ring removal) were below the 
LLQ (data not shown). However, in the study of the four, 2.3 mm orifice FCPs, 
variable drug concentrations in vaginal fluid were observed on days 15+1, +2, 
and +3 (1, 2, and 3 days after ring removal) (Fig. 5.2a and b).
Overall, the FCP rings exhibited a reduced release rate in vivo compared 
to in vitro release conditions (Fig. 5.3a). The average in vitro release rate and 
corresponding cumulative release calculated from residual drug extraction over 
15 days from rings containing two FCPs was 1.4 ± 0.08 mg/day (mean ± SD) and
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54 ± 3.2% for the three, 1.5 mm orifice design, and 2.5 ± 0.08 mg/day and 94 ± 
3.5% for the four, 2.3 mm orifice FCP intravaginal rings (Fig. 5.3a and c). We 
observed a 57% and 29% reduction in release in vivo for the three, 1.5 mm and 
four, 2.3 mm orifice FCP rings, respectively. This corresponded to average and 
cumulative in vivo drug release of 0.6 ± 0.1 mg/day and 23 ± 4.9% for the three,
1.5 mm orifice FCPs, and 1.8 ± 0.2 mg/day and 67 ± 7.6% for the four, 2.3 mm 
orifice FCPs (Fig. 5.3a). Devices with three, 2.3 mm orifices did not achieve 
controlled 30-day release in vitro with a significant drop in the release rate after 
~75% of the total load was released, as seen from the cumulative release 
plateauing on day 20 (Fig. 5.3c). Therefore, with ~67% cumulative release after 
15 days in vivo, the four, 2.3 mm orifice design would likely not result in 30-day 
controlled release. In summary, the four, 2.3 mm orifice design exhibited a higher 
overall release in 15 days, and less of a lag time to reach the higher drug 
concentration in the vaginal fluid compared to the three, 1.5 mm orifice device.
The two 15-day PK studies enabled us to select an orifice configuration 
that could result in 30-day controlled release in sheep. In the third ovine PK 
study, we evaluated an FCP design with an intermediate orifice area, FCPs with 
three, 2.3 mm orifices (13 mm2 compared to 5.3 mm2 for three, 1.5, and 17 mm2 
for four, 2.3 mm; Table 5.1). We observed variable drug concentration in vaginal 
fluid on the first 2 days with a limited number of samples below the LLQ and 
measured high drug concentration in vaginal fluid from day 3 to 30 with an 
average [range] of 270 [4.5-1,200] ^g/mL (Fig. 5.2c). From days 3-30, the drug 
concentration at the 11 and 5 cm from the introitus was statistically
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undistinguishable (p = 0.067-0.90, paired t-test for means at each time point) on 
all days except day 15 where a higher concentration was measured at the 5 cm 
location compared to the 11 cm location (p = 0.025). The three, 2.3 mm design 
did not achieve sustained and controlled drug release in vitro for 30 days (Fig. 
5.3c). In vivo this design exhibited an average drug release of 1.0 ± 0.21 mg/day 
(mean ± SD) corresponding to 75 ± 16% cumulative release (Fig. 5.3b). This 
together with the high and consistent drug concentration in vaginal fluid 
measured up to day 30 suggests the drug release was sustained over 30 days. 
We measured variable drug levels [range: 0.018 -  660 Mg/mL] after ring removal 
on days 30+1, +2, +3, and +5 (1, 2, 3, and 5 days after ring removal) in vaginal 
fluid with multiple samples below the LLQ (Fig. 5.2c).
Fluid eluted from the swabs collected while the rings were in place in the 
30-day study exhibited significantly greater antiviral activity on both days 10 (90 ± 
35%; mean ± SD; p = 0.0025, Mann-Whitney test) and 15 (91 ± 47%; p = 0.012) 
compared to the baseline activity (16 ± 36%; Fig. 5.4). Only two samples tested 
that were collected during ring use demonstrated low antiviral activity, whereas 
the remaining swabs yielded a viral inhibition of 107 ± 15% (N = 12). The two 
samples showing negligible antiviral activity absorbed 1-2 mg of vaginal fluid, 
suggesting that an insufficient amount of drug containing vaginal fluid was 
absorbed to demonstrate activity in this assay. No correlation between the 
antiviral activity and IQP-0528 concentration measured in adjacent swabs was 
observed (Spearman correlation, p = 0.39). This likely occurred since the antiviral 
activity of the swabs collected during ring use approached 100% and therefore
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was outside of the dynamic range of the assay.
5.5 Discussion
The non-nucleoside reverse transcriptase inhibitor IQP-0528 is a 
promising antiretroviral for HIV prevention due to its nanomolar activity, high 
therapeutic index, and chemical stability (27, 28), and has been formulated for 
vaginal delivery in a number of different dosage forms including gels (28, 29), a 
vaginal film (30), an osmotic pump tablet (23), and an intravaginal ring (26). 
Additionally, a gel formulation of IQP-0528 has an approved IND, which will 
accelerate development of future long-acting dosage forms. The drug release 
rate from the previous intravaginal ring was limited by the solubility of the drug in 
the vaginal fluid; moreover, the authors observed a concentration gradient of the 
drug in vaginal fluid along the vaginal canal (26). We engineered a new drug 
delivery system where the drug release rate is controlled by the device geometry, 
the chemistry of the water-soluble polymer contained within, and the drug loading
(16). In this system, drug release is not a function of the solubility or diffusivity of 
the drug in the ring elastomer. Drug release from this device occurs by hydration, 
swelling, and dissolution of the hydrophilic matrix at the orifice interface (Fig. 
5.1c). In the case of a hydrophobic drug like IQP-0528, the pump releases a 
semisolid gel containing microparticles of the drug substance. Upon release, the 
water-soluble polymer likely enhances the distribution of the drug along the 
vaginal canal. In this report, we evaluated the performance of FCP containing 
rings in sheep and measured the concentration of IQP-0528 in vaginal fluid, and
the antiviral activity of the vaginal fluid collected during ring use. The anatomical 
similarities of the sheep and human vaginal tracts enable testing of human-sized 
devices without altering the dimensions or design (24, 31). However, the device 
performance in sheep and humans could differ due to anatomical and biological 
disparities; therefore, long-term device retention and drug release in this ovine 
model may not directly translate to overall performance in humans.
It is known from animal studies that vaginal transmission of HIV can occur 
along the female reproductive tract (32) and therefore, the antiretrovirals should 
be well distributed in the vaginal tract to prevent early transmission events. 
However, the drug release rate necessary to completely inhibit HIV transmission 
in the vaginal mucosa is unknown and will depend in part on the drug activity, 
distribution, and elimination. The ongoing clinical studies of the dapivirine matrix 
intravaginal ring, depending on effectiveness, may clarify the required dose to 
achieve an adequate concentration in vaginal fluid and tissue to prevent sexual 
HIV transmission in women. For instance, dapivirine-releasing matrix rings 
achieved drug concentrations 103-104 times the in vitro IC50 in vaginal fluid of 
women (33-35). Despite slight differences between the IQP-0528 concentrations 
in vaginal fluid across the three FCP designs tested, the mean drug 
concentrations after the initial lag were at least 105 times the in vitro IC50 (27) 
suggesting a potentially sufficient drug concentration to prevent HIV-1 infection 
(Fig. 5.2). We measured variable antiviral activity in the baseline samples, and 
endogenous antiviral activity of cervicovaginal fluid is commonly observed in 
humans (36, 37). The swabs collected on day 10 and 15 of the 30-day study
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exhibited significantly higher antiviral activity compared to the baseline samples 
(Fig. 5.4). Furthermore, the assay represents a 24-2,000x dilution of the vaginal 
fluid depending on the amount of fluid absorbed, confirming the high 
concentration of drug present in the vaginal fluid during ring use and its potential 
to be effective in preventing HIV transmission.
Previous evaluations of intravaginal rings eluting hydrophobic drugs, IQP- 
0528 in macaques and dapivirine in women, revealed higher drug concentration 
in vaginal fluid proximal to the ring compared to distal locations (26, 33-35). 
However, in all three PK studies of the FCP rings, we measured similar drug 
concentrations in vaginal fluid at the two locations tested, 11 and 5 cm from the 
introitus (Fig. 5.2). The previous IQP-0528 intravaginal ring was a matrix design 
made from polyether urethane and due to higher solubility and diffusivity of the 
drug in this elastomer, the authors were able to achieve high average drug 
release rates in macaques of approximately 1 mg/d scaled to a human sized ring 
over a month duration (26). However, despite this high drug flux from the 
previous design, the FCP resulted in a more consistent drug concentration in 
vaginal fluid with respect to time and location in the vaginal canal. We propose 
the drug containing gel released from the FCP ring was well distributed in the 
vaginal canal from the native forces present in the vagina, predominately normal 
forces leading to squeezing flow, and gravity (38). However, the dissolution of the 
drug within the vaginal canal and the diffusion of the drug into vaginal tissue 
warrants further study. The rate of drug dissolution in the vaginal fluid may be 
limited by the solubility of the drug and therefore limit drug diffusion into the
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vaginal tissue. Additionally, this device delivers small quantities of gel in a 
sustained fashion, approximately 10 mg of gel over a day, compared to a 4 g 
bolus of a typical vaginal gel (39). Thus, a gel-eluting FCP ring may retain the 
superior drug distribution of a vaginal gel while not possessing negative 
stereotypical gel qualities, such as messiness and inconvenience of frequent 
application (2, 3).
We identified an initial lag time to reach a high and consistent drug 
concentration in vaginal fluid (Fig. 5.2) consistent with our in vitro release 
experiments (16). As a consequence, the first few days of ring use could present 
a potential window of susceptibility to infection. This lag time could be 
exaggerated in vivo due to the time required for the crystalline drug 
microparticles to distribute and dissolve in the vaginal fluid. In the 30-day study, 
drug was measured in the vaginal fluid up to 5 days after ring removal, 
suggesting a reservoir of drug in tissue that could diminish the potential window 
of susceptibility in the first few days during sequential ring use. We provide 
evidence that increasing the orifice area results in an increased drug release and 
drug concentration in vaginal fluid, and a shorter lag time (Fig. 5.2a, 5.2b, and 
5.3). With the higher release rate and drug concentration in vaginal fluid, we 
hypothesize the four, 2.3 mm design achieved a higher drug concentration in 
vaginal tissue than the three, 1.5 mm design. This is further validated by the 
higher drug concentration in vaginal fluid observed during washout in the three 
days after ring removal with the four, 2.3 mm compared to the three, 1.5 mm 
orifice FCPs. This could have resulted from higher IQP-0528 concentrations in
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the vaginal tissue that then acted as a drug reservoir upon ring removal. After the 
ring is removed, drug present in the vaginal tissue can diffuse not only towards 
the bloodstream or lymph system but also back through the vaginal mucosa and 
into the canal if a concentration gradient of the drug exists in both directions.
We hypothesized an intermediate orifice area compared to the designs 
evaluated in the two 15-day PK studies would exhibit a reduced lag time 
compared to the three, 1.5 mm design and result in a decreased release rate 
compared to the four, 2.3 mm design to achieve controlled release over 30 days. 
In the 30-day PK study, intravaginal rings with three, 2.3 mm diameter orifices in 
each FCP produced a brief lag time to reach high and consistent drug 
concentration in vaginal fluid through 30 days of ring use. Moreover, variable 
drug concentrations in vaginal fluid were observed after ring removal in the 30- 
day study (Fig. 5.2c), supporting the idea that high drug concentration in tissue 
was achieved. We measured a reduced release rate in vivo compared to in vitro 
release conditions which was comparable to the reduction observed with a 
similar device tested in rabbits (16). For this type of system, in vitro release 
conditions with complete, daily replacement of the release media do not 
accurately represent the vaginal mucosal environment. However, these data can 
be used to estimate the in vivo performance from in vitro release experiments. 
The reduced in vivo release rate could arise due to various complexities of the 
biological system including a limited amount of vaginal fluid to drive polymer 
hydration and release, a higher osmolarity of vaginal fluid compared to release 
media, and vaginal fluid dynamics and physiology controlling vaginal fluid
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clearance and production.
Incorporating an FCP as a segment of an intravaginal ring presented a 
number of design challenges. Initially the FCP casing was made of a softer 
polymer and we observed a significant burst release caused by constriction of 
the FCP lumen associated with ring compression previously observed in women
(40). Therefore, we utilized a harder polymer for the FCP casing, resulting in a 
segment that did not result in lumen collapse even during complete ring 
compression necessary for insertion. However, an intravaginal ring must also be 
compliant since a ring that is too stiff can cause tissue damage and discomfort
(41). To conserve ring compliance similar to commercially available rings, the 
less stiff, non-pump segment(s) must occupy a large percentage of the ring. In 
the present study, the non-pump segments were placebo; however, we envision 
integrating this design with other intravaginal ring technologies (17, 19, 24, 25,
31) to create multipurpose technology for not only the prevention of HIV but also 
other sexually transmitted infections or unwanted pregnancy in an effort to 
improve user demand and adherence (42). Incorporating a single FCP into a ring 
will result in a softer ring compared to the intravaginal rings with two FCPs 
evaluated here. The nonsymmetric mechanical properties could present an issue 
for product acceptability, and this would require clinical studies to assess. 
However, a segmented ring with a single stiff segment of comparable length is 
currently in a clinical study and the results of which will begin to answer 
questions associated with mechanically nonsymmetric, segmented vaginal rings 
(25). In this study, we did not investigate device safety. However, the
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components of the ring have all been previously examined in vaginal 
formulations (26, 29) and no adverse effects are expected from this drug-device 
combination.
5.6 Conclusions
In summary, we measured millimolar concentrations of IQP-0528, a 
nanomolar active reverse transcriptase inhibitor, in vaginal fluid. We observed a 
reduced drug release rate in vivo compared to in vitro conditions, and provide 
evidence that we are able to overcome this reduction by increasing the orifice 
area. A more detailed PK evaluation of this FCP ring is warranted to measure the 
drug concentration and distribution in vaginal tissue where the initial HIV 
transmission events occur. The FCP design only occupies a small portion of the 
ring, allowing for the incorporation of other intravaginal ring technologies for the 
delivery of agents for other women’s health applications.
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Figure 5.1. Photographs and schematic of flux controlled pumps, and an outline 
of the sheep PK studies. (a) Photographs of a FCP vaginal ring with FCP 
segments on the top and bottom of the ring and placebo segments on the left 
and right, and (b) a close up of a single FCP segment contained within the ring. 
Each FCP has three, 2.3 mm orifices. Both scale bars are 5 mm. (c) Illustration of 
a flux controlled pump with water entry through the orifices which leads to 
polymer hydration, swelling and dissolution from the device, and resulting release 
of the drug-loaded semisolid gel. (d) Diagram of the sheep PK study including 
ring insertion and removal, and time points of vaginal fluid sampling, marked with 
vertical lines, to measure drug concentration and antiviral activity of fluid eluted 
from the swabs.
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Figure 5.2. Drug concentration in vaginal fluid over 15 and 30 days of ring use at 
two locations, 11 and 5 cm from the introitus after administration of FCP 
containing intravaginal rings with (a) three, 1.5 mm or (b) four, 2.3 mm diameter 
orifices in each FCP over 15 days, and (c) three, 2.3 mm diameter orifices in 
each FCP over 30 days. Symbols represent individual samples and the bars 
represent the means; 1-2 swabs per distance per time point were analyzed. 
Samples with IQP-0528 concentration below LLQ were plotted as 1/10th of the 
calculated sample LLQ. The horizontal line at the top of the grey area represents 
the average LLQ for the experiment.
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Figure 5.3. Comparison of the in vivo and in vitro IQP-0528 release over 15 and 
30-days of ring use. IQP-0528 cumulative percent release and the average 
release rate for rings containing two FCPs comparing in vitro (blue) and in vivo 
(red) conditions after (a) 15 days and (b) 30 days of study. (b) FCPs with three,
2.3 mm orifices did not achieve 30-day release under in vitro release conditions 
and therefore were not included. Data represented with the symbols as individual 
FCPs, bars as means, and error bars as SD. (c) In vitro IQP-0528 cumulative 
release from rings containing two FCPs over 15 days for the three, 1.5 and four,
2.3 mm orifice FCPs and 30 days for the three, 2.3 mm FCPs. Data represented 
as the mean ± SD.
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Figure 5.4. Antiviral activity of vaginal fluid collected in the 30-day PK study. The 
ability of the vaginal fluid eluted from swabs to inhibit HIV-1 BaL infection of TZM-bl 
cells from the 30-day PK study evaluating FCPs with three, 2.3 mm orifices. 
Symbols represent individual swabs, and bars indicate the means.
CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
The aim of the work presented in this manuscript was to expand the range 
of achievable drug release rates and the types of molecules delivered from an 
intravaginal ring (IVR) by utilizing reservoir designs composed of polyether 
urethane tubing formed into an IVR and designing new technologies where the 
mechanism of drug release does not depend on diffusion of the drug molecule 
through the IVR elastomer. IVRs were initially designed to delivery hormones as 
a contraceptive or hormone replacement therapy. As such, traditional IVR 
technologies effectively deliver relatively small amounts of small hydrophobic 
molecules. However, the ongoing high prevalence of new HIV infections, 
particularly in young women in sub-Saharan Africa, has resulted in a resurgence 
of research and development of IVR delivery systems over the last decade. 
Despite these new technologies, vaginal sustained delivery of macromolecular 
agents, and micro- and nanoparticles for women’s health applications is still 
difficult to achieve since in both cases, it is essentially impossible to achieve 
diffusive release through the IVR elastomer while maintaining the required ring 
stiffness. To increase the diversity of the drugs that can be delivered from IVRs 
and to obtain a better control of the drug release, we created a new drug delivery
technology where the mechanism of drug release is controlled by the hydration 
rate of the hydrophilic matrix contained within the IVR and not the diffusivity of 
the drug in IVR the elastomer. Orifices in the casing control the hydration rate of 
the compressed pellets composed of a mixture of micronized drug and swelling 
polymer that are contained in the hollow core of the IVR, and flux of the drug- 
containing gel that is forced through the orifice by polymer swelling and diffusion. 
This system provides controlled and sustained drug release of any stable 
molecule.
In summary, this work was motivated by the need for new technologies to 
prevent the male to female sexual transmission of HIV, specifically IVRs for the 
topical delivery of antiretrovirals for improved adherence and drug 
pharmacokinetics (PK) compared to frequently administered oral tablets or 
vaginal gels. Included below are brief conclusions from each chapter, followed by 
recommendations for future research specifically in vaginal drug delivery with an 
IVR and more generally in HIV PrEP.
6.1 Chapter Conclusions
6.1.1 Chapter 2 conclusions
In Chapter 2, we described the PK and pharmacodynamics of the prodrug 
tenofovir disoproxil fumarate (TDF) delivered from an IVR in macaques. Major 
conclusions from this chapter are:
1) High mg/day release rates of the hydrolytically unstable prodrug TDF can 
be achieved by controlling the chemistry and dimensions of the polyether
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urethane tubing and formulation loaded inside of the IVR.
2) The IVR resulted in drug concentration in the surrounding tissue that were 
similar or exceeded previous levels associated with protection in this 
animal model.
3) The IVR completely protected macaques from multiple vaginal viral 
exposures.
6.1.2 Chapter 3 conclusions
In Chapter 3, we introduced the flux controlled pump (FCP) for the 
controlled topical delivery of macromolecules to the vaginal mucosa. We 
evaluated this new vaginal drug delivery system in rabbits to study the in vivo 
device performance with the aid of an oval vaginal retainer. Major conclusions 
from this chapter are:
1) Drug release depends on the hydration rate and release of the hydrophilic 
polymer contained within the core of the device, and not the solubility or 
diffusivity of the model macromolecules within the hydrophilic polymer.
2) The orifice size and the polymer chemistry of the hydrophilic pellet 
contained within the device controls the hydration rate of pellets contained 
in the device and thereby the drug release rate.
3) An oval holder made of a shape memory polymer enables nonsurgical 
intravaginal insertion and retention of solid dosage forms in rabbits.
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6.1.3 Chapter 4 conclusions
In Chapter 4, we further characterized the FCP to gain a better 
understanding of the mechanism of drug release for small molecule drugs in 
addition to macromolecules, and developed a model of drug release to enable 
quantitative predictions of the effect design changes have on the drug release 
profile. Major conclusions from this chapter are:
1) The dominate mechanism of drug release is not dependent on the drug 
solubility or diffusivity in the IVR elastomer.
2) The mechanism of drug release is predominately and in some cases 
completely controlled by the hydration and dissolution of the water-soluble 
polymer released from the device and not the solubility or diffusivity of the 
drug in that polymer.
3) The model accurately predicts the drug release rate when drug diffusion 
through the hydrated polymer matrix contained within the pump does not 
contribute to drug release, as was the case for hydrophobic small 
molecule drugs and macromolecular model compounds.
6.1.4 Chapter 5 conclusions
In Chapter 5, we evaluated the drug release and PK of FCP containing 
IVRs in sheep. We utilized a multiswab device to collect spatially registered 
vaginal fluid samples along the vaginal canal. Major conclusions from this 
chapter are:
1) The drug concentration was homogeneous along the vaginal canal,
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suggesting the semisolid gel released from the FCP containing the drug 
aids in the distribution along the tract.
2) The FCP displayed a reduced release rate in sheep compared to in vitro 
release conditions and this reduction can be overcome by increasing the 
orifice size.
3) The concentration of drug measured in the vaginal fluid was ~105 times 
the in vitro EC50 which corresponded to nearly complete inhibition of viral 
replication in a cell-based assay
6.2 Discussion and Future Recommendations
The human-sized version of the TDF IVR described in Chapter 2 has 
completed a Phase 1 safety and PK clinical study. Placebo and drug containing 
IVRs were used over a 14-day duration. This TDF IVR design completely protected 
macaques from multiple vaginal viral exposures; however, the required dose in 
humans is unknown. PK data from clinical studies in humans, and PK and 
pharmacodynamics data from macaque studies evaluating a tenofovir vaginal gel 
suggest that the TDF release rate should be sufficient. However, there are a 
number of differences, comparing the more potent prodrug TDF to tenofovir, and 
sustained delivery from an IVR compared to a bolus release with a vaginal gel. 
Despite these differences, the tenofovir concentration in vaginal fluid and tissue 
achieved with the IVR were similar and maintained for a longer duration than that 
achieved with the 1% tenofovir gel. With the IVR in addition to the tenofovir 
concentration in vaginal tissue and fluid, there is also TDF present. Together, this
145
supports the idea that the TDF IVR delivers sufficient drug to inhibit viral 
transmission in the vaginal mucosa. Further clinical studies are needed to 
determine the TDF dose delivered from an IVR necessary to prevent HIV 
transmission at the vaginal mucosa. However, the current TDF IVR design can be 
altered to increase or decrease the drug release rate.
A concern with tubing reservoir IVRs made of hydrophilic polyether urethane 
is the possibility of bacterial growth in the lumen of the device from bacteria either 
crossing the tubing wall or being introduced into the ring during manufacturing. This 
bacterial growth could alter the local microflora necessary for proper vaginal health 
and immunity and present safety concerns. We found that nanoparticles and 
quantum dots cannot diffuse across the wall of the polyether urethane tubing, 
suggesting that the pore size of the tubing used in this IVR is sufficiently small to 
not allow bacteria to enter the device after fabrication. Additionally, to reduce the 
lag time to reach high drug release rates, the formulation undergoes a heat- 
treatment step of 65°C for 5 days which effectively pasteurized the device to further 
limit the bacterial load inside of the IVR. As part of macaque and clinical studies of 
the TDF IVR, the fluid within the IVR was sampled and cultured. To date, no 
bacteria have been found inside of the ring after use, whereas bacteria was found 
on the surface of the IVR and was comparable to bacteria found in the vagina.
There are still a number of unanswered questions regarding the 
performance and acceptability of FCPs for vaginal drug delivery that require 
additional preclinical evaluation. A potential safety issue of vaginal drug delivery 
systems is adverse alterations of the native vaginal flora. This is particularly
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relevant for vaginal products that can absorb and/or release bacteria and could 
potentially select for pathogenic flora. Unlike the TDF IVR described in Chapter 2, 
the FCP are designed with multiple orifices for water influx and drug loaded gel 
efflux that are millimeters in diameter. The FCP has not been evaluated in an 
animal model with a comparable vaginal flora to women such as pigtailed 
macaques, and it is unknown if this system would alter the microflora and present 
safety concerns. PK and safety studies performed in pigtailed macaques where the 
vaginal microflora is monitored prior to and during IVR use would begin to address 
this concern. Moreover, Chapters 3 and 5 demonstrated that in vitro release 
conditions did not accurately represent the vaginal environment since a reduced 
release rate was observed in rabbits and sheep. This could be due in part to the 
relatively limited amount of vaginal fluid available to hydrate the internal contents of 
the device to drive drug release and/or a higher osmolarity of vaginal fluid 
compared to the release media. Since the amount of fluid present depends on a 
number of factors including presence of semen, atrophic vaginitis associated with 
menopause, or secretions due to sex or menses; variable amounts of vaginal fluid 
could drive variable drug release. However, at least for IVRs delivering hormones 
as a contraceptive or hormone replacement, this has not been established as an 
issue. The effect of increased amounts of fluid present in the vagina on the in vivo 
drug release rate could be measured in an animal model by measuring the drug 
remaining in the IVR after use with animals that are vaginally instilled with saline 
daily compared to a nontreated control. If the FCP yields consistent release rates in 
vivo needs to be evaluated in a diverse population of women not abstaining from
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vaginal intercourse.
There is a compelling interest in designing multipurpose prevention 
technologies (MPTs) that possess the ability to prevent HIV transmission and/or 
other sexually transmitted infections potentially combined with a contraceptive as 
an approach to improve user demand and adherence (1, 2). There are a number of 
possible approaches to design MPTs. For example, the condom is effective as a 
contraceptive and inhibits transmission of disease. The two main drug delivery 
approaches to designing MPTs is to either deliver multiple drugs (3-5), or deliver a 
drug that is active against multiple infectious agents (6). The first MPT IVRs in 
clinical studies deliver tenofovir or the tenofovir prodrug TDF to prevent HIV and 
HSV transmission, and tenofovir combined with levonorgestrel as a contraceptive 
(3, 6). Particularly in the case of delivering multiple drugs with disparate chemical 
properties and delivery requirements, multisegment IVRs are often necessary 
where separate segments are designed for the different drugs to achieve the 
desired release rate of drugs (3, 7, 8). The TDF IVR described in Chapter 2 could 
be combined with the FCP described in Chapters 3-5 to enable to deliver of multiple 
drugs with diverse chemical and delivery requirements. The FCP was designed as 
a segment of an IVR occupying approximately a quarter of the ring with the 
remainder containing a different design, and as such, incorporating the FCP into 
the TDF IVR only necessitate a small reduction in the length of the TDF segments, 
resulting in a marginal reduction in the drug release rate. Moreover, the TDF design 
could be altered slightly to compensate for the reduced length. For example, a 
slight reduction in the tubing wall thickness or utilizing a polyether urethane with a
148
higher equilibrium water uptake would increase the drug release rate. The FCP 
technology could also be utilized to simultaneously deliver more than one drug.
This could be useful to deliver different drugs for multiple indications or multiple 
drugs active against HIV in an attempt to increases effectiveness and reduce the 
emergence of drug resistant virus. The acceptability of a segmented IVR with 
asymmetric mechanical properties due to a single soft and hard segment like an 
FCP is unknown. However, an IVR with similar mechanical properties and 
segmented design (3) is currently in Phase 1 clinical study and may begin to 
address questions of acceptability of IVRs exhibiting asymmetric stiffness.
Chapter 5 describes the in vivo evaluation of IVRs containing FCPs in 
sheep, and presented the drug concentration in vaginal fluid but not tissue. 
Additional studies are required to determine the drug concentration in vaginal tissue 
achieved with the FCP. Since vaginal fluid is easier to collect and can be collected 
more frequently, it is often used as a measure of the drug release kinetics and 
reveals more detail of the kinetics of drug release particularly early. However, the 
drug concentration in vaginal tissue where the initial transmission events occur is 
more important for drugs that are active intracellularly. Future studies need to 
evaluate the drug concentration where inhibition of HIV transmission by a reverse 
transcriptase inhibitor occurs, i.e. vaginal and/or cervical tissue. Additionally, under 
the in vitro release conditions investigated, the FCP releases a semisolid gel 
containing drug microparticles that must dissolve for the drug to partition and diffuse 
into the surrounding tissue. In the sheep PK study, we did not differentiate between 
dissolved and undissolved drug released into the vaginal fluid. With the high,
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mg/day release rates of IQP-0528 that possesses micromolar water solubility, it is 
possible that drug dissolution was rate limiting and therefore, insoluble drug was 
present in the vaginal tract of the sheep. Measuring the drug concentration in the 
vaginal tissue would begin to address this question. A direct measure of the relative 
fraction of dissolved and undissolved drug in the vaginal fluid would be to aspirate 
fluid from the vaginal fornix, separate out the undissolved drug by centrifugation, 
and measure the volume and drug concentration of the two fractions.
Further improvements to the model of drug release from FCPs described in 
Chapter 4 would enable predictions of drug release for hydrophilic small molecule 
drugs. That takes into account the kinetics of the hydration and diffusion of the 
water-soluble polymer within the FCP. Higher drug release rates for hydrophilic 
drugs were observed experimentally compared to the model predictions. This 
suggests that in the case of more hydrophilic small molecule drugs, in addition to 
drug release from the extrusion of the water-soluble polymer, drug release also 
occurred from the drug diffusing through the swollen polymer matrix within the 
casing. Diffusive drug release could be included into the model by adding an 
additional component to the model. The concentration dependent diffusivity of the 
drug in the swollen polymer matrix as a function of the polymer concentration could 
either be determined by fitting to experimental drug release from the device, or 
measured using nuclear magnetic resonance (9, 10) or Franz cell diffusion (11) 
techniques. Chapter 4 presented the diffusivity of the hydrophilic drugs tenofovir, 
TDF, and maraviroc as a function of the water-soluble polymer concentration 
determined using Franz cells. Issues could arise by simply adding the additional
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component to the model of the drug diffusion since the drug dissolution kinetics 
inside the FCP will likely impact the drug concentration inside the device. The 
drug dissolution rate and the drug concentration will depend on the drug particle 
size, the water concentration, and the chemistry of the drug.
Topical pre-exposure prophylaxis (PrEP) is designed to chemically inhibit 
HIV transmission in the tissue where it occurs. Simply, sufficient drug must be 
present in the genital mucosa when and where HIV infection takes place. Non­
human primate animal models have guided clinical testing of oral and topical 
PrEP, and often parity between the effective drug concentrations is found (12,
13). However, there is still much unknown including the kinetics and extend that 
drug distributes throughout the genital tract after systemic and topical 
antiretroviral administration, and what drug concentration is required in what 
tissue to prevent the sexual transmission of HIV. Drug PK after topical 
administration of antiretrovirals is commonly measured in the vaginal fluid, 
vaginal and cervical tissue, and plasma. For nonterminal animal studies, the 
vaginal and cervical tissue is collected with a pinch biopsy. Typically, the tissue is 
homogenized prior to measuring the drug concentration and therefore represents 
an average concentration. A concentration gradient of the drug is hypothesized 
to exist within the epithelium with the highest drug concentration near the vaginal 
lumen that diminishes further into the tissue. Also many antiretrovirals are active 
intracellularly and therefore intracellular drug concentration, particularly in 
immune cells that carry the infection to the lymph system, is the most relevant. 
Therefore, an active segment of HIV prevention research is to measure the drug
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distribution in mucosal tissue both as a function of depth into the tissue, and cell 
type. A number of investigators are utilizing different mass spectroscopy 
techniques to map the drug distribution in mucosal tissue (14, 15). These mass 
spectroscopy imaging techniques include matrix-assisted laser 
desorption/ionization (MALDI) (16) and desorption electrospray ionization (DESI)
(17). Analyzing multiple tissue sections by mass spectroscopy to determine the 
drug content, and histology to determine the cell morphology enables the 
researcher to overlay the drug concentration profile over an image of the tissue 
section.
Despite decades of IVR acceptability research, most for hormone eluting 
IVRs but more recently for HIV prevention, it is still not known what the preferred 
duration for an IVR for HIV chemoprophylaxis is balancing the potential cost 
saving advantage of increasing the device duration, and the complexity of the 
ring design in the context of the desires and preferences of target populations. 
Contraceptive and hormone replacement IVRs currently available have durations 
ranging from three weeks to one year (18, 19), suggesting durations longer than 
one month could be acceptable. Many in the HIV prevention field have advocated 
for longer duration IVRs as a potential strategy to amortize cost. Potential 
disadvantages of IVRs that are designed to last longer than a month are 
predominately associated with menstruation. Menses was the leading 
circumstance for voluntary removal and involuntary expulsion in a recent 
acceptability study of IVRs in African women (20), and it is unknown if an IVR 
replaced monthly would be preferred over a longer duration IVR. Moreover,
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further education is required for sub-Saharan African populations to 
conceptualize using antiretrovirals for HIV prevention, and overcome the stigma 
associated with using antiretrovirals for HIV treatment (21). Further clinical 
studies in relevant populations are required where women use IVRs to begin to 
understand these and other questions including the preferred ring dimensions, 
stiffness, and color. A main conclusion of all of the recent clinical studies of HIV 
prevention agents has been that adherence and acceptability are fundamentally 
essential to designing effective HIV prevention modalities. Acceptability and 
adherence are particularly important for IVRs for HIV prevention since one of the 
main drivers for IVR development over other vaginal delivery systems is to 
improve adherence over dosage forms that require more frequent user 
interventions. If the dapivirine IVR is found to be effective in protecting women 
from HIV infection, programs to further educate potential users would be required 
since IVRs for contraception and hormone replacement therapy are not widely 
used in sub-Saharan Africa where these type of prevention modalities would 
have the greatest effect.
It is unknown how systemic administration of antiretrovirals prevents HIV 
transmission, whether preventing the initial transmission events in the local tissue 
or preventing the establishment of a systemic infection, and if systemic or topical 
delivery of antiretrovirals will result in better effectiveness. Different antiretrovirals 
display differential concentrations at the portal of virus entry compared to plasma 
drug concentration when administered systemically, suggesting that the relative 
contribution of preventing local and systemic infection will be different depending
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on the drug. For example, tenofovir derivatives are known to concentrate within 
HIV target cells in certain mucosal compartments, and TDF concentrates in the 
rectal, but not in the vaginal compartment after oral dosing (22-26). Upon 
parenteral administration, the concentration of cabotegravir is significantly lower 
at the rectal and vaginal mucosa relative to the blood (27) whereas rilpivirine 
concentration in plasma and vaginal tissue and fluid was similar (28). Oral 
administration of raltegravir confers higher drug concentration in gastrointestinal 
tissue compared to blood plasma, presenting a potential advantage to prevent 
rectal HIV transmission (29). The differential drug distribution that is specific to 
the antiretroviral and route of administration has critical implications relating to 
the use of systemic PrEP to prevent sexual transmission of HIV since there is 
mounting evidence that systemic PrEP can allow local viral replication at the 
mucosal site of infection if drug concentrations are inadequate. This localized 
infection could result in a systemic infection (30) if the drug concentration drops 
further, for example, for missed doses or a discontinuation of the dosing regimen. 
This could potentially fuel the development of drug resistant virus. A number of 
groups are developing improved parenteral antiretroviral formulations compared 
to the injectables of rilpivirine and cabotegravir currently in clinical development. 
These questions regarding how systemic and topical delivery of antiretrovirals 
inhibits HIV transmission are important as both topical and parenteral delivery 
systems are being evaluated in the clinic.
As proven with HIV therapy, delivering multiple drugs with different 
mechanisms of action for HIV prevention may result in a reduced incidence of drug-
154
resistant virus and more efficient protection (31-33); however, this hypothesis has 
not yet been confirmed for HIV PrEP. The most data are available for oral PrEP of 
either TDF alone or with emtricitabine; both drugs are nucleoside reverse 
transcriptase inhibitors. The variable adherence levels observed in different clinical 
trials make comparison between trials difficult. To date, there has only been a 
single trial evaluating both oral TDF alone and with emtricitabine, and no significant 
difference in effectiveness was observed in preventing HIV infection, suggesting 
that the difference, if any exists, is slight (34). Particularly since the effectiveness of 
oral PrEP in at-risk populations has been directly correlated to adherence, an 
important next step to maximize the public health impact is to effectively rollout oral 
PrEP to promote high adherence (35). Moreover, the lack of tenofovir resistant 
virus present in women who were infected during clinical studies of a tenofovir 
vaginal gel suggests that delivering multiple antiretroviral may not be necessary 
(36). The lack of drug resistance might also reflect low adherence and/or how 
quickly the drug is cleared after a single dose that might not be conducive for the 
selection of drug-resistant virus. The results of the Phase 3 studies of the dapivirine 
IVR are expected in 2016 and will likely shed light on the required dose and 
resulting drug concentration in vaginal fluid and tissue to prevent mucosal HIV 
infection, and importantly, if topical delivery of a single antiretroviral can effectively 
prevent infection.
The development of new IVR technologies for HIV prevention has led to a 
number of promising candidates for the delivery of a wide variety of drugs 
including small molecule, biologics, and synthetic macromolecules, and these
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delivery systems can be utilized for other women’s health applications. In 
summary, this dissertation describes the design and evaluation of 1) the PK and 
efficacy of a reservoir IVR for the vaginal delivery of TDF in macaques and 2) a 
new vaginal drug delivery device where the mechanism of drug release is 
predominately controlled by the hydration and diffusion of the water-soluble 
polymer contained within and not the drug diffusion through the polymers of the 
ring. The rate of new HIV infections has been in decline over the last decade; 
however, the number of new HIV infections remains persistently high, particularly 
for young women in sub-Saharan Africa and young men who have sex with men. 
This suggests that in addition to expansion of individual’s knowledge of their HIV 
status, treatment as prevention, and oral PrEP, new HIV prevention modalities 




1. Friend DR, Clark JT, Kiser PF, Clark MR. 2013. Multipurpose prevention 
technologies: Products in development. Antiviral Res 100:S39-S47.
2. Young Holt B, Romano J, Manning J, Hemmerling A, Shields W, Vyda 
L, Lusti-Narasimhan M. 2014. Ensuring successful development and 
introduction of multipurpose prevention technologies through an innovative 
partnership approach. BJOG: An International Journal of Obstetrics & 
Gynaecology 121:3-8.
3. Clark JT, Clark MR, Shelke NB, Johnson TJ, Smith EM, Andreasen 
AK, Nebeker JS, Fabian J, Friend DR, Kiser PF. 2014. Engineering a 
segmented dual-reservoir polyurethane intravaginal ring for simultaneous 
prevention of HIV transmission and unwanted pregnancy. PLoS One 
9:e88509.
4. Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, 
Gilman J, Butkyavichene I, Vincent KL, Motamedi M, Friend DR, Clark 
MR, Baum MM. 2012. Simultaneous delivery of tenofovir and acyclovir via 
an intravaginal ring. Antimicrob Agents Chemother 56:875-882.
5. Moss JA, Malone AM, Smith TJ, Kennedy S, Nguyen C, Vincent KL, 
Motamedi M, Baum MM. 2013. Pharmacokinetics of a multipurpose pod- 
intravaginal ring simultaneously delivering five drugs in an ovine model. 
Antimicrob Agents Chemother 57:3994-3997.
6. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja 
U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF.
2013. Intravaginal ring eluting tenofovir disoproxil fumarate completely 
protects macaques from multiple vaginal simian-HIV challenges. Proc Natl 
Acad Sci U S A 110:16145-16150.
7. Johnson TJ, Gupta KM, Fabian J, A lbright TH, Kiser PF. 2010. 
Segmented polyurethane intravaginal rings for the sustained combined 
delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 
39:203-212.
8. Baum MM, Butkyavichene I, Gilman J, Kennedy S, Kopin E, Malone 
AM, Nguyen C, Smith TJ, Friend DR, Clark MR, Moss Ja . 2012. An 
intravaginal ring for the simultaneous delivery of multiple drugs. Journal of 
Pharmaceutical Sciences 101:2833-2843.
9. Gao P, Fagerness PE. 1995. Diffusion in HPMC gels. I. Determination of 
drug and water diffusivity by pulsed-field-gradient spin-echo NMR. Pharm 
Res 12:955-964.
158
10. Ferrero C, Massuelle D, Jeannerat D, Doelker E. 2008. Towards 
elucidation of the drug release mechanism from compressed hydrophilic 
matrices made of cellulose ethers. I. Pulse-field-gradient spin-echo NMR 
study of sodium salicylate diffusivity in swollen hydrogels with respect to 
polymer matrix physical structure. Journal of Controlled Release 128:71­
79.
11. Alvarez-Lorenzo C, Gomez-Amoza JL, Martinez-Pacheco R, Souto C, 
Concheiro A. 1999. Microviscosity of hydroxypropylcellulose gels as a 
basis for prediction of drug diffusion rates. Int J Pharm 180:91-103.
12. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira 
JV, McMahan V, Bushman LR, Casapia M, Montoya-Herrera O, Veloso 
VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallas EG, 
Grant RM, iPrEx Study T. 2012. Emtricitabine-tenofovir concentrations 
and pre-exposure prophylaxis efficacy in men who have sex with men. 
Science translational medicine 4:151ra125.
13. Anderson PL, Glidden DV, Bushman LR, Heneine W, Garcia-Lerma
JG. 2014. Tenofovir diphosphate concentrations and prophylactic effect in 
a macaque model of rectal simian HIV transmission. J Antimicrob 
Chemother 69:2470-2476.
14. Thompson CG, Cohen MS, Kashuba AD. 2013. Antiretroviral 
pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 63 Suppl 
2:S240-247.
15. Bokhart MT, Rosen E, Thompson C, Sykes C, Kashuba AD,
Muddiman DC. 2014. Quantitative mass spectrometry imaging of 
emtricitabine in cervical tissue model using infrared matrix-assisted laser 
desorption electrospray ionization. Analytical and bioanalytical chemistry.
16. Schwartz SA, Reyzer ML, Caprioli RM. 2003. Direct tissue analysis 
using matrix-assisted laser desorption/ionization mass spectrometry: 
practical aspects of sample preparation. J Mass Spectrom 38:699-708.
17. Wiseman JM, Ifa DR, Song QY, Cooks RG. 2006. Tissue imaging at 
atmospheric pressure using desorption electrospray ionization (DESI) 
mass spectrometry. Angew Chem Int Edit 45:7188-7192.
18. Brache V, Faundes A. 2010. Contraceptive vaginal rings: a review. 
Contraception 82:418-427.
19. Dezarnaulds G, Fraser IS. 2003. Vaginal ring delivery of hormone 
replacement therapy - a review. Expert Opin Pharmaco 4:201-212.
20. Montgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, 
von Mollendorf C, Bekker L, Ganesh S, Young K, Romano J, Nel A,
159
Woodsong C. 2012. Vaginal ring adherence in sub-Saharan Africa: 
expulsion, removal, and perfect use. AIDS Behav 16:1787-1798.
21. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, 
Montgomery ET, Team V-CS. 2014. Perspectives on use of oral and 
vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in 
Johannesburg, South Africa. Journal of the International AIDS Society 
17:19146.
22. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito 
C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, 
Gomez K, Richardson BA, Bumpus NN. 2013. MTN-001: randomized 
pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral 
tablets in vaginal tissue and other compartments. PLoS One 8:e55013.
23. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, 
Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, 
Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W. 2010. 
Intermittent prophylaxis with oral truvada protects macaques from rectal 
SHIV infection. Science translational medicine 2:14ra14.
24. Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, 
Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix
CW. 2013. Single dose pharmacokinetics of oral tenofovir in plasma, 
peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. 
AIDS Res Hum Retroviruses 29:1443-1450.
25. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney 
JF, Cohen MS, Kashuba AD. 2011. Penetration of tenofovir and 
emtricitabine in mucosal tissues: implications for prevention of HIV-1 
transmission. Science translational medicine 3:112re114.
26. Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, 
Kashuba AD, Akkina R. 2014. HIV pre-exposure prophylaxis: mucosal 
tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor 
Maraviroc in a humanized mouse model. Virology 464-465:253-263.
27. Spreen W, Ford SL, Chen S, W ilfret D, Margolis D, Gould E, Piscitelli
S. 2014. GSK1265744 Pharmacokinetics in Plasma and Tissue Following 
Single-Dose Long-Acting (LA) Injectable Administration in Healthy 
Subjects. J Acquir Immune Defic Syndr 67:481-486.
28. Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, 
Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.
2014. A compartmental pharmacokinetic evaluation of long-acting 
rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clinical 
pharmacology and therapeutics 96:314-323.
160
29. Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, 
Madanick RD, Jennings S, Cohen MS, Kashuba AD. 2013. Differential 
penetration of raltegravir throughout gastrointestinal tissue: implications 
for eradication and cure. Aids 27:1413-1419.
30. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, 
Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew k R, 
Pambuccian S, Lifson JD, Carlis JV, Haase AT. 2009. Glycerol 
monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038.
31. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, 
Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP. 2005. 
Protection of macaques from vaginal SHIV challenge by vaginally 
delivered inhibitors of virus-cell fusion. Nature 438:99-102.
32. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. 2009. 
Reverse transcriptase inhibitors as potential colorectal microbicides. 
Antimicrob Agents Chemother 53:1797-1807.
33. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. 2011. 
Combinatorial approaches to the prevention and treatment of HIV-1 
infection. Antimicrob Agents Chemother 55:1831-1842.
34. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, 
Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, 
Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart 
G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, 
Haberer JE, Bangsberg D, Celum C, fo r the Partners Pr EPST. 2014. 
Single-agent tenofovir versus combination emtricitabine plus tenofovir for 
pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a 
randomised, double-blind, phase 3 trial. The Lancet. Infectious diseases.
35. Baeten JM, Haberer JE, Liu AY, Sista N. 2013. Preexposure prophylaxis 
for HIV prevention: where have we been and where are we going? J 
Acquir Immune Defic Syndr 63 Suppl 2:S122-129.
36. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter 
C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z,
Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, 
Taylor D, Group CT. 2010. Effectiveness and safety of tenofovir gel, an 





University of Michigan, B.S.E. in Biomedical 
Engineering 2009
University of Utah, Ph.D. in Bioengineering 2015
Publications
1. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber 
AM, Kiser PF, Herold BC. 2012. Intravaginal ring delivery of tenofovir 
disoproxil fumarate for prevention of HIV and herpes simplex virus 
infection. J Antimicrob Chemother 67:1730-1738.
2. Rastogi R, Teller RS, Mesquita PM, Herold BC, Kiser PF. 2013. 
Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. 
Antiviral Res 100:255-258.
3. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja 
U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF.
2013. Intravaginal ring eluting tenofovir disoproxil fumarate completely 
protects macaques from multiple vaginal simian-HIV challenges. Proc Natl 
Acad Sci U S A 110:16145-16150.
4. Nixon B, Jandl T, Teller RS, Taneva E, Wang Y, Nagaraja U, Kiser PF, 
Herold BC. 2014. Vaginally Delivered Tenofovir Disoproxil Fumarate 
Provides Greater Protection than Tenofovir against Genital Herpes in a 
Murine Model of Efficacy and Safety. Antimicrob Agents Chemother 
58:1153-1160.
162
5. Teller RS, Rastogi R, Johnson TJ, Blair MJ, Hitchcock RW, Kiser PF.
2014. Intravaginal flux controlled pump for sustained release of 
macromolecules. Pharm Res 31:2344-2353.
6. Srinivasan P, Dinh C, Zhang J, Pau C-P, McNicholl JM, Lo Y, Herold 
BC, Teller R, Kiser P, Smith JM. 2014. Pharmacokinetic evaluation of 
tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed 
macaques after 6 months of continuous use. J Med Primatol 43:364-369.
7. Smith JM, Srinivasan P, Teller RS, Lo Y, Dinh CT, Kiser PF, Herold
BC. 2015. Tenofovir Disoproxil Fumarate Intravaginal Ring Protects High- 
Dose Depot Medroxyprogesterone Acetate-Treated Macaques From 
Multiple SHIV Exposures. J Acquir Immune Defic Syndr 68:1-5.
